ACPA Resource Guide
To
Chronic Pain Treatment
An Integrated Guide to Physical, Behavioral
and Pharmacologic Therapy

2016 Edition

American Chronic Pain Association
P.O. Box 850
Rocklin, CA 95677
Tel 800-533-3231
Fax 916-652-8190
E-mail ACPA@theacpa.org
Web Site http://www.theacpa.org

Copyright 2016 American Chronic Pain Association, Inc.
All rights reserved. No portion of this book may be reproduced without permission of the
American Chronic Pain Association, Inc.
# Table of Contents

**INTRODUCTION** .............................................................................................................. 7  
**PAIN TREATMENT OVERVIEW** ...................................................................................... 8  
  - PAIN TYPES & CHRONIC PAIN CLASSIFICATION .......................................................... 9  
  - PAIN IN PREGNANCY .................................................................................................... 10  
  - PAIN IN CHILDREN ........................................................................................................ 10  
  - PAIN IN OLDER PERSONS ............................................................................................ 11  
**ACTIVE INTERVENTIONS - INTERDISCIPLINARY** .......................................................... 12  
  - FUNCTIONAL RESTORATION PROGRAMS & APPROACHES ......................................... 12  
**ACPA GROUPS: SELF-MANAGEMENT** .............................................................................. 13  
**ACTIVE INTERVENTIONS - INDIVIDUAL** .................................................................... 14  
  - EDUCATION .................................................................................................................. 14  
  - EXERCISE (ACTIVE THERAPY) ....................................................................................... 14  
  - FUNCTIONAL TRAINING ................................................................................................ 16  
  - TAI CHI ............................................................................................................................ 16  
  - YOGA ............................................................................................................................... 18  
  - GRADED MOTOR IMAGERY ............................................................................................. 20  
  - ART & MUSIC ............................................................................................................... 21  
  - PET THERAPY ................................................................................................................ 21  
  - PSYCHOLOGICAL & BEHAVIORAL APPROACHES ...................................................... 22  
  - MIND-BODY INTERVENTIONS ....................................................................................... 23  
**MEDICATIONS IN GENERAL** ......................................................................................... 27  
  - HOW MEDICATIONS CAN HELP & HARM ..................................................................... 27  
  - MEDICATIONS AND CHRONIC PAIN ............................................................................ 29  
  - IF MEDICATIONS ARE NOT RELIEVING PAIN ................................................................. 30  
  - WEANING OFF OF PAIN MEDICATIONS ........................................................................ 31  
  - WARNING ABOUT INTERNET MEDICATION PURCHASES ........................................... 34  
  - MEDICATION IDENTIFICATION .................................................................................... 35  
  - MEDICATION SIDE EFFECTS, DRUG ALLERGIES, & DRUG INTERACTIONS ............. 36  
  - OFF-LABEL MEDICATION USE ...................................................................................... 38  
  - CLINICAL TRIALS .......................................................................................................... 39  
**MEDICATION TYPES FOR THE TREATMENT OF PAIN** ............................................... 40  
  - NON-PRESCRIPTION PAIN RELIEVERS ......................................................................... 41  
    - OVER-THE-COUNTER (OTC) PAIN RELIEVERS ............................................................. 41  
    - ACETAMINOPHEN - SPECIAL WARNINGS .................................................................. 44  
    - HERBAL MEDICINES, SUPPLEMENTS, & VITAMINS .................................................. 46  
    - MEDICAL FOODS ......................................................................................................... 50  
  - NON-OPIOID PAIN RELIEVERS ...................................................................................... 52  
    - GASTROINTESTINAL (GI) PROTECTIVE MEDICATIONS ................................................. 56  
  - OPIOID PAIN RELIEVERS AND THEIR SAFE USE ......................................................... 58  
    - WHAT ARE OPIOIDS? .................................................................................................... 58  
    - OPIOID DELIVERY ........................................................................................................ 59  
    - SHORT-ACTING, SUSTAINED-RELEASE AND LONG-ACTING OPIOID AGONISTS ...... 59  
    - GENERAL OPIOID ADVERSE SIDE EFFECTS ............................................................... 66  
    - DEFINITION OF TERMS REGARDING OPIOIDS ............................................................ 70  
    - THE OPIOID DILEMMA ............................................................................................... 74  
    - OPIOID DOSING ........................................................................................................... 76  
    - CLINICAL GUIDELINES FOR THE USE OF OPIOID IN NON-CANCER CHRONIC PAIN ................................................................................................................................. 76  
    - KEY STEPS TO USE OPIOIDS SAFELY ......................................................................... 77

American Chronic Pain Association  
Copyright 2016
Authors, Contributors & Reviewers

Written, reviewed & updated yearly by Senior Author Steven Feinberg, MD, MPH; with Co-authors Jennifer Christian, MD, MPH; Rachel Feinberg, DPT, PT; Donna Kalauokalani, MD, MPH; Mel Pohl, MD, FASM, Donald Manning, MD; Vladimir Bokarius, MD; & Sarah Rizvi, PhD

Steven Feinberg, MD, MPH, is a practicing pain medicine physician in Palo Alto, California, and is an Adjunct Clinical Professor at Stanford University School of Medicine. He is a former Board member and Past President of the American Academy of Pain Medicine. He is a member of the ACPA Board of Directors. Dr. Feinberg served on the ACOEM Chronic Pain Guidelines Panel Chapter Update and also as Associate Editor, as a Medical Reviewer for the ACOEM 2014 Opioid Guidelines.

Jennifer Christian, MD, MPH, is board certified in occupational medicine with specialization in work disability prevention and management. She chairs the Work Fitness & Disability Section of the American College of Occupational & Environmental Medicine. She is President of Webility Corporation, a management consulting and training company.

Rachel Feinberg, DPT, PT, is Chief Physical Therapist and Director of the Feinberg Medical Group Functional Restoration Program in Palo Alto, California. She has special expertise assisting injured people regain function and in assisting them in returning to productive life activities.

Donna Kalauokalani, MD, MPH, completed post-graduate training in Internal Medicine and Anesthesiology at Washington University in St. Louis, and additional training in Pain Management, Preventive Medicine, Public Health, and Health Services Research at the University of Washington in Seattle where she completed a prestigious fellowship in the Robert Wood Johnson Clinical Scholar’s program and obtained her master’s degree in Public Health. Dr. Kalauokalani co-founded the Disparities in Pain section of the American Pain Society and continues to advocate for equal access to treatment and educate practitioners and policy makers in various settings about optimal pain treatment. She is a pain management specialty practitioner, educator and consultant, is the Medical Director of Folsom Pain Management and for Inpatient Pain Management Services at Dignity Health in Northern California. She is the immediate Past-President of the Board of Directors for the American Chronic Pain Association.

Mel Pohl, MD, FASAM is a Board Certified Family Practitioner. He is the Medical Director of Las Vegas Recovery Center (LVRC) - A unique program prepared to simultaneously treat chronic pain and opiate dependence or addiction. Dr. Pohl was a major force in developing LVRC’s Functional Restoration Program. He is certified by the American Board of Addiction Medicine (ABAM). He is the author of A Day without Pain, revised edition (Central Recovery Press, 2011). His new book with Kathy Ketcham is The Pain Antidote - Stop Suffering from Chronic Pain, Avoid Addiction to Painkillers, and Reclaim Your Life (Da Capo Press).
Vladimir Bokarius, MD, PhD, Lac, is Board Certified in Psychiatry and Pain Medicine. He is the Medical and Research Director of Comprehensive Care Consultants and Medical Director of Center for Occupational Health. Throughout the last decade, Dr. Bokarius has founded and overseen multidisciplinary pain programs in California. He is an author of multiple publications in psychiatry and pain and has presented on these topics at leading professional conferences around the world. He continues to be actively involved in treatment of patients with chronic pain and psychiatric conditions, including addiction and insomnia.

Donald Manning MD, PhD received his Doctorate in Pharmacology for work in the laboratory of Dr. Solomon H Snyder at Johns Hopkins University where he also earned his MD. He pursued residency training in Anesthesiology, fellowship training in Regional Anesthesia and Pain Management and a Post-Doctoral Fellowship in the Department of Neurosurgery under Dr. James Campbell all at Johns Hopkins. Dr. Manning has held clinical academic faculty positions in the Departments of Anesthesiology at Johns Hopkins, where he was co-director of the Pain Management Center and The University of Virginia Health Sciences Center where he founded the Women’s Pelvic Pain Center. Dr. Manning is currently the Chief Medical Officer for Adynxx Inc., a research-based early stage development company working on molecular biologic approaches to pain treatment and prevention. Dr. Manning has lectured and published widely on pain management topics and is a past-president of the Eastern Pain Association, a regional affiliate of the American Pain Society and previously served on the Board of Directors for the Reflex Sympathetic Dystrophy Association of America. He is currently President of the Board of Directors for the American Chronic Pain Association.

Sarah Rizvi, PhD, is Director of Psychological Services at Feinberg Medical Group in Palo Alto, CA. She specializes in Cognitive-Behavioral Therapy and the treatment of chronic pain, depression and anxiety. She also specializes in group psychotherapy.

Special Acknowledgments

The ACPA would like to thank Joe Paduda, MS, CompPharma President, and acknowledge contributions from member companies including Nichole Wilson, PharmD/MBA (Coventry), Dianne Tharp, BPharm, PharmD, BCPS, CPE and Deborah Conlon RPh, PharmD (HealthCare Solutions/Optum Rx), Brigette Nelson, MS, PharmD, BCNP (ExpressScripts) and Sarah Randolph, PharmD RPh (ExpressScripts).

The ACPA would also like to thank Healthesystems Chief Medical Officer Robert Goldberg, MD, and pharmacists Regina Mears, RPh, Fiona Steele, PharmD, Alicia Bryant, PharmD and Cheryl Hayes, PharmD.

The ACPA would also like to thank myMatrixx Director of Clinical Pharmacy Michael Nguyen, PharmD, CPh, along with Chief Clinical officer Phil Walls, RPh.

Special thanks to Yvonne Selden for her editing assistance.
A STATEMENT FROM THE ACPA BOARD OF DIRECTORS

Since 1980, the American Chronic Pain Association (ACPA), a non-profit, tax exempt organization, has offered a support system for people with chronic pain through education in pain management skills and self-help group activities. To learn more about the ACPA and how to become a member, please visit our web site at http://www.theacpa.org or call the National Office at 800-533-3231.

The American Chronic Pain Association (ACPA) advocates a multi-modal strategy for dealing with chronic pain. The ACPA focuses on pain management skills and self-help strategies that individuals can use with the approval of their health care professionals.

The ACPA considers the use of medication and other treatments to be a matter for individuals to determine in conjunction with their health care professionals. The ACPA takes no position on medical treatment choices. Thus, information the ACPA provides about medical care is educational and informative only.

The ACPA Resource Guide to Chronic Pain Treatment is an unbiased consensus document that combines practical clinical experience and the most recent scientific information presented in an easy to read format for consumers.
INTRODUCTION

The ACPA believes that people with chronic pain benefit from being well informed about their treatments and especially about their prescribed medications. This knowledge may relieve the fears that can interfere with receiving maximum benefits from such treatment and medications. Education can also prevent unrealistic expectations that lead to disappointment or even worse.

This Guide is not meant to serve as medical advice for medical conditions or guidance regarding treatment needs. Remember that the best source of information about one’s health and treatment needs is through open dialogue with a health care professional.

With the emerging and ever increasing growth of the Internet, information is now available on almost every topic. Finding information is easy, but finding reliable, understandable and factual information that answers your questions is NOT so easy.

The information in this ACPA Resource Guide to Chronic Pain Treatment covers general information compiled from multiple sources. It is updated yearly and includes web links for certain medications and treatments and relevant Internet sites of interest. For medications, generic names are primarily listed with brand names in parentheses.

Unfortunately, there are some risks associated with almost any treatment for chronic pain. The best approach is for people with pain to ask questions about the benefits and risks or side effects when they are about to embark on any particular treatment approach or new medication. How often is this treatment effective -- compared to other options? Does the risk justify the possible benefit? How do the risks and benefits compare with those of other treatment options?

Although this guide covers many medications and treatments, the topics covered are not exhaustive. If something is not mentioned, that does not imply that it is not useful. Contact the ACPA with comments, corrections, or recommendations for topics to be covered in future editions at http://www.theacpa.org/contactUs.aspx.

The best advice the ACPA can offer is to discuss all treatment and medication questions with a health care professional! In this Guide, this term includes physicians, prescribing advanced practice nurses, nurse practitioners, physician assistants, and others who do not prescribe medications but provide other health care services including psychologists, pharmacists, physical and occupational therapists and others.

A primary care physician is usually a good resource. There may be a referral to a physician who specializes in Pain Medicine who may have more information or experience about the use of different medications and treatments for various chronic pain problems. Also, be open to referral to a psychiatrist, psychologist, or other mental health professional who can help the person with pain reach his/her goals. Other professionals, like pharmacists, may assist with understanding medications and their uses and side effects.
PAIN TREATMENT OVERVIEW

It's hard to know how to move forward once chronic pain has changed your life. It often seems like all you need is the right medication or treatment to take away the pain. But sometimes that is not enough – especially in the case of chronic pain. Perhaps the best that medication, injections or surgery has done so far, or can ever do for you, is give 25 or 30 percent relief.

There are many other treatment approaches to chronic pain. Better relief may be obtained when medications, passive therapies, and invasive interventions are accompanied by or even replaced by other active rehabilitation and educational approaches and behavioral-psychological treatments. These support, develop, and strengthen the capability of the person living with chronic pain to manage his or her own symptoms in a way that permits a full and satisfying life. In fact, rehabilitation through cognitive, behavioral, and physical reactivation treatments (also called functional restoration) often lessens the need for medications and other more invasive procedures.

It may help to use this mental picture: Imagine a car with four totally flat tires, going nowhere. That's what life can look like for someone whose life has been totally changed by chronic pain. Medical treatment only puts air in one of our tires. We still have three flat tires and can't move forward. The ACPA’s definition of “successful” treatment of a person with chronic pain is that the person has learned how to independently self-manage his/her condition in a way that allows life to continue, maximizing participation in everyday life activities, minimizing discomfort and side effects, and avoiding other bad consequences of treatment. Note: This does not mean that the person will be pain free but rather be able to manage pain and lead a productive, satisfying, and happy life.

So it is important to ask what else we need to fill our other three tires so that we can resume our life’s journey. Unlike traditional medicine where the “patient” is a passive participant, living a full life with pain requires that the person take an active role in the recovery process. The individual needs to work with his or her health care providers to get what is needed to fill up the other three tires. Biofeedback, physical therapy, counseling, pacing of daily activities, nutritional counseling, a support group, life coaching, and a host of medical modalities are a few examples of the ways we can fill those other tires.

For each person, the combination of therapies and interventions needed may differ, based on individual need. It is the responsibility of the person in pain to decide whether any particular health care professional has actually helped them get their “car of life” moving forward again -- and if not, to make a change.

Once we have all four tires filled, it is our responsibility to maintain our car. We would not take our car back to the dealer and ask them to fill it up with gas or wash our windshield. That is our responsibility--to take good care of our car. We take it in for inspections and if something goes wrong, we go to a professional. It's the same with our wellness. You see, pain management is much more than one simple modality. It takes a team effort, with the person with pain taking an active
role, to live a full life in spite of chronic pain. Go to *A Car With Four Flat Tires* at the ACPA web site at [http://www.theacpa.org/a-car-with-four-flat-tires](http://www.theacpa.org/a-car-with-four-flat-tires) to watch a short educational video narrated by ACPA Founder and CEO, Ms. Penney Cowan.

**PAIN TYPES & CHRONIC PAIN CLASSIFICATION**

Many pain specialists recommend that the term “chronic pain” should be referred to as “persistent pain” – which can be continuous or recurrent and of sufficient duration and intensity to adversely affect a person’s well-being, level of function, and quality of life. This document continues to use the term “chronic pain” given its universal acceptance.

Acute pain is characterized as being of recent onset, transient, and usually from an identifiable cause.

Chronic or persistent pain can be described as ongoing or recurrent pain, lasting beyond the usual course of acute illness or injury healing, more than 3 to 6 months, and which adversely affects the individual’s well-being. Another definition for chronic or persistent pain is **pain that continues when it should not**.

Chronic pain is classified by pathophysiology (the functional changes associated with or resulting from disease or injury) as nociceptive (due to ongoing tissue injury), neuropathic (resulting from damage to the brain, spinal cord, or peripheral nerves), or a mixture of these.

Central pain syndrome is a neurological condition caused by a process that specifically affects the central nervous system (CNS), which includes the brain, brainstem, and spinal cord. The disorder occurs in people who have or who have experienced strokes, multiple sclerosis, Parkinson's disease, brain tumors, limb amputations, brain injuries, or spinal cord injuries. It may develop months or years after injury or damage to the CNS. This also includes conditions such as chronic headaches, fibromyalgia, and Complex Regional Pain Syndrome (CRPS).

Continuous pain is pain that is typically present for approximately half the day or more.

Flare-up pain (the term break-through pain was coined to refer to cancer-related flare-ups) can be described as a transitory increase in pain in someone who has relatively stable and an adequately controlled level of baseline pain. It may be caused by changes in an underlying disease including treatment, or involuntary or voluntary physical actions such as coughing or getting up from a chair or other changes in activity level. It can also be caused by stress and emotions such as anxiety, anger, fear, or worry. Activity imbalance—doing too much or too little—can also flare pain.
**PAIN IN PREGNANCY**


The following is an abstracted summary:

The U.S. Food and Drug Administration (FDA) is aware of and understands the concerns arising from recent reports questioning the safety of prescription and over-the-counter (OTC) pain medicines when used during pregnancy. As a result, we evaluated research studies published in the medical literature and determined they are too limited to make any recommendations based on these studies at this time. Because of this uncertainty, the use of pain medicines during pregnancy should be carefully considered. We urge pregnant women to always discuss all medicines with their health care professionals before using them.

Severe and persistent pain that is not effectively treated during pregnancy can result in depression, anxiety, and high blood pressure in the mother. Medicines including nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, and acetaminophen can help treat severe and persistent pain. However, it is important to carefully weigh the benefits and risks of using prescription and OTC pain medicines during pregnancy.

Pregnant women should always consult with their health care professional before taking any prescription or OTC medicine. Women taking pain medicines who are considering becoming pregnant should also consult with their health care professionals to discuss the risks and benefits of pain medicine use.

**PAIN IN CHILDREN**

Chronic pain is a significant problem in the pediatric population, conservatively estimated to affect 20 to 40 percent of children and adolescents around the world. The most common chronic pain conditions in children and adolescence are musculoskeletal pain, headaches, and abdominal pain. They may experience physical and psychological pain and their families may experience significant emotional distress and social consequences as a result of pain and associated disability. Research suggests that the family dynamic and how parents respond to their child’s pain can have a significant impact on the course of the child’s pain and on their function. One of many resources is the book “Conquering Your Child's Chronic Pain: A Pediatrician's Guide for Reclaiming a Normal Childhood” by Lonnie K. Zeltzer, MD, and Christina Blackett Schlank.

Childhood pain brings significant direct and indirect costs from health care utilization and lost wages due to parents taking time off work to care for the child. In addition, longitudinal studies provide convincing evidence to suggest that childhood chronic pain predisposes the continuation of pain later in life and the development of new forms of chronic pain in adulthood (from Assessment and Management of Children with Chronic Pain, A Position Statement from the American Pain Society - 1/4/12 [http://americanpainsociety.org/uploads/about/position-](http://americanpainsociety.org/uploads/about/position-).
PAIN IN OLDER PERSONS

Persistent or chronic pain is common in older adults. While medications are certainly an important part of treating chronic pain, use in older persons is fraught with potential problems. Physical rehabilitation and other interventional therapies, which may include targeted injections and acupuncture, can be helpful to reduce pain, maximize physical function, and decrease the need for medications. In fact, the medical literature is full of studies showing the advantage of regular physical exercise in older adults. Additionally, psychological supports including relaxation techniques, mindfulness practices, and positive self-talk should always be considered for managing pain in elderly people.

In addition to chronic pain, older adults are more likely to have multiple medical conditions and to be taking multiple medications. Medication risks are greater for an individual when multiple medications are taken and it is important to discuss all medications (including over-the-counter or verbal/homeopathic medications with your health care provider). Certain medications carry greater risks than others, especially when used in combination. Some older individuals may be more sensitive to medications, more likely to experience side effects, and more likely to be using multiple drugs with the associated risk of interactions between the drugs.

In general, 30 percent of hospital admissions among the elderly may be linked to an adverse drug-related event or toxic effect from opioids and sedatives (i.e., a tranquilizer). Nearly one-third of all prescribed medications are for persons over the age of 65 years. Unfortunately, many adverse drug effects in older adults are overlooked as age-related changes (general weakness, dizziness, and upset stomach) when in fact the person is experiencing a medication-related problem.

In all persons, medication should be initiated at a low dose and adjusted slowly to optimize pain relief while monitoring and managing side effects. Multi-modal analgesia, which is the careful use of multiple pain-relieving drugs together, can be seen as potentially advantageous. Combining smaller doses of more than one medication may minimize the dose-limiting adverse effects of using a particular single drug. This statement is not meant to endorse certain drug combinations such as opioids with benzodiazepines which we know are hazardous.

ACTIVE INTERVENTIONS - INTERDISCIPLINARY

“Active” means that the treatment is not passive and that the individual is fully engaged in his or her medical care. “Interdisciplinary” means the involvement of several health care providers (physician, psychologist, physical therapist, occupational therapist) providing coordinating services and communication at the same facility. Although there are many different beneficial active interventions described below, research increasingly supports a “whole person” approach for those dealing with chronic pain. This is often described as a functional restoration approach. Functional restoration encompasses many interventions in a coordinated, goal-oriented manner.

FUNCTIONAL RESTORATION PROGRAMS & APPROACHES

Functional restoration refers to a philosophy and approach to medical care that is unique and is based on a biopsychosocial model of medical diagnosis and care that focuses on not just the biology (injury/illness and associated pathology) but also on the individual as a whole person including psychological and social aspects.

Functional restoration involves multiple disciplines that work together in a coordinated fashion with shared treatment goals. Functional restoration approaches are focused on maximizing function, returning to pre-injury productivity (with sufficient functional capacity to avoid recurrent injuries), and preventing needless disability, unnecessary medical and surgical care, and health care related complications.

Functional restoration can be defined as the process by which an individual acquires the skills, knowledge, and behavioral changes necessary to assume or re-assume primary responsibility for his/her physical and emotional well-being. Functional restoration thereby empowers the individual to achieve maximum functional independence, to have the capacity to regain or maximize activities of daily living, and to return to vocational and avocational activities.

Fundamental elements of a functional restoration approach include assessment of the person’s dynamic physical, functional, and psychosocial status. This is followed by a treatment plan that includes directed conditioning and exercise, cognitive behavioral therapy, patient and family education, and counseling, functional goal setting, ongoing assessment of participation, compliance, and complicating problems, and progress toward achievement of goals.

A functional restoration approach can include the limited/adjunctive use of medications and appropriate interventions for the specific purpose of supporting the individual’s effort to reach and maintain maximum functional improvement; institution of preventive measures, expectation management, education for relapse prevention, proper activity and work pacing, ergonomic
accommodation; and when appropriate, transitional return to gainful employment with as little disruption to the work site and coworkers as possible.

Functional restoration involves objective measures of physical performance that guide treatment progression. At the same time, physical and occupational therapists, psychologists, nurses, and case managers provide education on pain management, coping skills, return to work issues, and fear-avoidance beliefs. They often use a cognitive behavioral therapy (CBT) approach consistent with the biopsychosocial view of chronic pain/disability.

Ultimately, successful individuals with chronic pain take control of and re-engage in life activities and have achieved mastery over when and how to access the medical community in a way that is most beneficial for them. The goal is a mitigation of suffering and return to a productive life despite having a chronic/persistent pain problem.

These programs involve an integrated team of professionals providing intensive, coordinated care, which may include pain specialist physicians/health care professionals, physical therapists, occupational therapists, psychologists, vocational counselors, nurses, and case managers providing individualized treatment in a structured setting.

**ACPA Groups: Self-Management**

A significant part of being involved in your recovery is being involved with your peers. ACPA groups welcome anyone who is living with an ongoing pain problem. The goal of an ACPA group is to provide support, validation, and education in basic pain management and life skills. Groups are facilitated by group members themselves and the success of the group is a shared responsibility. ACPA groups do not focus on symptoms or provide treatment of any kind. Rather, they are a means for people to share what they have learned and to encourage others to create more satisfying lives. Hear members' thoughts about the value of the kind of peer support offered by ACPA groups at [http://www.theacpa.org/What-ACPA-Groups-Offer](http://www.theacpa.org/What-ACPA-Groups-Offer).
ACTIVE INTERVENTIONS - INDIVIDUAL

EDUCATION

Active interventions are some of the best medicine for chronic pain because they engage the individual in learning and making positive changes to increase function and reduce pain.

Education of the patient and family should be a primary emphasis in the treatment of chronic pain. Currently, many persons with chronic pain and their practitioners often think of education last, after medications, passive therapy, other invasive interventions, and surgery. It is critical for all concerned to develop and implement effective strategies and skills to educate persons with chronic pain. No treatment plan is complete without addressing issues of individual and/or group education as a means of facilitating self-management of symptoms and prevention.

Education regarding chronic pain should start as soon as the pain has been identified as chronic. Early topics should include helping a person understand that they may not be “fixed” but rather, that his or her pain must be managed. It can be helpful to think of chronic pain similar to other chronic diseases such as diabetes. A person needs to manage his or her diabetes and prevent it from getting worse and causing other problems. Diabetes is not quickly cured or fixed. The same is true for chronic pain. Further education on chronic pain should also include understanding that pain is not “all in your head” (but it surely affects your brain) and that an active approach that focuses on the whole person is the most effective way to treat chronic pain.

What someone can and cannot do should be defined as clearly as possible. Many times, the only guidelines a person may hear are restrictions given right after the injury or surgery. These same restrictions may no longer be needed, but patients are not always told updated ones. Unfortunately, it is also common that patients have either been told incorrect information or have misinterpreted education from a past health care provider. Many health care providers have only minimal exposure to assessing or treating chronic pain. A lack of consistent information can confuse the patient. Phrases like, “the back of an 80-year-old man” or “you will end up in a wheelchair if you sneeze,” can keep a person fearful and disabled.

EXERCISE (ACTIVE THERAPY)

The overwhelming theme in the treatment of most persons with chronic pain is to keep as physically active as possible. In fact, advancement of activity levels and education is recommended, as inactivity is detrimental despite the temporary relief of symptoms that often accompanies it.
There is strong evidence that exercise programs are beneficial for persons with chronic pain. In fact, one of the best treatments for chronic low back pain is exercise. After consultation with a health care professional and/or physical therapist, a therapeutic exercise program should be initiated at the start of any chronic pain treatment program. Such programs should emphasize education, independence, and the importance of an on-going self-directed exercise regimen.

Therapeutic exercise can be classified to include 1) range-of-motion exercises; 2) stretching; 3) strength training; and 4) cardiovascular conditioning.

Active therapy is based on the philosophy that therapeutic exercise and/or activity are beneficial for restoring flexibility, strength, endurance, function, and range of motion, and can alleviate discomfort. Active therapy requires an internal effort by the individual to complete a specific exercise or task.

Aquatic therapy or exercise may be beneficial for individuals who have comorbidities that preclude participation in weight-bearing exercise or for those whose pain or weakness limits them from participating in even a low-level land program. Hydrostatic principles and buoyancy can provide decreased stress on weight-bearing joints. Once the individual gains strength and flexibility in the water, the person should transition, at least in part, to a land-based exercise program.

Persons with chronic pain can become discouraged when their pain temporarily increases due to therapeutic exercise, and they will sometimes terminate treatment too early before achieving maximal benefit. A flare-up of pain with exercise should be expected even with safe exercise, but can also be due to poor body mechanics, guarded or stiff movement, high levels of demand on an injured site, or compensatory movements. It is important to have a health care professional who is knowledgeable about treating chronic pain assist not only with setting up a graded and careful exercise program, but also with distinguishing new symptoms that may signify problems from the “good” discomfort that normally goes along with an increasing exercise program.

**PILATES**

Pilates is a method of exercise performed on a mat or using special apparatus that consists of low-impact and endurance movements. Pilates is named for its creator, Joseph Pilates, who developed the exercises in the early 1900s. The Pilates method emphasizes the breath, core strength and stabilization, flexibility and posture. Improving these areas can be beneficial when learning to manage chronic pain. Mat work may be too challenging as a starting point for people with chronic pain. Because it lacks the support associated with the Reformer and the Trapeze table (exercise machines used in Pilates), mat work can result in excessive strain to the body resulting in a poor movement. Appropriate modifications and simplifications to mat exercises do exist, which can be incorporated into a home program.
GYROTONICS

The Gyrotonic Expansion System® includes the Gyrotonic and Gyrokinesis methods. Both Gyrotonic and Gyrokinesis exercise sequences are composed of spiraling, circular movements, which flow together seamlessly in rhythmic repetitions and are paired with specific breathing patterns. These carefully crafted sequences create balance, efficiency, strength and flexibility. As compared to yoga, Pilates and other exercise methods, Gyrotonics places more emphasis on rotation and spiraling movements. Gyrotonic exercises are performed on custom-designed Gyrotonic equipment, whereas Gyrokinesis exercises are performed on a mat and chair. The benefits of this approach include increased strength and flexibility, improved posture, balance and agility, renewed energy and vitality, and a general sense of calm and well-being.

FUNCTIONAL TRAINING

Chronic pain can limit even the simplest daily activities as well as the ability to perform higher-level work activities. A successful active program focuses on increasing the ability to perform functional tasks. For example, this could mean being able to perform household tasks or return to work again. Being more independent leads to a higher quality of life. Functional activity training is just as important as performing a daily exercise program. Lifting, carrying, pushing, pulling, reaching, bending, digital dexterity, and handling are all examples of functional movements that are used on a daily basis. It is helpful to think of practicing daily activities similar to performing exercises. It is important to first determine the current ability to perform this task. Each task is then practiced with appropriate pacing of activity, flare management, and slow progression. Recreational activities are included in this category. The ability to perform a higher level of recreational activities serves many purposes including exercise, socialization, time utilization, and general enjoyment.

TAI CHI

Tai Chi is an ancient Chinese system of meditative movements practiced as exercises. Originally, Tai Chi was used as a form of combat. Today, it is a gentle form of exercise, popularized in the Western world in the 1980s and 1990s. Now, people of all ages use these movements to gain strength and flexibility. Ongoing research suggests that Tai Chi is an effective treatment in improving physical functioning of those with chronic pain including arthritis, low back pain, and fibromyalgia.

Tai Chi is a series of soft, flowing movements choreographed into a slow routine. Each specific movement corresponds with either the inhalation or exhalation of a deep, gentle breath. This coordination of movement and breath is believed to free the flow of “chi,” a life-force energy that when blocked, purportedly can cause stress and illness. By improving the mind/body connection, Tai Chi brings the “yin and yang” (opposite and contrary forces) of a person back into natural harmony, exercising emotions just as it does the muscles. Tai Chi revolves around a series of
movements called “forms” which can last anywhere from 5 to 20 minutes. There are over 100 different stances to learn.

As a low-impact exercise, Tai Chi is great for people with joint problems because it actually helps build connective tissue and improve circulation. Additionally, this form of exercise improves balance and posture by emphasizing correct form with each movement. As opposed to developing bulky muscles and brute force, exercisers tackle tension and stress while improving body awareness.

**QIGONG**

Qigong is a Chinese term used to describe human performance and movement that is characterized by focus and concentration, full body presence, breath awareness/coordination, and skill. In theory, Qigong has existed for thousands of years. In practice, contemporary Qigong is the grand category that encompasses many healing Asian practices, including traditional Chinese medicine, breath, and movement practice. “Qi” means vitality or energy, and “gong” means work; together in the term “Qigong” the literal translation of the practice is “the work of energy or vitality.” In common everyday terms, such a practice relates to human function, encompassing such things as mental focus, the natural movement of the body’s limbs, blood flow in the body, and a sense of balance and harmony in the body’s systems (nervous system, vestibular system, digestive system, etc.).

In the Qigong “tradition,” there are forms and practices that are categorized by purpose and appropriateness to the season, the environment, and the practitioner. The form of Qigong that is most appropriate in health settings is the Qigong for improving function and increasing vitality. This type of Qigong has been referred to in some circles as “Bu Zheng Qigong” or “Qigong for Health and Vitality” or “Medical Qigong.” This basic approach is geared toward strengthening the body and mind through various safe and gentle practices. In this type of Qigong, the focus for the practitioner is to perform movement in a slow and restful way while observing the physical phenomena associated with the movement and, in more advanced practice, directing the attention to influence the flow of energy. The practitioner observes such things as range of motion of the limbs, rate of breath and heart, temperature and pressure changes, etc.

In its everyday practical sense, the regular practice of Qigong for health improves concentration, posture, balance, range of motion, and confidence. A Qigong practice session for health can typically involve breath practice, self-massage, and exploratory range of motion exercises that take the joints through their range of motion, and move the spine in six directions: extension, flexion, right side bending, left side bending, and finally twisting left and right. Slow movements keep the muscles mildly engaged to promote circulation, and then the mind/attention is engaged to follow sequences and combinations of movement. Practitioners, however, would agree that Qigong is not only movement of the body, but is also surprisingly mentally engaging, meditative, and restful.
Yoga creates a greater sense of health and well-being by emphasizing mindful practice, breath awareness, and proper body alignment. Yoga helps to manage chronic pain through movements that increase flexibility, strength, and relaxation. People with chronic pain should begin with a gentle, slow-paced class where props are available for support. Benefits of a regular yoga practice include improved sleep and reduced stress and anxiety. Studies have shown that yoga is beneficial for fibromyalgia, among other pain conditions.

Working with a Yoga Therapist on a one-to-one basis is an excellent way to experience the benefits of yoga in a safe environment and with a professional who is trained to modify different poses for specific conditions.

These styles of yoga are good for beginning students:

- Viniyoga refers to a therapeutic style of yoga that adapts the practice to the unique conditions and needs of each individual. It emphasizes repetitive movement combined with breath work. Although all yoga is therapeutic, Viniyoga’s emphasis on the individual’s physical needs makes it especially so.

- Iyengar Yoga utilizes straps, blocks, and chairs as props to assist participants in the precise alignment of their poses. Because of this assistance, Iyengar is an ideal style of yoga for beginners or those suffering from chronic pain. Unlike ‘flow yoga,” Iyengar poses are held in order to focus on safe alignment and to build endurance.

- Yin Yoga focuses on the body's connective tissue, ligaments, and joints as opposed to the muscles. Yin Yoga is practiced on the floor, and most poses are either sitting or reclining. To affect change in the connective tissue, poses are held for time – sometimes up to 10 minutes. Although challenging, Yin Yoga has a deeply soothing effect on the nervous system and for that reason is more relaxing than Iyengar Yoga.

- In Restorative Yoga, the body is supported in the poses by a variety of props. This encourages passive stretching and deeper awareness of the breath. Because of their passive nature, restorative poses are often held for up to 20 minutes.

- Hatha Yoga has come to represent a gentle, basic yoga classes with no flow between poses. However, Hatha actually describes any kind of yoga in which poses are done. Therefore, before participating in a Hatha Yoga class, it is important to clarify what type of Yoga will be taught.

- Therapeutic Yoga combines restorative yoga, breath work, and meditation techniques to bring the body into a greater sense of balance and reducing stress. What makes this type of Yoga Therapy unique is that the instructor has the skills to prescribe specific poses or breathing techniques for specific conditions. The instructor may build a program ranging from gentle to
more vigorous program depending on the individual’s needs. Group classes can be designed for those with particular therapeutic needs.

These styles of yoga require strength and endurance:

- Ashtanga Yoga is characterized by constant movement, or flow, from one posture to another. It is vigorous and fast-paced, earning it the nickname of “Power Yoga.” The focus is on deep breathing during each pose.

- Vinyasa is similar to Ashtanga Yoga in its emphasis on flowing through postures, particularly Surya Namaskar (Sun Salutation). The goal of Vinyasa is to improve coordination, strength, and balance by following the sequence of active poses.

- Bikram or "hot" Yoga literally refers to the fact that the practice studio is heated to 104 degrees Fahrenheit. The practice consists of 26 poses that are repeated twice. The intense sweat produced is thought to purify the body.

- Kundalini Yoga focuses on purifying the emotions, the mind, and the body while placing emphasis on the effects of breathing in each pose. Chanting mantras and meditation are common practices of Kundalini. The word Kundalini refers to an energy, which is said to reside at the base of the spine. The intention of Kundalini practice is to release this energy.

**FELDENKRAIS**

The Feldenkrais Method® uses gentle movement and directed attention to improve ease and efficiency of movement, increase range of motion, and improve flexibility and coordination. This method is based on the principle of becoming aware of one’s habitual movement patterns through movement sequences. The Feldenkrais Method is taught through Functional Integration® and Awareness Through Movement®. Functional Integration is a hands-on approach in which the practitioner subtly positions the client through gentle touching and cueing to allow improved positioning and movement. Awareness Through Movement classes use verbal instruction to guide the participate through movement sequences. Chronic pain can lead to guarded and stiff movement and Feldenkrais can be used to allow improved ease of movement and body awareness.

**POSTURAL RE-TRAINING**

There is considerable debate regarding the link between posture and spinal pain and much of the research indicates that there is either a weak correlation or no correlation between posture and pain. However, most clinicians believe that poor posture is a risk factor to spinal pain and maintaining good posture can benefit other structures of the body. Many rehabilitation programs focus on improving posture. Two of the more well-known methods are the Egoscue Method
and the Gokhale Method. The Egoscue approach focuses on posture therapy and claims to get to the root of your chronic pain by returning your body to proper alignment, function, and balance. Egoscue uses a series of gentle exercises and stretches to return musculoskeletal balance and symmetry back to the body. The Gokhale Method focuses on regaining healthy posture and movement to help restore the body’s structural integrity. This approach emphasizes correcting positioning in everyday movement rather than periodic exercise sessions.

**ALEXANDER TECHNIQUE**

The Alexander Technique is a method that teaches how to find an improved balance in one’s body by releasing unnecessary tension and changing inefficient habits of movement. The philosophy of this technique includes bringing attention to tensions throughout the body that have previously gone unnoticed, and that these tensions are very often the root cause of many common ailments. It is not a series of treatments or exercises, but rather a reeducation of the mind and body. The Alexander Technique allows one to become aware of balance, posture, and coordination while performing everyday actions.

**GRADED MOTOR IMAGERY**

Research has shown that there are altered connections and reorganization of the brains of those who suffer from chronic pain, although it is not clear whether these changes are a consequence of the chronic pain or they may have led to the pain becoming chronic. Treatment of chronic pain has started to include techniques called graded motor imagery, which focus on brain re-training.

Graded motor imagery is a set of rehabilitation processes used to treat pain and movement problems related to an altered nervous system. The three different treatment techniques include limb laterality training, motor imagery exercises, and mirror therapy. These techniques are delivered sequentially or individually.

People suffering from chronic pain often lose the ability to identify left or right images of their painful body parts. Limb laterality training includes viewing photographs of left or right body parts in a variety of postures focused on improving speed and accuracy. Motor imagery involves thinking about a movement but not actually performing that movement. By imagining movements, similar areas of the brain are used as would be used when the person performs the same movement. This technique is commonly used in competitive sports training. Mirror therapy involves movement of the limb inside a mirror-box such that visual feedback of the affected hand is replaced with that of the (reflected) unaffected hand. Mirror therapy is thought to reconnect motor output and sensory feedback and active pre-motor cortices. Mirror therapy has been found to be effective for CRPS and phantom limb pain in particular.
**ART & MUSIC**

Art and music are creative forms of expression and have been used for some time in psychotherapy to help people express their thoughts and feelings. While these creative tools can help chronic pain patients maintain their emotional stability, they can also impact them biologically. Art and music stimulate the healing process by helping to decrease stress and release neurotransmitters that can decrease the experience of pain. Engaging in creative activity can release endorphins, which are the body’s natural pain killers. Many people, when engaged in the creative arts, report that they are less aware of their pain. Art and music are excellent tools for any pain management plan and can be personalized to the taste and preferences of the individual.

**PET THERAPY**

There is good evidence to demonstrate the positive human-animal interactions improve the physical, emotional and psychological lives in people.
Pain Psychology

Living in constant pain can be emotionally distressing and result in depression and anxiety, or can exacerbate existing mental disorders. This does not mean that the person in pain is weak, but rather it is a normal reaction to a stressful situation. Other psychological factors that impact pain and functioning include, but are not limited to, life stress, fear of movement and reinjury, avoidance behaviors, lack of motivation, sleep disturbance, poor social support, substance abuse and negative thinking patterns. Treatment of chronic pain in the biomedical model neglects to address the psychological and social issues that can exacerbate chronic pain.

Pain Psychology is the cutting edge of where psychology meets medicine. Utilizing a combination of Cognitive Behavioral Therapy, relaxation strategies, and education, Pain Psychology can help empower a person to manage their pain more independently by helping them understand their neurological gates in the central nervous system. The foundation of Pain Psychology is the Biopsychosocial Model, which treats the patient as a “whole” and not an injured body part. Often individuals are relieved when exposed to the Biopsychosocial model because they have only been offered few, typically not helpful, tools to help them cope with the emotional and mental distress they have been experiencing. It is important to remember that Pain Psychology is not meant to “cure” the patient, but rather provide strategies to function and thrive with pain.

Cognitive Behavioral Therapy (CBT)

Most physicians could tell you that their patients engage in negative behaviors that harm their health. This may include smoking, lack of exercise, or bad eating habits. What most people don’t understand is what triggers these harmful behaviors. Human beings are always acting on their thoughts, but very often those thoughts are not facts or are generally maladaptive. Cognitive Behavioral Therapy explores the relationship between thoughts, emotion, actions, and pain. People are trained in identifying negative thoughts/behaviors, which can open their neurological gates, and replace them with more adaptive alternatives, that can close neurological gates and increase functioning. These are interventions that patients can learn to do independently. Once the individual has control over their thoughts and emotions, it is easier to control their behaviors.

There are several negative beliefs that can impact the functioning of an individual living with chronic pain.

1. Sinister beliefs are when a person believes that pain is indicative of tissue damage. This belief is associated with fear, which keeps people from engaging in activity that may be beneficial, although physically uncomfortable.

2. Disability beliefs are when a person believes his or her pain is disabling them. The more disabled a person thinks he or she is, the more disabled the person will act. The person is not exaggerating or lying about the condition, but just perceives him or herself
as very disabled and acts accordingly.

3. Reliance on medication or a medical intervention. If someone believes that only a medical intervention will cure them, then they will put their effort into seeking medical interventions and not into trying self-management techniques. They may also experience high levels of distress when their medications are unavailable or treatment they believe will cure them is not authorized. Often people become depressed or anxious when their surgeries or treatments fail.

4. Catastrophic beliefs are when people believe an event or situation is a disaster. For example, a patient may think of a pain flare as an indication that their condition is worsening rather than a temporary elevation in pain levels.

All these beliefs can trigger emotional distress, such as sadness, anxiety, fear, hopelessness, or anger. They can also limit adaptive behavior, such as use of physical and psychological self-management tools. Pain Psychology replaces these maladaptive thoughts with more positive thoughts, which results in more positive behaviors and adaptive coping.

While Cognitive Behavioral Therapy is an appropriate treatment for pain, it can also be used to treat the psychological factors that impact pain including depression, anxiety, and sleep disturbance. A combination of education, behavioral modification, and the changing thinking patterns can help alleviate these psychological issues, resulting in improved functioning. Leaving psychological symptoms untreated can be costly. For example, a patient may be too depressed to be motivated in physical therapy and will be unlikely to benefit from other interventions until the depression is under control. Patients may also be taking higher doses of medication to cope with psychological distress, which can put them at risk for addiction or substance abuse.

**MIND-BODY INTERVENTIONS**

Often people dealing with chronic pain feel that their mind and body are at war with each other and this causes stress for the individual. Modern medicine has known for some time that stress can be harmful for the body. It increases heart rate, breathing rate, blood pressure, releases stress hormones, and impacts the digestive system. Short term stress is not necessarily harmful, but long term stress, like the stress associated with living with chronic pain, can negatively impact the mind and body. Stress reduction is a critical component to pain management. There are numerous mind-body interventions including relaxation, meditation, guided imagery, biofeedback, hypnosis, and art and music. These treatments can be used individually or as part of Cognitive Behavioral Therapy.

Many people feel that they are relaxing when they are sitting in front of the TV, but active relaxation takes effort and time. Active relaxation strategies can harness the mind in order to harness the body. The mind is a powerful tool and being able to relax it at will is one of the most important skills a person with chronic pain can learn.
ACPA offers a five-minute relaxation video. This five-minute relaxation exercise can help you let go of physical stress and begin to reduce your sense of suffering. The relaxation video can be found at http://www.theacpa.org/Relaxation-Guide.

**Mindfulness-Based Stress Reduction (MBSR)**

There are a variety of meditative practices; the most studied one for chronic pain being mindfulness-based stress reduction (MBSR). It is a variant of meditation that has been applied to stress reduction and created by biologist Jon Kabat-Zinn. In recent years, studies have found that patients who used MSBR reduced medication use, increased their activity levels, and felt increases in self-esteem. MSBR cultivates a greater awareness of the relationship between the mind and body. This awareness can highlight, in a non-judgmental manner, how our negative thinking and emotions adversely impact our actions and our health. This tool is an excellent supplement to Cognitive Behavioral Therapy, but also a treatment intervention on its own. For more information on Mindfulness, read “Mindfulness for Beginners: Reclaiming the Present Moment-and Your Life,” by Jon Kabat-Zinn.

**Guided Imagery**

Another way to relax the mind is to use guided imagery. This technique uses the imagination to take the mind to a relaxing place, such as the beach or the forest. Imagery can also be used to increase self-confidence by helping patients imagine themselves being successful at a task or reaching their goals. This technique of visualizing success has often been used by sports psychologists to help athletes improve their performance.

**Biofeedback**

The above strategies can help the psychological components of stress, but there are also strategies that target the biological components of stress. Stress has several biological features, like increased heart rate and muscle tension. Biofeedback uses feedback from sensors and a computer to give information about the body’s stress response and then teaches the patient to control the stress response. This may involve consciously relaxing muscles or changing breathing. Biofeedback has been particularly helpful for headaches and chronic pain, which often causes increased pain due to muscle tension and fatigue.

**Hypnosis**

Hypnosis is a state of deep relaxation that involves selective focusing, receptive concentration, and minimal motor functioning. A National Institutes of Health Technology Panel found strong support for the use of hypnosis for the reduction of pain. Individuals can be taught to use hypnosis themselves (self-hypnosis), and the use of self-hypnosis can provide pain relief for up to several hours at a time.
Pain does not just impact the individual living with it; it impacts everyone around the individual. This includes family, friends, employers, and coworkers. The individual with chronic pain may be more reliant on physical support from others, but also in need of the emotional support. They will actually function better if they have enough support. When someone has an acute injury, their support system is quick to offer help. However, when the pain does not resolve in a few months, the support system starts to become strained and dwindles. Friends and family return to their lives and the person in pain feels like they are struggling alone. Also, being in pain can be an emotional roller coaster and this can negatively impact communication with loved ones, which strains relationships.

There are many ways to build support.

1. Communicating and reaching out to others. It is important to start with expressing feelings, needs, and desires. Often we assume others know what we need or want and we become frustrated when they don’t give it to us. One must be careful to not assume and start by expressing themselves clearly.

2. Reaching out to new communities, such as support groups, neighbors, churches or other religious organizations. This can be challenging at first, but can really be beneficial. One must be careful when choosing a structured chronic pain support group. Some groups can feel negative depending on the format and it is important to find groups that highlight successes and strengths and explores coping. These groups can be in person or online.

3. Providers can also be part of the support system. This includes doctors, nurse case managers, and mental health practitioners.

There are a number of mental health therapists who offer psychotherapy and behavioral therapy for persons with chronic pain and who are specially trained and licensed by the state in which they practice.

- Psychologists are doctors who have a Doctor of Philosophy (PhD) in Clinical Psychology or Counseling Psychology or Doctor of Psychology (PsyD) and specialize in human behavior and emotional health. They have training in working with individuals, couples, and families and do so either in group or individual sessions. They can also administer and interpret psychological tests. They have expertise in dealing with most emotional and behavioral problems. In some states, psychologists can prescribe medications for emotional problems.

- Social Workers have Masters Degrees (MA or MS) and are sometimes called Licensed Clinical Social Workers (LCSW). They receive specialized training in how people function in their environment and solve personal and family problems. Some also have experience in case management and can assist in finding government and local resources in the community that meet the needs of people with pain.
• Masters-Level Counselors have Masters Degrees (MA or MS) in either clinical or counseling psychology. They are sometimes called Licensed Marriage & Family Therapists or Licensed Professional Counselors. They have specialized training in dealing with individuals and families particularly in relationship problems.

It is important for the public to realize that few doctoral and masters programs offer courses in pain psychology and not all providers who treat chronic pain are focused on improving functioning. Some providers are simply offering support during difficult transitions while others are inadvertently reinforcing negative behaviors. The most common example is that a mental health provider may discourage a chronic pain patient from engaging in a certain activity because it is uncomfortable and distressing. A provider trained in Pain Psychology focuses on teaching skills so that the patient can engage in more activity, ask for support when they need it, and set realistic goals for themselves. In order to find a provider who is truly trained in Pain Psychology, it is important to ask them three questions:

1. Do they understand the Gate Control Theory of Pain?
2. Do they understand the biopsychosocial model?
3. Are they familiar with working with multidisciplinary teams? A good indication of this would be that the provider is associated with a functional restoration program or they are part of a clinic that includes biopsychosocial interventions.

In conclusion, chronic pain can impact every corner of a person’s life, not just their physical functioning. The longer the pain condition lasts, the more emotional and mental distress a person tends to feel. This distress can make pain worse over time and decrease functioning. Chronic pain is best treated by the biopsychosocial model, which addresses the emotional, mental, and social aspects of pain as well as the physical. A mental health practitioner is an essential component of the multidisciplinary team. These interventions lead to less stress, more positive behaviors and a focus on functioning rather than cure.

Choosing to engage in a multidisciplinary approach and focus on managing pain rather than curing it is not “giving up.” It is simply choosing to live life to the fullest and find ways to thrive, despite pain. With the right mindset and coping strategies, a life with pain can still be a life full of hope and joy.
MEDICATIONS IN GENERAL

HOW MEDICATIONS CAN HELP & HARM

Many people with chronic pain are able to manage adequately without medications and can function at a near-normal level. Others find that their overall quality of life, in terms of comfort and function, is improved with medications.

However, even the most potent medications used for pain rarely completely eliminate pain but rather, may reduce the severity of pain. As such, medications are rarely adequate alone and should be considered as an optional part of a comprehensive approach to pain management and functional improvements.

While medications can help relieve symptoms, they also can cause unpleasant side effects that at a minimum can be bothersome and at their worst can cause significant problems including death. These side effects can often be avoided or at least managed with the help of a health care professional.

It is important that the health care professional be aware of all prescription medications, over-the-counter (OTC) medications, and fitness, nutritional and herbal supplements that are being taken for general health or for pain or other medical conditions to ensure these are being taken appropriately and safely and that they do not interact with other prescribed medications or therapies. Some substances and drugs may cause serious side effects if they are combined with other medications. Even over-the-counter and herbal preparations have possible side effects and the potential to cause serious interactions with other nonprescription and prescription medications and with each other. These include various OTC supplements and vitamins, homeopathic remedies, items grown in a home garden or bought in a store, and other “substances” such as caffeine, alcohol, tobacco, and even marijuana and illicit drugs.

It is strongly advised that all current medications in the original bottles or boxes or tubes and other items that are taken (including non-prescribed medications, vitamins and supplements) be taken to any appointments with the health care professional. It is essential that the health care professional be told about all substances that are being taken (even if they are not legal) or if obtained from someone other than the prescriber. Even medications that may be used only occasionally such as cough and cold medications can have significant medication interactions.

People with any medical condition including pain should keep a list of all of their medications in their wallet or purse. This list will be useful in an emergency.
The following Internet links may be helpful:

- A *Guide to Safe Use of Pain Medicine* from the Food and Drug Administration (FDA) is available at:
  

- FDA Educational Resources: The Center for Drug Evaluation and Research (CDER) maintains a collection of educational materials on topics related to buying and using medicine safely.

  [http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm296593.htm](http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm296593.htm)

Individuals who take medications should know what medications they are taking, why they are taking them, when they’re taking them, how they are to take them, which should be taken every day, and which should be taken just when needed. Optimal pain relief depends on knowing how much and how often each medication should be taken and whether to take the medication before, with, or after meals or at bedtime. Medications can be confusing, especially if taken for more than one condition. The type of medication and dose may vary depending on the medical condition, body size, age, and any other medications that are taken. It is important to understand the potential side effects of the medications and how these can be prevented or managed effectively. Because of the possibility of interactions between drugs, some medications should not be taken together or should be taken at different times during the day to avoid unwanted reactions. This information can be obtained by reading the labels on the medication containers and asking the health care professional or pharmacist. If you’re already taking prescription medications, do not take any OTC medication without consulting your health care professional.


The label on the medication bottle may show a brand name (for example, Tylenol®) or the generic name (for example, acetaminophen) or both. It is often less expensive to buy medications by their generic name rather than by the brand name. The health care professional can be asked to prescribe generic rather than brand-name drugs to hold down the cost of prescription medications. The color and shape of the pill may be different, but FDA-approved generic drugs are considered to be interchangeable with brand name drugs. Generic drugs are required to show the same quality and effectiveness as brand name drugs before they are approved by the FDA. Any noticeable differences in the response to a drug if switching from one drug to another or a brand drug to a generic drug should be discussed with a health care professional. It is essential that the dose and directions written on the medication label be followed. The dose should not be changed without consulting the health care professional and medications that have been prescribed for someone else should never be taken.
MEDICATIONS AND CHRONIC PAIN

Prescription medications are lawfully available only from a health care professional licensed to prescribe them. Prescription medications should only be taken by the individual prescribed them by a licensed professional. Do not use, buy, or sell prescription drugs from family members, friends, or others.

The use of analgesics (pain relievers) and other medications is a common method of chronic pain treatment. Pain medications can be helpful for some patients with chronic pain, but they are not universally effective. It is important to remember that each person may respond in a different manner to any medication. In fact, in some individuals, pain medications may actually worsen their symptoms over time or cause unwanted or dangerous side effects.

Medication-related problems would rank fifth among the leading causes of death in the United States if they were considered a disease. In particular, the overuse, misuse, and abuse of opioid (narcotic) pain medications has now become a national issue. Deaths due to overdoses of opioid prescription drugs have risen sharply and now outnumber all other causes of accidental death including motor vehicle accidents. The abuse of prescription opioid pain medications now ranks second - only behind marijuana - as the nation’s most prevalent drug problem.

Short-term use of opioid medications for most people with acute pain is rarely worrisome, although side effects are most problematic while initiating treatment and tend to diminish with prolonged use. Some people though are more susceptible to misuse and abuse when started on opioids.

Prolonged use of opioids past a few weeks increases the possibility over time of adverse reactions such as gastrointestinal distress including constipation, internal organ problems, balance troubles, hormone problems, sexual dysfunction, and memory and concentration problems. After prolonged use, an increase in pain sometimes occurs that is thought to be due to opioids causing changes in the peripheral and central nervous systems over time, a phenomenon referred to as opioid-induced hyperalgesia.

A realistic goal when using medications is usually partial rather than full relief of pain symptoms.

Therefore, each person with chronic pain should be medically managed individually and the decision to use and continue pain medication should be determined by weighing benefit vs. harm and comparing with alternative medications and nonpharmacologic techniques while factoring in the cost, potential side effects, and the person’s other medical problems. Reliance on medication alone is rarely satisfactory. Implementing a balanced approach incorporating physical rehabilitation and self-management strategies is generally more effective in restoring one’s ability to function most fully.
In general, people who begin using other methods to relieve pain (such as those taught by the ACPA) may be able to reduce or discontinue medication use.

**IF MEDICATIONS ARE NOT RELIEVING PAIN**

Successful treatment reduces a person’s distress and restores health, function, and well-being so he or she can resume full participation in everyday life (although adjustments may need to be made).

If an individual has been taking pain medicine every day for a long time and it doesn't seem to reduce pain and allow the person to be more functional, the treatment plan should be re-evaluated. Often a treatment is unsuccessful because it needs to be changed.

It is important to periodically evaluate the big picture and ask how life is going overall. Even if months or years have passed, people with pain should tell their health care professionals whether they have regained the ability to engage in and enjoy everyday life activities. If not, it is time to discuss how to change the treatment plan. A minor tweak may be all that is needed but often bigger changes such as a more comprehensive approach may be required.

There are many other methods for pain relief besides pain medications. Symptoms can usually be greatly relieved by learning and strengthening self-care skills. Although some self-care methods can be self-taught, they often require instruction and supervision by an experienced peer or professional at the beginning.

Multidisciplinary pain programs and organizations like the ACPA teach many specific self-care techniques that can help to reduce pain. Mastering them may allow the person with pain to find relief and minimize the things that often make pain worse, such as stress, inactivity, uncertainty, feeling powerless, being out of shape, lack of sleep, boredom, fear, and anger, which are all normal human reactions to pain and life disruption.

According to scientific studies, there are several non-invasive medical treatments that often work as well or better than pills, patches, injections, and surgery. These treatments usually have fewer side effects, are less hazardous, and are more likely to restore a satisfying everyday life. A health care professional may be able to prescribe these treatments to help relieve the pain while the patient learns the self-care approaches that can help get life back on track.

Changing medications should always be done under the direction of a health care provider because it can be dangerous as well as uncomfortable to stop some medications too rapidly and without medical supervision. This is particularly true in those taking high doses or more than one medication. See the next section on “Weaning Off of Pain Medications.”
WEEANING OFF OF PAIN MEDICATIONS

In today’s health care system, it is sometimes easier to start taking medications than to stop taking them. This can often lead to a person taking multiple and possibly mechanism-overlapping medications. The questions to discuss with a health care professional are: Are the medications actually making a difference? Are they making the person’s life better and improving function? Are the benefits worth any side effects and negative effects? In other words, taking pain medications is a choice that each person must make by weighing the benefits vs. the risks.

When the risks appear to outweigh the benefits of taking a pain medication, reducing the dose and ultimately discontinuing the medication should be considered. This is called weaning or tapering (sometimes referred to as “detoxification” in certain cases with opioid medications). The goal of weaning down the dose is to safely discontinue medications that do not seem helpful in reducing pain while allowing the body to adjust and monitoring for negative effects. Oftentimes, people discover they feel better taking lower doses, fewer medications, or not taking medications at all.

It is best to check with the health care professional before altering the medication regimen by taking less of the medication or stopping it. It is dangerous to abruptly stop taking some medications (sometimes referred to as going “cold turkey”). Because the body develops “physical dependence” to some medications when they are taken regularly, abrupt withdrawal or too rapid a reduction in the dose of these medications can be very uncomfortable or even hazardous to one’s health. It depends on the type of medication, how much, and for how long the medication has been taken.

Some medications may be safe to stop abruptly:

- A medication that is taken for just a few days or only taken once in a while (e.g., once a week).
- Medications that are prescribed when necessary (prn - as needed, not taken regularly).
- Some medications that do not produce physical dependence (e.g., acetaminophen, nonsteroidal anti-inflammatory drugs [NSAIDs – like aspirin, ibuprofen and others]).

Some medications always require medical supervision when stopped:

- Opioids that have been taken in regular daily doses for several days or longer.
- Benzodiazepines, muscle relaxants, antidepressants, and anticonvulsant medications that have been taken in regular daily doses for several days or longer.
- Barbiturates taken frequently for headache (butalbital).
The safest approach is to always talk to a health care professional before making any medications changes. Following are suggestions that will guide the discussion:

- Provide the health care professional with a list that includes the following information about all over-the-counter (OTC) and prescribed medications that are being taken:
  - Name of the medication
  - Dose (e.g., “325 mg”)
  - Directions on the bottle (e.g., “take 2 tablets by mouth every 6-8 hours as needed for pain”)
  - Understanding of why the health care professional prescribed this medication – what it is supposed to do.
  - Actual usage: How often and how much of the medication has the person actually been taking.
  - What has the individual noticed about its effects – the good AND bad effects?
- Bring the bottles of all of the OTC and prescribed medications to the appointment so the health care professional can see the labels and examine the pills.
- The health care professional should answer the following questions about each medication, and the person with pain should write down the answers beside the name of each medication during the visit:
  - Is the medication essential?
  - If it is essential, how often should it be taken?
  - If the decision is made to stop taking the medication for a while, can it be abruptly stopped or should the dose be gradually weaned down?
  - If the dose should be weaned down:
    - How can this be done safely?
    - How uncomfortable will this process be?
    - What symptoms are danger signs and which are simply a bother?
    - How long will it take?
  - Are there specific instructions on how to reduce the dose?
  - Will the health care professional help with the weaning process?
  - How often does the person with pain need to see the health care professional during the weaning process?

Weaning off of medications may be complicated by the potential for increased levels of pain that may accompany dose reduction, but can be done safely under medical supervision. The health care professional determines the rate at which the dose is reduced and adjustments can be made as necessary. For example, reasonable opioid weaning protocols suggest decreasing pill intake by 10-20 percent per week, as tolerated. Hydration (drinking water), relaxation, and emotional support are all important to enhance the likelihood of success.

Sometimes weaning or discontinuing medication (especially opioids) is most safely accomplished under the close supervision of a specialist (such as a pain or addiction medicine specialist) in a medically-supervised detoxification program to prevent complications and severe withdrawal symptoms.
Symptoms of withdrawal from opioids can include:

- Worsening of pain
- Sleeplessness
- Anxiety
- Sweating
- Agitation
- Stomach cramps
- Nausea, vomiting, diarhrrea
- Body aches (flu-like symptoms)
- Feeling as though the skin is “crawling”
- Muscle cramps

Prescription medications recommended by your healthcare provider that can help diminish symptoms of opioid withdrawal include:

- Alpha-2 agonists (clonidine) – blood pressure needs to be monitored while taking this medication
- Muscle relaxants (methocarbamol, Lioresal, others)
- Stomach relaxants (dicyclomine)
- Anti-inflammatory pain relievers (ibuprofen, naproxen, others)
- Sleep aids (trazodone, amitriptyline, hydroxyzine, others)
- Anti-anxiety agents (phenobarbital*, diazepam* (but should be avoided due to abuse potential), hydroxyzine, others)

On occasion, alternative opioids may be substituted on a temporary basis during detoxification.

These include:

- Methadone*
- Buprenorphine*

*May be habit-forming, so use is limited to short term

**Medication Disposal:** Once the person with pain has discontinued a medication, it is important to dispose of the remaining supply appropriately. For more information, review the FDA website: Medication Disposal: Questions and Answers at [http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/EnsuringSafeUseofMedicine/SafeDisposalofMedicines/ucm186188.htm](http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/EnsuringSafeUseofMedicine/SafeDisposalofMedicines/ucm186188.htm).
**WARNING ABOUT INTERNET MEDICATION PURCHASES**

Buying medication over the Internet may seem like a good way to save money, but up to 96 percent of online drugstores don’t meet U.S. pharmacy laws or practice standards. Standards for protecting the public are available from the National Association of Boards of Pharmacy (NABP - http://www.nabp.net/).

Internet sites may purport to be legitimate or in a country with drug laws comparable to the United States (e.g., Canada) but may (a) not be located in that country; (b) be located in that country but dispense prescriptions from another country that has no comparable law; (c) not handle and store medicines in a manner that maintains potency and shelf life; or (d) purchase medicines from dubious sources, including knowingly or unknowingly selling counterfeit medicines that may contain amounts of the expected pharmaceutical ingredients that vary from those stated, may contain other unnamed pharmaceutical ingredients, may contain no active pharmaceutical ingredients, or may contain toxic chemicals or microbial contaminants.

<table>
<thead>
<tr>
<th>Patient Tips for Safe Medication Purchasing*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Purchase all medications from state-licensed pharmacies located in the United States.</td>
</tr>
<tr>
<td>2. When purchasing medications from online pharmacies, perform the following checks:</td>
</tr>
<tr>
<td>a. Ensure that the retailer is in good standing and is licensed to dispense medications in the United States. A pharmacy’s status can be verified by contacting the appropriate state board of pharmacy or the National Association of Boards of Pharmacy (NABP) at <a href="http://www.nabp.net">http://www.nabp.net</a> or calling 1-847-391-4406.</td>
</tr>
<tr>
<td>b. Examine the site to see if it has posted the Verified Internet Pharmacy Practice Sites (VIPPS) Accreditation Program seal of approval. The NABP established VIPPS to ensure that online pharmacies meet all appropriate state and federal regulatory and licensing requirements for proper operation. A list of VIPPS approved pharmacies can be found at <a href="http://www.vipps.info">http://www.vipps.info</a>.</td>
</tr>
<tr>
<td>c. All legitimate online pharmacies will:</td>
</tr>
<tr>
<td>i. Make available a licensed pharmacist to answer any medication related questions you may have.</td>
</tr>
<tr>
<td>ii. Require a prescription from a physician or other licensed health care professional who can prescribe medications.</td>
</tr>
<tr>
<td>iii. Provide accurate contact information for customer inquiries.</td>
</tr>
<tr>
<td>3. Be familiar with all of your medications, especially their physical characteristics such as size, color, shape, smell, hardness, taste, or texture. Speak with your pharmacist immediately if anything appears suspicious after refilling a medication.</td>
</tr>
<tr>
<td>4. Be observant for any altered or open medication containers, variations in packaging, raised or hazy printing, flat printing (instead of imprinting or embossing), missing expiration dates or lot numbers on the package, or sticky residue on the container. All are signs of potential package tampering.</td>
</tr>
<tr>
<td>5. Carry a list of all medications you currently take (prescription, over-the-counter, herbal, dietary, and vitamin) with you when you visit your doctor or pharmacist so that they can screen for appropriate use and drug-drug interactions. Keep this list on your person at all times.</td>
</tr>
<tr>
<td>6. Be proactive. If you have questions about your medications, ask your pharmacist or physician.</td>
</tr>
</tbody>
</table>
MEDICATION IDENTIFICATION

It is always very important to be able to visually identify medications. If a pill cannot be identified, it is best to contact a pharmacist for assistance.

Pill identification resources can be used to confirm that the medication is correct. The most definitive tool for identifying a pill is the imprint code that can be on one or both sides of the pill.

Drugs.com has a Drug Pictures Database at: http://www.drugs.com/pill_identification_drug_picture.html

Drugs.com also has a Pill Identifier at http://www.drugs.com/pill_identification.html where there is a Pill Identification Wizard. After clicking on “I Agree,” the drug name, imprint(s), shape, or color can be typed in.

DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts). This Web site provides a standard, comprehensive, up-to-date, look-up and download resource of medication content and labeling found in medication package inserts. The website can be found at http://dailymed.nlm.nih.gov/dailymed/index.cfm.

The National Library of Medicine of the National Institutes of Health provides the following Pillbox website and can be used to find rapid identification a reliable information regarding medications. Pillbox's image explorer is a photo album for pills. The website can be found at http://pillbox.nlm.nih.gov/pillimage/search.php.
**MEDICATION SIDE EFFECTS, DRUG ALLERGIES, & DRUG INTERACTIONS**

Consumers and health care professionals can now go to a single Web page on the U.S. Food and Drug Administration's Website to find a wide variety of safety information about prescription drugs titled Postmarket Drug Safety Information for Patients and Providers at [http://www.fda.gov/Cder/drugSafety.htm](http://www.fda.gov/Cder/drugSafety.htm).

**MEDICATION SIDE EFFECTS**

Every person is unique in how they respond to a particular medication. Side effects are not uncommon but can usually be managed or tolerated. However, some side effects may be harmful to health or even life-threatening. **It is important to notify a health care professional of any medication side effects.**

When taking any medicine, it is important to be aware of any change in the body and to tell a health care professional if something unusual happens.

It may be hard to know if an adverse reaction is caused by a medical problem or by a medicine. The health care professional will want to know all medications that are being taken, when the symptoms started, and whether they are different from other symptoms that have occurred from an illness.

The following are some common adverse drug reactions that might be noticed (this list is not all-inclusive):

- Skin rash
- Itchiness (pruritus)
- Headache
- Dry mouth
- Easy bruising or bleeding
- Edema (swelling)
- Stomach distress - pain, nausea / vomiting
- Diarrhea or constipation

- Drowsiness
- Confusion, mental / behavioral changes
- Anxiety
- Breathing difficulties
- Abnormal heartbeat
- Increased blood pressure
- Urinary retention

**DRUG ALLERGIES**

Drug allergies should be documented appropriately in the medical record and should include a description of the reaction. Some medications can trigger an immune response in individuals with a drug allergy. In other cases, as in a type of reaction to drugs such as aspirin or niacin, allergy-like symptoms may occur but do not involve the immune system. Like many other allergies, a drug allergy can cause a range of responses from a mild rash to life-threatening effects on many body systems.
When reviewing drug allergy information with the health care professional, it is important to differentiate drug intolerance or side effects (e.g., stomach upset) from true allergic reactions.

Some pain medicines such as opioid analgesics (e.g., morphine and meperidine) can stimulate histamine release that may seem like an allergic reaction. Common symptoms include lightheadedness, dizziness, a fast heart rate, facial flushing, sweating, or itching. In some cases, the symptoms can be treated with an antihistamine and the opioid analgesic can be continued. If symptoms are severe, an opioid that is not associated with histamine release or a non-opioid alternative may be substituted.

Allergic reactions to drugs can occur within hours or days to as much as three weeks after drug treatment is started. The person with an allergy may experience itching, welts, swelling, and wheezing. An uncommon effect of drug allergy is a life-threatening reaction called anaphylaxis, which is a severe whole-body allergic reaction. Symptoms of anaphylaxis develop very quickly, usually in a matter of minutes. Symptoms may include abdominal pain or cramping, anxiety, confusion, difficulty breathing, dizziness, hives/itchiness, nausea/vomiting, skin redness, slurred speech, and wheezing.

It is important to notify the health care professional immediately or possibly seek emergency medical help depending on the symptoms.

More information about drug allergies can be found at the Mayo Clinic web site at

http://www.mayoclinic.org/diseases-conditions/drug-allergy/basics/definition/CON-20033346

Other sources of information include emedicinehealth or on the American Academy of Allergy, Asthma & Immunology (ACAAI) website at

http://acaai.org/allergies/types/drug-allergies

**DRUG INTERACTIONS**

A drug interaction occurs when the amount or the action of a drug is altered by the administration of another drug or multiple drugs. It is wise for individuals to try to use the same pharmacy for all of their prescriptions so that the pharmacist can screen health information and current medications to prevent drug interactions. Drug interactions will be discussed in later sections that are more drugs specific.
**Off-Label Medication Use**

Prescription medications are often used for conditions not listed on their FDA-approved labels. This is called off-label use of the medication. It is legal for health care professionals to use a medication “off-label,” but the insurer, health plan, or pharmacist may question its use as recommended by the health care professional. Ask the health care professional to explain that the medication is being prescribed off-label and for what reason.

A drug is used off-label when the health care professional prescribes that drug for a medical use or a diagnosis other than the one that received FDA approval for at a dose or dosing schedule that differs from the approved label. Off-label prescribing is a commonly used and accepted medical practice. These drugs do have FDA approval, but for a different use. For example, health care professionals frequently prescribe FDA-approved anticonvulsant medications for persons who do not have seizures, but who may have nerve related pain or an antidepressant to help with sleep; or prescribe an antihistamine to reduce anxiety.

Drugs can have more than one effect. Because of this, a drug may be used for a variety of unrelated conditions. For example, aspirin is used to reduce inflammation and pain in arthritis but is also used as a blood thinner to prevent heart attacks. Thus, it may be confusing to think of aspirin as an “arthritis” or “pain” medicine alone.

Similarly, many of the medicines used to treat chronic pain were originally designed and marketed for unrelated conditions such as seizures, cardiac arrhythmias, and depression. The fact that a health care professional recommends such a drug for pain treatment does not mean that the person with pain has epilepsy or some other condition. The same is true with antidepressants; the fact that they are prescribed for chronic pain does not mean that the health care professional has made a diagnosis of depression.

The FDA (http://www.fda.gov) allows drugs to be sold and advertised for specific conditions where data prove the drug is safe and effective for its intended use. Once on the market, drugs can be prescribed for off-label usage for any condition, particularly those with clinical data supporting effectiveness. The process of obtaining FDA-approval for another use of the medication can be costly, so a company may not be able to fund research studies to prove all the uses for a drug. This approval issue is especially true if the medication is no longer protected by a patent and other companies can sell it.

Further discussion about off-label medication use can be found at


http://www.webmd.com/a-to-z-guides/features/off-label-drug-use-what-you-need-to-know
CLINICAL TRIALS

Clinical Trials (see http://clinicaltrials.gov for more information) are health-related medical research studies in human beings that follow a pre-defined plan. Choosing to participate in a clinical trial is an important personal decision. It is often helpful to talk to a physician or other health care professional, family members, or friends about deciding to join a trial. The results of the clinical trial may lead to new treatments or therapies becoming available for many people coping with chronic pain.

Information about Learn About Clinical Studies can be found at http://clinicaltrials.gov/ct2/about-studies/learn

The Clinical Trials Transformation Initiative (CTTI) is a public-private partnership to identify practices that will increase the quality and efficiency of clinical trials at http://www.ctti-clinicaltrials.org/ states that it is “Here to identify and promote practices that will increase the quality and efficiency of clinical trials.”
MEDICATION TYPES FOR THE TREATMENT OF PAIN

There are four major types of medications used in the treatment of chronic pain:

1. **Non-opioids**: Aspirin, NSAIDs, and acetaminophen.

2. **Opioids (also called narcotics)**: Examples of opioids include but are not limited to morphine, codeine, hydrocodone, oxycodone, and methadone. Tramadol and tapentadol are not true opioids biochemically but work similarly to opioids primarily on the same receptors.

3. **Adjuvant analgesics**: Medications originally used to treat conditions other than pain but may also be used to help relieve specific pain problems; examples include some antidepressants and anticonvulsants.

4. **Other**: Medications with no direct pain-relieving properties may also be prescribed as part of a pain management plan. These include medications to treat insomnia, anxiety, depression, and muscle spasms.

Some medications are available over-the-counter without a prescription, and some require a prescription.

Prescription medications are lawfully available only from a licensed professional. The individual should only use medication that was prescribed for him or her by such a professional.
NON-PRESCRIPTION PAIN RELIEVERS

OVER-THE-COUNTER (OTC) PAIN RELIEVERS

OTC drugs are those drugs that are available to consumers without a prescription. A trip to the local drug store reveals numerous tablets, suppositories, patches, sprays, creams, lotions, and ointments, all with claims of providing pain relief.

The following article is from the FDA: Over-the-Counter Medicines: What's Right for You? It can be found at


The two most common types of OTC pain relievers are acetaminophen and NSAIDs.

Acetaminophen is an active ingredient found in more than 600 OTC and prescription medicines, including pain relievers, as well as for pain relief and fever reduction in cough suppressant and cold medication combinations.

NSAIDs are common medications used to relieve fever and minor aches and pains. They include aspirin, naproxen, and ibuprofen. They can be found alone and in many combination medicines taken for colds, sinus pressure, and allergies. They act by inhibiting an enzyme that helps make specific chemicals in the body responsible for pain and inflammation.

The traditional OTC pain group currently includes aspirin (Bayer®), acetaminophen (Tylenol®), naproxen (Aleve®), ibuprofen (Advil®, Motrin®IB), and various combinations. Most analgesic OTC drugs are based on one of these FDA-approved ingredients. Many manufacturers add other ingredients in an effort to tailor the medication to particular symptoms. For example, a pain reliever, such as acetaminophen, and an antihistamine, such as diphenhydramine (Benadryl®) may be combined and sold as a nighttime pain and cold medication because the antihistamine induces drowsiness. Adding a decongestant makes a medication marketable for sinus problems.

When using OTC drugs, be aware that the brand name is often specific to the manufacturer and may not indicate the product’s active ingredients. Look for active ingredients, usually listed by generic name, on the label. For example, this will provide information that Tylenol® PM not only contains acetaminophen but also contains diphenhydramine hydrochloride.

Some OTC medications are labeled “extra strength.” This usually indicates that the item contains more amounts (e.g., milligrams) of drug per dosage unit (e.g., tablet) than the standard product by the same manufacturer.

The key to the effective use of OTC medications is to understand the drug(s) that is taken and the maximum safe dosage of all ingredients. This requires reading the medication label and/or...
discussing OTC medications with the health care professional or a pharmacist before taking them, especially if prescription medications are also taken. The selected OTC medication should contain an appropriate amount of the drug needed to treat the symptom(s) and should not include medications or ingredients that are not needed.


THE SAFETY OF OTC MEDICATIONS

OTC medications rarely cause significant health problems when used occasionally. In certain situations, however, they can be dangerous. This is especially true if used in combination with prescription medications or in dosage amounts that are higher than recommended.

As mentioned, the most common OTC medications used for pain are NSAIDs and acetaminophen.

The NSAIDs (aspirin, ibuprofen, and others) can reduce the stomach’s protective mucous layer and natural protection against irritation of the stomach lining from stomach acid. Thus, they can be associated with gastric (stomach) bleeding, and such risk increases with age, dose, use with certain medications (such as warfarin), and duration of use. They also may cause kidney failure in people with damaged kidneys, liver disease, and certain other conditions such as high blood pressure. Use with diuretics can increase this danger. Finally, the use of these medications has been associated with increased risk of cardiovascular disease (CVD), particularly in patients with risk factors for CVD or a prior history of CVD. The risk of heart attack or stroke can begin is always the first week of NSAID use and the risks may increase with longer NSAID use. Individuals with any of these conditions should check with their health care professional before taking any NSAID medication. The following ACPA video on this topic may be helpful; view at http://www.theacpa.org/NSAIDs-safety.

The American Heart Association (AHA) recommends health care professionals change their approach to prescribing pain relievers for patients with or at risk for heart disease. Research in the AHA journal Circulation found that heart attack survivors who take NSAIDs face a significantly increased risk of a second heart attack or death.

OTC pain medications can be useful and effective. Even though they are considered safe enough to be dispensed without a prescription, remember they are real medicines. There is often a mistaken belief that because the medication can be obtained without a prescription, it is safe and without potential for harm. Nothing could be further from the truth.

For instance, acetaminophen is the medication most involved in fatal overdoses, but it is important to consider the relative risk when compared to taking NSAIDs for chronic pain. For example, OTC acetaminophen has been proven to be safe and effective when used as directed. However, when the labeled dosing of acetaminophen is exceeded (overdose), serious liver damage may occur. In contrast, gastrointestinal bleeds, injury, and death from NSAIDs have been known to occur at labeled doses, especially in cases where they are used chronically.

American Chronic Pain Association
Copyright 2016
“The Food and Drug Administration (FDA) advises consumers to follow directions when using common pain and fever reducers. **Using more than recommended can cause serious injury.**” The active ingredients, acetaminophen and NSAIDs, are safe and effective when the label directions or the advice from a health care professional or pharmacist are followed. This is especially important when taking both OTC medications and prescription medications. “Using Acetaminophen and Nonsteroidal Anti-inflammatory Drugs Safely” can be found at [http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/UnderstandingOver-the-CounterMedicines/SafeUseofOver-the-CounterPainRelieversandFeverReducers/ucm164977.htm](http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/UnderstandingOver-the-CounterMedicines/SafeUseofOver-the-CounterPainRelieversandFeverReducers/ucm164977.htm).
**ACETAMINOPHEN - SPECIAL WARNINGS**

Acetaminophen (the ingredient in Tylenol® and a number of other OTC pain and cold remedies) can be toxic to the liver, especially with heavy alcohol use or in those with liver problems, even at fairly low doses. The FDA also issued a warning for rare, but possible skin reactions: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP).

Since acetaminophen is contained in many prescriptions, individuals need to pay close attention to their total daily dose of acetaminophen.

The current recommendations are that self-treating users take only the recommended maximum daily dosage of 3,000 mg. Patients may take a higher daily dosage—up to 4,000 mg—if their health care professional instructs them to do so. The maximum daily dosage may be decreased for patients who consume alcohol or for those with elevations in liver enzymes.

**Acetaminophen Overdose and Liver Injury - Background and Options for Reducing Injury**


The abbreviation “APAP” on the label of a drug means the medicine contains acetaminophen. However, not all OTC and prescription drugs with acetaminophen will say APAP, so it is important to ask the health care professional or pharmacist what ingredients are in prescribed medicines before taking them. Some prescription medications have acetaminophen in them (see the list on the next page). For example, the label on the bottle may read, Hydrocodone/APAP 5/325. The amount of acetaminophen in each tablet is the number after the forward slash. In this case, each tablet has 325 milligrams of acetaminophen in it. The amount of acetaminophen from all sources, both from prescription and OTC medications, must be added together when calculating how much acetaminophen is taken daily.

When acetaminophen is used in combination with NSAIDs, increased risk of developing kidney abnormalities exists. However, this adverse event is often only seen with long-term use.

In January 2011, the U.S. Food and Drug Administration (FDA) asked drug manufacturers to limit the strength of acetaminophen in prescription drug products, including combination acetaminophen and opioid products, to no more than 325 mg per tablet, capsule, or other dosage unit. Then in January 2014, the FDA recommended that health care professionals discontinue prescribing and dispensing prescription combination drug products that contain more than 325 mg of acetaminophen per tablet, capsule, or other dosage unit. The FDA has stated that limiting the amount of acetaminophen per dosage unit in prescription products may reduce the risk of severe liver injury from acetaminophen overdosing.

Please visit the FDA website for more information on acetaminophen dosing: http://www.fda.gov/Drugs/DrugSafety/ucm239821.htm http://www.fda.gov/Drugs/DrugSafety/ucm381644.htm
Acetaminophen is an ingredient in many OTC and prescription medicines. Here are some - but not all - of the most common OTC and prescription drugs that contain acetaminophen. The amount of acetaminophen varies in combination products and it is important to note the amount of acetaminophen in each tablet so that accurate accounting of daily dosage can be made.

**Examples of Prescription Drugs with Acetaminophen**

- Acetaminophen and Butalbital (Axocet®)
- Acetaminophen and Codeine Phosphate Oral Solution and Tablets (Tylenol® with Codeine)
- Acetaminophen, Isometheptene, and Dichloralphenazone Capsules (Midrin®)
- Butalbital, Acetaminophen and Caffeine Tablets (Esgic®, Fioricet®, Zebutal®)
- Oxycodeone and Acetaminophen Tablets, Capsules, Elixir (Percocet®, Endocet®, Roxicet®, Tylox®)
- Pentazocine HCl and Acetaminophen Tablets (Talacen®)
- Tramadol and Acetaminophen Tablets (Ultracet™)

**Examples of OTC Drugs with Acetaminophen**

- Backaid® Maximum Strength Backache Relief
- Benadryl® Allergy and Sinus Headache Caplets
- Contac® Day or Night Cold/Flu Caplets
- CVS® 8 Hour Acetaminophen Extended-Release Caplets/Cold and Flu Relief – Day- or Night-time Softgels/Infants’ Non-Aspirin Suspension Drops/Non-Aspirin Children’s Suspension/Non-Aspirin Extra Strength Gels or Caplets/Sinus Headache Decongestant Caplets
- Duane Reade® Acetaminophen Tablets, Caplets, or Geltabs/Children’s Acetaminophen Elixir/Extra Strength Acetaminophen Gelcaps, Geltabs, Caplets, or Tablets/Extra Strength Acetaminophen PM Caplets or Gelatin Caplets/Infant’s Acetaminophen Drops
- Excedrin® Aspirin-Free Tension Headache/Quicktabs Fast Dissolving Pain Reliever Tablets
- FeverAll® Infants’ or Children’s Acetaminophen Suppositories
- HealthLine™ Acetaminophen Caplets Extra Strength
- Inholtra® Caplets With Acetaminophen
- Legatrin® Advanced Formula PM Pain Reliever-Sleep Aid Caplets
- Pamprin® Cramp Caplets/Multi-Symptom Caplets Maximum Strength
- Percogesic® Analgesic Acetaminophen Caplets Extra Strength/Analgesic Acetaminophen Tablets/Aspirin-Free, Pain Reliever, Fever Reducer Tablets
- Premsys® PMS Maximum Strength Premenstrual Syndrome Relief with Acetaminophen
- Rite Aid® Children’s Acetaminophen, Non Aspirin, Oral Suspension Liquid/Complete Allergy-Sinus-Headache Caplets/Extra Strength Acetaminophen/Extra Strength Acetaminophen PM/Infants’ Acetaminophen, Non Aspirin, Suspension Drops/Non-Aspirin, Non-Drowsy Sinus Formula Geltabs Pain Reliever Nasal Decongestant
- Robitussin® Robitussin Cold, Cough and Flu, Multi-Symptom Cold, Nasal Congestion, Cold+Flu Daytime, Cold+Flu Nighttime
- Sudafed® Sinus & Cold Liquid Capsules
- Theraflu Packets Severe Cold
- Triaminic® Cold, Cough and Fever
- Tylenol® 8 Hour Extended Relief/Allergy Sinus - Day or Night; Caplets, Geltabs or Geltabs/Arthritis Pain Caplets/Chewable Tablets/Children’s Cold Plus Cough Liquid/Children’s Soft-Chews/Cold - Day or Night; Caplets or Geltabs/Extended Release Caplets or Geltabs/Flu Gelcaps Day and Night/Infant Cold Drops/Junior Strength Soft-Chews or Chewable Tablets/Nighttime Liquid Severe Cold and Flu/PM Extra Strength/Severe Allergy Sinus - Day or Night/Sore Throat Maximum Strength Adult Acetaminophen Liquid
- Vicks® DayQuil LiquiCaps Non-Drowsy/DayQuil LiquiCaps or Liquid/NyQuil LiquiCaps or Liquid
Herbal supplements come from plants and claim to have medicinal properties that can improve health or aid in managing various medical conditions. The may claim that they can cure, treat, or prevent disease but according to FDA regulations, claims for supplements can only reference supporting healthy function of the body and not management of disease states.

Nutraceuticals are nutrient products such as fish oils and megavitamins.

Even though these products may be billed as “natural” on the label, this does not ensure their efficacy, purity, or safety. Manufacturers of dietary supplements can market their products without receiving approval from the FDA. However, the FDA can remove products from the market if they have been proven to pose serious or unreasonable risk to consumers.

Prior to taking supplements or herbal preparations, it is advisable to discuss with your health care provider to determine potential benefit and any risk of drug interactions with other medications.

While there may be proven health benefits for some herbal and nutraceutical products, potentially harmful effects exist for others. Dietary supplements are not standardized, unlike FDA-approved prescription medications. The same ingredients can be found in different products in varying amounts and this can lead to toxic levels that may cause harmful reactions in the body. Herbal remedies and medicinal agents undergo little oversight of safety, efficacy, sterility of production, bio-equivalency, or stability of product life.

Certification symbols, such as a United States Pharmacopeia (USP) symbol, verifies that the product contains the ingredients in stated amounts and strength, is pure, meets limits for contaminants, and disintegrates quickly. The NSF International verifies products for content and label accuracy, purity, contaminants, and manufacturing processes. ConsumerLab.com independently tests supplements for purity and active ingredients.

**Possible Benefit of Herbal Supplements for Pain**

There are some herbal remedies for which there is some evidence with regards to the management of acute low back pain and osteoarthritis. White willow bark (Salix) extract has been studied in low back pain. A principal ingredient is salicin with salicylic acid as the principal metabolite. This is similar to ingredients in aspirin.

Extract of *Harpagophytum procumbens* (devil’s claw root) has been used in Europe to manage musculoskeletal symptoms with some evidence that it may relieve acute low back pain, acute episodes of chronic low back pain, and osteoarthritis. Mild gastrointestinal upset has been reported at higher doses.
There is some evidence that the antioxidant alpha lipoic acid (ALA) significantly and rapidly reduces the frequency and severity of symptoms of the most common kind of diabetic neuropathy. Symptoms decreased include burning and sharply cutting pain, prickling sensations, and numbness. Unfortunately, studies in people with neuropathy due to cancer chemotherapy revealed no benefit.

There is also evidence that acetyl-L-carnitine (ALC) not only improves the symptoms of diabetic neuropathy, but also helps regenerate nerve fibers and vibration perception. Unfortunately, studies in people with neuropathy due to cancer chemotherapy revealed no benefit and may have caused worsened neuropathy.

Recently, much attention has been given to glucosamine and chondroitin sulfate. Early research suggested that glucosamine and chondroitin sulfate were effective in improving pain and decreasing functional impairment from symptomatic osteoarthritis. The more recent Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT) implied that glucosamine and chondroitin sulfate did not reduce pain in individuals with knee osteoarthritis, although a small select group of patients with moderate-to-severe osteoarthritis may benefit from treatment. When using glucosamine and chondroitin sulfate, the recommended daily dose is 1500 mg per day. Currently, a majority of studies do not show medical benefit with this supplement. Glucosamine may also worsen insulin resistance.

Coenzyme Q10, or CoQ10 as it is often called, is commonly taken in supplement form to counteract the muscle pain and weakness associated with cholesterol-lowering statin drugs. Whether it is truly beneficial for this purpose is the subject of current studies.

Statins do appear to lower levels of CoQ10, a substance that has several important roles in the body. But those who take it should do so carefully, because in some cases it can blunt or amplify the effects of other drugs, particularly those that are used to control blood sugar and blood pressure.

Curcumin, a compound found in turmeric and ginger roots and spices, is a potent antioxidant. Multiple studies have provided good evidence that it is also a potent anti-inflammatory agent. A randomized, placebo controlled study found that curcumin was more effective than placebo and diclofenac sodium (one brand name is Voltaren®) for reducing joint pain in patients with active rheumatoid arthritis. Another study found that a curcumin blend was superior to celecoxib for pain relief and increasing walking distance in people with knee osteoarthritis. Taken on its own, curcumin only has about 5 percent bioavailability. Evidence suggests that piperine (derived from black pepper) and fat (e.g., vegetable oil or butter) increase the bioavailability of curcumin because curcumin is fat soluble, and because the black pepper slows liver metabolism of curcumin. Piperine inhibits CYP 450 enzymes important for drug metabolism. For this reason, check with a health care professional before taking piperine to ensure it will not interact with any medications currently being taken. There are several commercially available curcumin products that combine piperine and a lipid agent in the capsule.

Low levels of Vitamin D are associated with chronic pain in general and with reduced immunity. Low levels of Vitamin B are thought to affect neuropathic pain. Pain may be reduced by optimizing vitamin levels. Vitamin B and D levels can be checked to decide if supplementation is indicated.
Consumer Lab is an independent laboratory that tests the quality of nutritional supplements and posts its results at [www.consumerlab.com](http://www.consumerlab.com). It is a third party verification group that provides certification for nutritional products and supplements that meet its quality standards.


### CAUTIONS REGARDING THE USE OF HERBAL PREPARATIONS, SUPPLEMENTS, & VITAMINS

All of these OTC products have the potential for toxic side effects and cross reactivity with each other and with prescription medications. Unexpected toxicity or drug interaction from any product or medication may occur due to many variables such as age, gender, nutritional status, other illnesses, and surgery.

Many adverse events from herbal medicines have been reported including hypersensitivity reactions, anaphylaxis (shock), hepatitis, nausea, vomiting, diarrhea, platelet inhibition, lower seizure threshold, elevated digoxin levels, central nervous system depression, skin sensitivity to light, chest pain, electrolyte alterations, low blood pressure, irregular heartbeat, kidney failure, carcinogenicity (may cause cancer), and autoimmune (disease caused by antibodies or lymphocytes produced against substances naturally present in the body) effects. Herbal medicines can affect the ability of blood to clot. Therefore, information on current use of herbal medicines should be provided to the health care professional prior to undergoing any surgery or interventional pain procedure.

The American Society of Anesthesiologists recommends that individuals discontinue or taper off herbal products and nutraceuticals at least two weeks prior to surgery and that individuals taking herbals having urgent or emergency surgery bring the original containers to the hospital for review by the anesthesiologist and surgeon.

Some of the undesirable effects of a few of the more commonly used herbals are shown below.

<table>
<thead>
<tr>
<th>Possible Adverse Side Effects of Herbal Preparations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aloe vera</td>
</tr>
<tr>
<td>Astragalus</td>
</tr>
<tr>
<td>Belladonna</td>
</tr>
<tr>
<td>Chaparral</td>
</tr>
<tr>
<td>Ephedra – banned in the US due to serious side effects including death</td>
</tr>
<tr>
<td>Ginkgo biloba</td>
</tr>
<tr>
<td>St. John’s wort</td>
</tr>
<tr>
<td>Kava products</td>
</tr>
<tr>
<td>Garlic</td>
</tr>
</tbody>
</table>
The National Institutes of Health (NIH) National Center for Complementary and Alternative Medicine (NCCAM) and the National Library of Medicine (NLM) have partnered to create CAM on PubMed, a subset of NLM's PubMed. PubMed provides access to citations from the MEDLINE database and additional life science journals. It also includes links to many full-text articles. More information on the National Center for Complementary and Alternative Medicine can be found at http://nccam.nih.gov/.


A Guide to Herbal Supplements can also be found on SparkPeople at the following web address http://www.sparkpeople.com/resource/articles_print.asp?id=506.
**MEDICAL FOODS**

At the most fundamental level, medical foods can be viewed as dietary supplements that are marketed for the management of a specific disease. By law, dietary supplements are not allowed to be labeled for a specific disease. Drugs, on the other hand, can be labeled for a specific disease because the FDA requires that the drug developer conduct clinical trials to show that it is indeed safe and effective for the said disease. Since dietary supplements are not required to be tested for safety and efficacy, they can only be claimed to support body functions.

Dietary supplements (and many medical foods) are essentially vitamins, minerals, or plant extracts. They are naturally occurring in substances humans may consume as food. As science evolved and knowledge is accumulated about the roles or function of these vitamins and minerals in the body, the idea that drove the evolution of the dietary supplement industry was to extract relevant vitamins and minerals and consume them as supplements to food.

For example, CoenzymeQ10 (CoQ10) also known as ubiquinol is naturally occurring in certain meats and vegetables. Once it was discovered that CoQ10 is used by the mitochondria to produce energy and that certain organs, notably the heart, contain high concentrations of mitochondria it was purported that providing the body with extra CoQ10 would help the heart to perform better. Therefore, the only claim that manufacturers of CoQ10 can make is that it helps support heart function.

Pursuant to the Nutritional Labeling and Education Act of 1990, a special category of medical food was created and resides midway between dietary supplement and drugs. For all intents and purposes, this new category allowed manufacturers of dietary supplements to market their products as medical foods, which can be claimed to treat a specific disease. Unfortunately, there is still little oversight over this class of products and for that reason, the field of chronic pain management has seen capitalization by certain manufacturers purporting their medical food product for the management of chronic pain. Some common examples of medical foods targeted for pain management are presented in the table below:

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Ingredients</th>
<th>Targeted Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metanx®</td>
<td>L-methylfolate, vitamin B6 and B12</td>
<td>Neuropathy</td>
</tr>
<tr>
<td>Theramine®</td>
<td>Choline Bitartrate • L-Glutamine • 5-Hydroxytryptophan • L-Serine • L-Arginine • Cinnamon bark • GABA • Grape seed extract • Cocoa • Metabromine.</td>
<td>Pain and inflammation</td>
</tr>
<tr>
<td>Limbrel®</td>
<td>Scutellaria Baicalensis extract (baicalin), Acacia catechu extract (catechin) • Zinc (citrated zinc bisglycinate)</td>
<td>Osteoarthritis</td>
</tr>
</tbody>
</table>

For these product’s role in chronic pain management, it is important to consider:

- Medical foods have not been approved by the FDA as safe and effective for the conditions for which they are marketed.
- Medical foods are not currently recommended by any nationally recognized pain guideline.
• Despite the composition of “natural” ingredients, safety (especially long-term safety) is largely unknown.

Many of these products are marketed in comparison to the current alternative medications for pain. Since the risk of current alternatives is well recognized (e.g., addiction with opioids, gastrointestinal bleeding, cardiac injury with NSAIDs), it may be tempting to gravitate towards these products as safer and possibly as effective or non-inferior alternatives to current pain medications.

In the case that medical foods are trialed for chronic pain, people with pain should be counseled to immediately report signs or symptoms that may be associated with an adverse reaction. In the case that medical foods are used in combination with other prescription pain medication as a part of a regimen of medications including opioids, NSAIDs, and skeletal muscle relaxants, prescribers should assess the therapeutic value (i.e., the individual contribution of the medical food to the overall therapeutic outcome). Essentially, does the addition of the medical food contribute to lower pain scores, better function, or reduction of other drugs?
Aspirin, NSAIDs, and acetaminophen are the most widely used medications for most pain conditions. But these drugs are not without risk. These medications have an analgesic “ceiling effect.” This means that after a certain dose, additional quantities do not provide added pain relief.

NSAIDs can cause gastric distress with ulceration and bleeding, while acetaminophen can cause liver toxicity, particularly when taken in excess. Fortunately, non-opioids do not produce physical or psychological dependence. There is some evidence suggesting that long-term use of common analgesics, such as aspirin, acetaminophen, or NSAIDs, appears to increase the risk for hypertension.

Aspirin and acetaminophen are available OTC while NSAIDs are available both by prescription and some by non-prescription OTC purchase. Additionally, aspirin, acetaminophen, and NSAIDs are available in combination with opioids by prescription.

These non-opioid analgesic pain relievers are effective for pain and fever. Aspirin and NSAIDs are also indicated for pain that involves inflammation, whereas acetaminophen does not have anti-inflammatory activity.

The effectiveness of a medication varies by the individual. Therefore, the person may need to try several different medications to determine which one works best.

The cyclooxygenase-2 (COX-2)-selective inhibitors are NSAIDs that can be prescribed and have a lower risk of gastrointestinal (GI) side effects with short-term use. The only agent of this type currently available in the United States is celecoxib (Celebrex®), which is more expensive than most of the nonselective NSAIDs and has not be definitively proven to provide better pain relief. Although celecoxib is associated with a lower risk for developing a stomach ulcer when taken for less than 6 months, serious stomach ulceration can still occur without warning with this drug. This is especially true if taking a daily aspirin – even if low dose – for protection of the heart. As with other NSAIDs, individuals who take celecoxib should be monitored for this serious side effect. Additionally, NSAIDs are associated with potential kidney effects and heart (cardiovascular) complications, especially when taken for prolonged periods. Remember also that when acetaminophen (Tylenol®) is used in combination with NSAIDs, there is an increased risk of developing kidney problems. This effect is usually only seen with long-term use.

While the increased risk of cardiovascular events, such as stroke and myocardial infarction, associated with COX-2 inhibitors has been well established, data are emerging that demonstrate similar risk increases associated with NSAIDs that are not selective for COX-2. Currently, data show that celecoxib 200 mg or less per day does not seem to increase the risk of cardiovascular events any more than the risk associated with traditional (nonselective) NSAIDs. Discussing the risk-benefit ratio of NSAIDs with a health care professional is advised. The risk of experiencing adverse events or side effects with NSAIDs increases with the duration of use and the dose. Therefore, it is often recommended that these medications be used for the shortest period and at the lowest dose required to achieve therapeutic improvement. Individuals taking aspirin for its
ability to protect the heart should consult with their health care professional prior to utilizing NSAIDs on a long-term basis. The regular use of NSAIDs inhibits aspirin’s ability to protect the heart.

In order to improve the side effect profile of NSAIDs, topical NSAIDs have been developed and approved by the FDA. recent FDA warnings for risks are assigned equally to topical and oral NSAID preparations. It is important to discuss the use of any topical medications with your health care professional, especially if you are also prescribed oral medications.

Diclofenac Products*: Diclofenac Gel (Voltaren® 1% Gel) has been approved for the treatment of chronic pain associated with osteoarthritis in joints close to the skin surface (e.g., hands, knees, and ankles). In 2007, a topical NSAID patch containing diclofenac (Flector®) was approved by the FDA for the treatment of acute pain due to minor strains, sprains, and contusions. In 2009, the FDA issued an advisory that transdermal and topical patches that contain metal, which includes Flector®, need to be removed prior to MRI procedures. A topical solution of diclofenac sodium (Pennsaid®) is approved for the treatment of signs and symptoms of knee osteoarthritis.

*Warning: All Diclofenac products are not recommended as first line analgesics due to an increased risk profile for cardiovascular events (heart attack and stroke) and for increased risk of liver dysfunction (use has resulted in liver failure and death). With the lack of data to support superiority of oral diclofenac over other oral NSAIDs and the possible increased liver and cardiovascular risk associated with its use, alternative analgesics and/or non-pharmacological therapy should be considered.

Intravenous (IV) formulations of the NSAIDs ibuprofen (Caldolor®) and ketorolac (Toradol®) are given most often in the inpatient setting to manage short-term moderate-to-severe pain in adults; ketorolac may also be given intramuscularly (IM). IV ibuprofen is approved also for reduction of fever in adults. In November 2010, IV acetaminophen (Ofirmev®) was FDA approved for the management of mild-to-moderate pain, severe pain with adjunctive opioid analgesics, and reduction of fever in adults and children two or more years old. Similar to the IV NSAIDs, IV acetaminophen is administered in an inpatient setting for short-term pain management and helps reduce the amount of opioid medication needed to manage pain. The FDA has approved dosages of up to 4,000 mg per day of IV acetaminophen. The side effect profile for IV acetaminophen is the same as other acetaminophen dosage forms: headache, agitation, nausea, vomiting, and constipation. Injection site reactions such as redness and swelling may occur with any of the IV non-opioids.
## Non-Opioid Analgesic Drugs & Their Uses

The following chart summarizes the uses and cautions that apply to many of the non-opioid analgesic medications now on the market.

<table>
<thead>
<tr>
<th>Medications (Generic) and Brand Names*</th>
<th>May Be Useful for</th>
<th>Pros</th>
<th>Cons</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aspirin</strong>&lt;br&gt;Bayer®&lt;br&gt;Bufferin®&lt;br&gt;&amp; other Salicylates</td>
<td>Headache, muscle ache, fever, menstrual cramps, arthritis pain, and inflammation. May reduce the risk of heart attack and stroke.</td>
<td>Anti-inflammatory; inexpensive.</td>
<td>May irritate stomach. Inhibits platelets and can cause prolonged bleeding. Can precipitate asthma in aspirin-sensitive patients.</td>
<td>May cause Reye’s syndrome in children and teenagers and should not be used during viral syndromes; may be harmful for women in late pregnancy, people with kidney or liver disease, asthma, high blood pressure, or bleeding disorders.</td>
</tr>
<tr>
<td><strong>Acetaminophen</strong>&lt;br&gt;FeverALL®&lt;br&gt;Tylenol®</td>
<td>Headache, muscle ache, backache, fever, and arthritis pain (especially osteoarthritis).</td>
<td>More gentle to the stomach than NSAIDs; safer for children. Does not promote bleeding (or protect against heart attack and stroke).</td>
<td>Does not reduce inflammation; may be less effective than aspirin for soft tissue pain.</td>
<td>May be harmful for people with kidney or liver disease or those who drink alcohol heavily. May increase bleeding time in individuals receiving anticoagulation therapy.</td>
</tr>
<tr>
<td><strong>Ibuprofen</strong>&lt;br&gt;Advil®&lt;br&gt;Motrin®</td>
<td>Headache, muscle ache, fever, sprains, menstrual cramps, backache, and arthritis pain.</td>
<td>Stronger and generally longer lasting than aspirin.</td>
<td>May irritate stomach. Increased risk of serious gastrointestinal adverse events. Serious risk of cardiovascular events.</td>
<td>May be harmful for people with kidney or liver disease, asthma, bleeding disorders, or those who drink alcohol heavily.</td>
</tr>
<tr>
<td><strong>Ketoprofen</strong>&lt;br&gt;Orudis®&lt;br&gt;Oruvail®</td>
<td>Headache, muscle ache, fever, menstrual cramps, cold or flu aches.</td>
<td>Helps reduce inflammation. More gentle to the stomach than aspirin.</td>
<td>May irritate stomach. Increased risk of serious gastrointestinal adverse events. Serious risk of cardiovascular events.</td>
<td>May be harmful for people with kidney or liver disease or those who drink alcohol heavily. Not recommended for children without a health care professional’s supervision.</td>
</tr>
<tr>
<td>Medications (Generic) and Brand Names*</td>
<td>May Be Useful for</td>
<td>Pros</td>
<td>Cons</td>
<td>Comments</td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>-------------------</td>
<td>------</td>
<td>------</td>
<td>----------</td>
</tr>
<tr>
<td><strong>Naproxen Sodium</strong>&lt;br&gt;Aleve® (OTC)&lt;br&gt;Anaprox®&lt;br&gt;Naprelan®&lt;br&gt;Naprosyn®</td>
<td>Headache, muscle ache, fever, menstrual cramps, backache, arthritis pain, and inflammation.</td>
<td>Stronger and generally longer lasting than aspirin for menstrual cramps, toothache, and inflammation.</td>
<td>May irritate stomach. Increased risk of serious gastrointestinal adverse events. Serious risk of cardiovascular events.</td>
<td>Not recommended for children without a health care professional’s supervision.</td>
</tr>
<tr>
<td><strong>Meloxicam</strong>&lt;br&gt;Mobic®</td>
<td>Arthritis pain</td>
<td>Associated with less risk of ulcers vs. other NSAIDs.</td>
<td>May irritate stomach. Increased risk of serious gastrointestinal adverse events. Serious risk of cardiovascular events.</td>
<td>Generally well-tolerated but still need to be concerned about GI side effects.</td>
</tr>
<tr>
<td><strong>COX-2 Inhibitors</strong>&lt;br&gt;Celebrex®</td>
<td>Muscle aches, joint pain, arthritis pain, and inflammation.</td>
<td>Helps reduce inflammation; less stomach irritation vs. other NSAIDs.</td>
<td>May irritate stomach. Increased risk of serious gastrointestinal adverse events. Serious risk of cardiovascular events.</td>
<td>Generally well-tolerated but still need to be concerned about GI side effects. No effect on bleeding time. Use caution with sulfa allergies and celecoxib.</td>
</tr>
</tbody>
</table>

Other NSAIDs include the following:

- Diclofenac (Cataflam®, Voltaren®, Zipsor®, others) – see comments below
- Diflunisal (Dolobid®)
- Etodolac (Lodine®, Lodine® XL)
- Fenoprofen (Nalfon®)
- Flurbiprofen (Ansaid®)
- Ibuprofen (Caldolor®) - NSAID available intravenous for acute pain and fever
- Indomethacin (Indocin®, Indocin® SR)
- Ketorolac (Toradol®, others) – Oral, intranasal and injectable – 5-day use only in adults
- Mefenamic acid (Ponstel®)
- Nabumetone (Relafen®)
- Oxaprozin (Daypro®)
- Piroxicam (Feldene®)
- Sulindac (Clinoril®)
- Tolmetin (Tolectin®)
Meloxicam (Vivodex®)**
Diclofenac (Zorvolex®)**
Indomethacin (Tyvorbex®)**

** lower dose microbead formulations

* Brand names are the trademarked property of the medication’s manufacturer.

**Diclofenac Warning:** According to the Official Disability Guidelines, all oral diclofenac products are not recommended as first line analgesics due to increased risk profile for cardiovascular events (heart attack and stroke) and for increased risk of liver dysfunction (use has resulted in liver failure and death). With the lack of data to support superiority of diclofenac over other NSAIDs and the possible increased hepatic and cardiovascular risk associated with its use, alternative analgesics (pain medications) and/or non-medication therapy should be considered.

**GASTROINTESTINAL (GI) PROTECTIVE MEDICATIONS**

As mentioned earlier, the NSAID medications can increase the risk of ulcers and other stomach and digestion problems. Often people are prescribed an additional medication to help protect their GI system, sometimes called cytoprotective medications, which are medications that protect cells from noxious chemicals or other harmful stimuli.

Taking antiulcer agents along with an NSAID pain medication is recommended for individuals who will benefit from an NSAID but also have a high GI risk factor profile. Individuals considered being at elevated risk include those with a history of prior GI bleed/uncomplicated ulcer or H. pylori infection, the elderly, diabetics, cigarette smokers, and those with concurrent use of aspirin (including low dose), corticosteroids, or anticoagulants (blood thinners). Long-term NSAID treatment increases the risk among those most susceptible, although anyone can potentially develop an adverse effect at any time.

There are four commonly used antiulcer drug types:

Proton pump inhibitors (PPIs): esomeprazole (Nexium®), lansoprazole (Prevacid®), omeprazole (Prilosec®), pantoprazole (Protonix®), and rabeprazole (Aciphex®). PPIs are more effective and long-lasting acid inhibitors than H2 receptor antagonists. There is an increased risk in individuals over 50 years of age of hip, wrist, and spine fractures amongst PPI users.

H2 receptor antagonists (H2RAs): famotidine (Pepcid®), nizatidine (Axid®), ranitidine (Zantac®), and cimetidine (Tagamet®). They are still used for treatment and maintenance therapy of peptic ulcer disease, treatment of gastroesophageal reflux disease, and management of dyspepsia. However, they achieve less acid suppression than proton pump inhibitors. Many of the studies on H2 blockers show that they have negligible value in the protection of the gastric mucosa.

Misoprostol (Cytotec®) - a prostaglandin analog which is effective in preventing NSAID-induced ulcers but has no established roll for healing ulcers. Prostaglandins increase the contraction ability in the uterus, so females should not take misoprostol if pregnant or
planning to become pregnant. More specifically the FDA states that misoprostol tablets should not be used for reducing the risk of NSAID-induced ulcers in women of childbearing potential unless the patient is at high risk of complications from gastric ulcers associated with use of the NSAID, or is at high risk of developing gastric ulceration.

Antacids such containing aluminum and magnesium hydroxide or calcium carbonate (TUMS®) and sucralfate (Carafate®) have not been proven in the treatment of peptic ulcers. Sucralfate (Carafate®) works via interactions with hydrochloric acid found in the stomach and digestive tract. The combination forms a paste-like substance, which forms a protective coating that acts locally to protect the stomach and gastrointestinal tract lining.
OPIOID PAIN RELIEVERS AND THEIR SAFE USE

WHAT ARE OPIOIDS?

OPIOID AGONISTS

Opioids are morphine-like substances. Some forms have been available for centuries to relieve pain. The term opioid is derived from opium, which is an extract from the poppy plant.

Opioids come in naturally occurring, synthetic, and semisynthetic forms. In 1975, it was discovered that the body generates its own (internal or endogenous) opioids (called endorphins, enkephalins, and dynorphins).

Most opioids are agonists, a drug that binds to a receptor of a cell and triggers a response by the cell. An agonist produces an action. It is the opposite of an antagonist, which acts against and blocks an action. The body has opioid receptors that, when occupied by an opioid agonist, create the sensation of analgesia (pain relief).

Opioid medications are sometimes also referred to as narcotics. There are numerous opioids available by prescription (see lists below). Examples include morphine, hydromorphone, fentanyl, methadone, and oxycodone.

All of the opioids have similar clinical effects that vary in degree from one drug to another. The potency, speed of onset, and duration are unique to each drug. Opioids differ in the typical route of administration, whether injection, skin patch, or in pill form. There are both short- and long-acting opioid formulations. Some are used around-the-clock in scheduled doses, while others are used as needed for intermittent or breakthrough pain.

Opioids should be kept in a secure place in the home to prevent diversion/misuse by family members and visitors.

OPIOID mixed AGONISTS/ANTAGONISTS

There are a number of opioid analgesics (pain relievers) that are partial agonists, such as buprenorphine (e.g., Belbuca™, Buprenex®, Butrans®, Subutex®), and mixed or combination agonists/antagonists, such as butorphanol (Stadol®), nalbuphine (Nubain®), pentazocine (Talwin®), and buprenorphine/naloxone (Bunavail®, Suboxone®, Zubsolv®).

The mixed agonists/antagonists are characterized as having an analgesic “ceiling” effect in which the analgesic benefit plateaus and no further benefit is obtained by increasing the dose. Given their antagonist nature, these medications can reverse the effects (analgesia and side effects) of full agonist opioids, such as morphine, fentanyl, hydromorphone, and oxycodone, and therefore should be used with caution in those taking a full agonist opioid.
Symptoms of withdrawal include sweating, gooseflesh, or goose bumps (a temporary local change in the skin when it becomes rougher due to erection of little muscles, as from cold, fear, or excitement), runny nose, abdominal cramping, diarrhea, nervousness, agitation, hallucinations, and a fast heartbeat. The health care professional or pharmacist should be informed about these symptoms.

**OPIOID DELIVERY**

Opioids are commercially available orally (swallowed by mouth), intravenously, by intramuscular injection (although not recommended), via nasal spray, transdermally (through the skin), oral transmucosally (absorbed under the tongue and between the gum and inside of the cheek), buccally (absorbed between the gum and inside of the cheek), sublingually (absorbed under the tongue), via suppository, via an epidural (injection of an anesthetic into the space between the spinal cord and the covering membrane called the dura), and intrathecally (injection into the sheath surrounding the spinal cord, also called “spinal injection” – also see discussion on Implanted Targeted Intrathecal Drug Delivery Systems - “Pain Pumps”).

**SHORT-ACTING, SUSTAINED-RELEASE AND LONG-ACTING OPIOID AGONISTS**

Short-acting oral opioids (affects only last a short time) and immediate-release (IR) opioids and drug is active immediately), often contain an opioid as the only active ingredient (e.g., morphine, hydromorphone, oxycodone, tramadol\(^1\) and oxymorphone), while others contain a combination of an opioid and a non-opioid such as acetaminophen or ibuprofen.

Examples of short-acting opioid and opioid-combination products include:

- codeine
- oxycodone (combined with acetaminophen - Percocet\(^\circledR\), combined with aspirin - Percodan\(^\circledR\); combined with ibuprofen - Combunox\(^\circledR\))
- hydrocodone (combined with acetaminophen - Lorcet\(^\circledR\), Lortab\(^\circledR\), Vicodin\(^\circledR\), Norco\(^\circledR\); combined with ibuprofen - Vicoprofen\(^\circledR\))
- tramadol (combine with acetaminophen - Ultracet\(^\circledR\))
- hydromorphone (Dilaudid\(^\circledR\))
- fentanyl (Actiq\(^\circledR\)) - not indicated for noncancer pain
- oxymorphone (Opana\(^\circledR\))
- tapentadol (Nucynta\(^\circledR\)) – (an agonist of the mu receptor but not truly an opioid biochemically)

Short-acting oral opioids, true to their description, exert a rapid-onset but short-lived therapeutic effect. These agents typically start working 15–30 minutes after administration, with peak analgesic effect within 1–2 hours. Sustained pain relief is maintained for only about 3 to 4 hours.

\(^1\) tramadol is not chemically a true opioid biochemically but works similarly to opioids primarily on the same receptors
They are a potent option for treating acute pain (e.g., from a serious athletic injury or after a root canal) and are usually prescribed for pain that is anticipated to last only a few days.

Because of their short half-life and rapid clearance from the body, short-acting opioids must be taken every 3 to 4 hours. Therefore, these drugs are not ideal for long-term therapy of chronic pain, and there is little medical evidence to support their use in long-term therapy of chronic non-cancer pain. Short-acting opioids may be effective, however, as an initial “trial” therapy in patients with moderate or severe chronic pain who have not previously received opioid treatment. In this case, short-acting agents are used to establish a patient’s response and tolerance to opioid therapy and lay the groundwork for long-term dosing of long-acting opioid therapy if and when that is prescribed and assuming other non-opioid nonpharmacological therapies are not sufficiently improving function and relieving pain.

In addition to their importance in managing acute pain and initiating therapy for chronic pain, short-acting agents are often used with a long-acting agent during long-term therapy as “rescue medication.” Rescue medication may be necessary for addressing flare-ups that occur despite ongoing, long-term analgesic treatment.

For patients with continuous moderate to severe chronic pain in whom long-term opioid therapy is medically necessary, long-acting (sometimes called slow-release) medications may be preferred. Slow-release formulations are described as having sustained, extended, or controlled release of drug and are abbreviated as SR, ER, or CR, respectively.

Examples of sustained-release opioids include:

- morphine (oral sustained release, e.g., MS Contin®, Avinza®, Kadian®)
- oxycodone (oral controlled release, e.g., OxyContin®; oral biphasic release with acetaminophen, e.g., Xartemis® ER)
- oxymorphone (oral extended release Opana® ER)
- hydrocodone (oral extended release Zohydro® ER, Hysingla®)
- hydromorphone (oral extended release EXALGO®)
- fentanyl transdermal system (Duragesic®)
- tapentadol (Nucynta® ER)
- buprenorphine transdermal system (Butrans®)

Examples of long-acting opioids include:

- methadone (oral, e.g., Dolophine®, Methadose®)

The prolonged effects of these agents are due to their long half-lives or slow delivery into the body via controlled-release opioid preparations. Because of the slower release of active drug, long-acting opioids can provide prolonged, steady pain relief for 8–12 hours. Long-acting drug preparations are given at regularly scheduled times, such as every 12 hours. For example, hydromorphone EXALGO®) is a once-daily medication with reported sustained blood levels for 18-24 hours.
Slow-release tablets should be swallowed whole and are not to be broken, chewed, dissolved, or crushed. Taking broken, chewed, dissolved, or crushed slow-release pills can lead to rapid release and absorption of a potentially fatal dose of the drug.

<table>
<thead>
<tr>
<th>Examples of Medical Opioid Agonists</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Codeine</strong> (with acetaminophen - Tylenol® with codeine No. 2, No. 3, No. 4)</td>
</tr>
<tr>
<td><strong>Dihydrocodeine bitartrate, Aspirin, Caffeine</strong> (Synalgos-DC®)</td>
</tr>
<tr>
<td><strong>Hydrocodone</strong></td>
</tr>
<tr>
<td>• Hydrocodone alone – Zohydro® ER, Hysingla® ER</td>
</tr>
<tr>
<td>• With acetaminophen – Lortec®, Lortab®, Norco®, Vicodin®, Hycet®, Xodol®</td>
</tr>
<tr>
<td>• With ibuprofen – Reprexain™, Vicoprofen®</td>
</tr>
<tr>
<td>• With aspirin – Azdone, Lortab ASA, Panasal</td>
</tr>
<tr>
<td>Examples of Medical Opioid Agonists</td>
</tr>
<tr>
<td>-----------------------------------</td>
</tr>
<tr>
<td><strong>Fentanyl</strong> (Actiq®, lozenge, Fentora® buccal tablet and ONSOLIS™ buccal film, Abstral® sublingual tablet, Subsys® sublingual spray, Duragesic® transdermal patch, Lazanda® nasal spray, and also Ionsys iontophoretic transdermal system - only approved for use in hospital settings)</td>
</tr>
<tr>
<td><strong>Hydromorphone</strong> (Dilaudid®, EXALGO®)</td>
</tr>
<tr>
<td><strong>Levorphanol</strong> (Levo-Dromoran®)</td>
</tr>
<tr>
<td><strong>Meperidine</strong> (Demerol®)</td>
</tr>
</tbody>
</table>
Examples of Medical Opioid Agonists

| Methadone (Dolophine®, Methadose®) | Although methadone possesses analgesic properties, it must be used carefully and with a great deal of caution. It has a long half-life and can accumulate in the body, which can lead to an overdose. It interacts with a large number of other medications, including OTC drugs. It is strongly recommended that the individual on methadone not use any OTC or herbal medications without the approval of the prescribing health care professional. The addition of other commonly used pain medications (e.g., antidepressants, anticonvulsants, and NSAIDS) can increase the likelihood of methadone negatively influencing the heart’s ability to conduct electrical signals properly. Prior to starting methadone, patients should undergo an electrocardiogram to check for any pre-existing heart abnormalities that may contraindicate its use. Methadone can also be associated with the development of central sleep apnea. Benzdiazepines should be utilized with extreme caution by individuals who take methadone, secondary to the synergistic negative respiratory and cardiac effects. |
| Morphine (Avinza®, Duramorph®, Kadian®, MS Contin®, Oramorph SR®) | Morphine is considered to be the prototypical opioid and is available in many formulations. |
| Oxycodone (OxyContin®, Roxicodone®, Oxecta®) | Oxycodone has the same properties as morphine with respect to the potential for habituation, tolerance, physical dependence, and withdrawal syndrome. |
|   - Endocet® (containing acetaminophen, oxycodone)  
   - Endodan® (containing aspirin, oxycodone)  
   - Lynox® (containing acetaminophen, oxycodone)  
   - Percocet® (containing acetaminophen, oxycodone)  
   - Percodan® (containing aspirin, oxycodone)  
   - Primlev® (containing acetaminophen, oxycodone)  
   - Roxicet® (containing acetaminophen, oxycodone) |
<table>
<thead>
<tr>
<th>Medical Opioid Agonists</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oxymorphone</strong> (Opana® and Opana® ER)</td>
<td>Oxymorphone has the same properties as morphine with respect to the potential for habituation, tolerance, physical dependence, and withdrawal syndrome.</td>
</tr>
<tr>
<td><strong>Tapentadol</strong> (Nucynta®, Nucynta® ER)</td>
<td>Tapentadol is a dual mechanism drug with both opioid and antidepressant-like activity. The drug is not a true opioid but binds to opioid receptors and also inhibits the reuptake of the neurotransmitter norepinephrine. The short-acting formulation is approved for acute pain treatment, and the extended-release formulation is approved for the management of continuous severe chronic pain. Tapentadol may have an improved GI side effect profile in comparison with other opioids.</td>
</tr>
<tr>
<td><em><em>Tramadol</em> (Ultram®, Ultram® ER)</em> and tramadol combined with acetaminophen** (Ultracet®) is considered a “weak” opioid-like analgesic</td>
<td>Tramadol is a weak analgesic that acts on the central nervous system in two ways. It binds modestly to opioid receptors and thus produces some analgesia by the same mechanism as opioids. It also affects certain neurotransmitters in the brain to decrease the perception of pain. He also carries the risk of excessive serotonin activity leading to a serotonin syndrome. While tramadol is considered a weak opioid-like drug, it is not completely free of the risks associated with opioids and may trigger addiction even in those without a history of drug abuse or previous addiction. Tramadol reduces the respiratory rate to a lesser extent than opioids in overdoses and does not cause the sort of GI irritation produced by NSAIDs. Tramadol reduces the threshold for seizures, which may manifest in overdose. Seizures may also be provoked in those with a history of seizure disorders, head trauma, etc., or in those taking other drugs that reduce the seizure threshold such as certain antidepressants. Tramadol is a centrally acting synthetic analgesic, not an NSAID, and thus it has no anti-inflammatory activity. Also unlike NSAIDs, tramadol does not have the potential to compromise the efficacy of certain antihypertensive agents (diuretics and ACE-inhibitors). Tramadol should be used cautiously, if at all, in patients with underlying liver and kidney disease.</td>
</tr>
</tbody>
</table>

*In July 2014, the DEA, citing evidence of possible abuse, dependence and diversion, reclassified all meds containing tramadol as Schedule IV controlled substances (those with a recognized medical use and relatively low potential for abuse & dependence), however there are known cases of addiction to Tramadol, so it should be taken with the same precautions as other opioids.
Examples of Medical Opioid Partial Agonists & Mixed Agonists/Antagonists

<table>
<thead>
<tr>
<th>Buprenorphine</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>- Buprenex® injectable (indicated for pain relief/analgesia)</td>
<td></td>
</tr>
<tr>
<td>- Butrans® Transdermal (indicated for pain relief/analgesia)</td>
<td></td>
</tr>
<tr>
<td>- Subutex® (indicated for the treatment of opioid dependence/addiction)</td>
<td></td>
</tr>
<tr>
<td>- Belbuca™ (indicated for pain relief/analgesia)</td>
<td></td>
</tr>
</tbody>
</table>

In addition to its use for the treatment of chronic pain, buprenorphine is used to help alleviate unpleasant withdrawal symptoms associated with opioid detoxification and to treat addiction. Maintenance dose is generally in the 4–24 milligram range and higher doses have not been demonstrated to provide any clinical advantage. Higher doses are thought to be ineffective for pain control and are not used due to cardiac concerns regarding prolongation of the QT interval. Some clinicians believe that the “ceiling effect” with buprenorphine offers advantages when compared to other medications used to manage addiction because there is a lower abuse potential, lower level of both physical dependence and withdrawal, and there is possibly a decreased incidence of dose related side effects. If Subutex® is swallowed instead of dissolved under the tongue, the patient may experience no effect due to the poor bioavailability and first pass metabolism of buprenorphine.

Buprenorphine/naloxone is a combination drug indicated for the treatment of opioid dependence/addiction. Naloxone is a pure opioid antagonist, meaning it blocks the effects that opioid drugs have on the receptors. Naloxone inhibits respiratory depression, hypotension, sedation, and analgesia. When given sublingually (under tongue), naloxone has no significant effects on buprenorphine. However, if the sublingual tablet is crushed or injected, naloxone will block the effects of buprenorphine. This characteristic discourages misuse of the formulation. If buprenorphine/naloxone products are swallowed instead of dissolved under the tongue or inside the cheek, the patient may experience no effect due to the poor bioavailability and first pass metabolism of buprenorphine.

<table>
<thead>
<tr>
<th>Buprenorphine/naloxone</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>- BUNAVAIL® (buccal film)</td>
<td></td>
</tr>
<tr>
<td>- Suboxone® (sublingual film or sublingual tablet)</td>
<td></td>
</tr>
<tr>
<td>- Zubsolv® (sublingual tablet)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Butorphanol (Stadol®, Stadol NS®)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Available in injection or nasal spray formulations but not typically used for chronic pain treatment.</td>
<td></td>
</tr>
</tbody>
</table>
**GENERAL OPIOID ADVERSE SIDE EFFECTS**

Common opioid side effects, particularly with higher doses, include:

- Nausea
- Vomiting
- Constipation
- Thought and memory impairment
- Drowsiness

Many of these side effects can usually be treated with dose adjustments, wane over time (with the exception of constipation), or can be offset by other alternative medications. There is a risk though of too many additional medications being prescribed (also known as polypharmacy) to treat the opioid side-effects when less opioids may be more appropriate.

Lower opioid dosages carry the lowest risks.

Remember also that taking opioids does not result in being pain-free but rather the goal should be less pain, more function and either manageable or minimal side effects.

Approximately 40 percent of individuals taking opioid therapy for non-cancer pain experience constipation (less than three bowel movements per week) secondary to opioid treatment. Most individuals taking opioid medications will not develop tolerance to opioid-induced constipation. Therefore, an effective preventive bowel regimen including diet changes and a stimulant laxative plus a stool softener will have to be maintained throughout the course of opioid treatment. Even individuals that utilize appropriate laxative therapy often still experience constipation that may impede the appropriate use of opioid pain medication and thus result in higher levels of pain, so attention to and prevention of this side effect is essential. Medications used for constipation include OTC laxatives (pills, suppositories, enemas, etc.) including stimulant laxatives and polyethylene glycol 3350 (PEG) (Miralax) and prescriptions drugs such as lactulose, lubiprostone (Amitiza™), naloxegol (Movantik™), methylnaltrexone (Relistor®) and linaclotide (Linzess®). For more information on OTC laxative please visit Mayo Clinic Site: [http://www.mayoclinic.org/diseases-conditions/constipation/in-depth/laxatives/art-20045906?pg=1](http://www.mayoclinic.org/diseases-conditions/constipation/in-depth/laxatives/art-20045906?pg=1). For more facts about opioid induced constipation: [http://www.theacpa.org/opioid-induced-constipation](http://www.theacpa.org/opioid-induced-constipation).

The preferred method of treating opioid-induced constipation (OIC) is opioid reduction.

Non-pharmacological interventions that can assist with constipation include: 1) increasing fluid intake, 2) increasing physical activity, and 3) encouraging daily bowel movements at the same time, often after a meal.

In cases that do not respond, other forms of laxative treatment can be considered. Bulk forming laxatives, such as psyllium, are contraindicated for opioid induced constipation as they can produce colon obstruction. New approaches to treating opioid-induced constipation are being developed.
Mild nausea is also common with opioid therapy. It can be treated with medications, but if it does not resolve within a few days, a trial of an alternate opioid may be appropriate.

**Mild sedation and impaired judgment or coordination** also should be anticipated, especially at the beginning of opioid therapy and with significant dose increases. If safe to consume, caffeinated beverages may help to reduce mild sedation until tolerance to this side effect develops. Until tolerance or a baseline is reached, the patient and family need to be warned against driving and the potential for falls. Psychostimulants while not recommended in current guidelines and not covered by insurance plans, or sometimes used in selected patients to treat sedation but can be habit-forming and have serious side effects. Additionally, psychostimulants can have cardiovascular concerns, along with side effects of anxiety and insomnia.

**Hormonal Changes:** A side effect of long-term opioid use is a decrease in certain hormones, particularly sex hormones. This reduction may cause a loss in “sex drive,” sometimes called libido and erectile dysfunction. This tends to be associated with using these medications regularly for many months. Low testosterone levels are associated also with weight gain and mood disturbances/depression. Because of hormonal abnormalities (decreased estrogen levels), bone density may be diminished which may result in the risk of fractures. For this reason, some doctors test bone density periodically in both women and men on long-term opioid medications.

**Respiratory Depression:** A serious side effect, particularly in opioid-naïve individuals (those who have not been taking opioids regularly), is respiratory depression (slowed rate of breathing or loss of urge to breathe). Tolerance to respiratory depression can occur with regular opioid use, but this has been called into question now and it is even thought that respiratory depression may increase with prolonged use contributing to some postoperative respiratory morbidity in people receiving long-term opioid therapy, especially when combined with benzodiazepines and other sedatives preoperatively. Individuals with chronic obstructive pulmonary disease (COPD), obstructive sleep apnea and does use smoke the greater risk for respiratory depression.

A genuine **allergy** to opioids is very rare. If an allergy does occur, opioids from another class should be chosen. For example, morphine, hydromorphone, oxycodone, and oxymorphone belong to the same class of opioid. Fentanyl and meperidine (Demerol) belong to a different class.

**Summary of Possible Opioid Side Effects**

- Central nervous system (CNS)
  - A sense of emotional well-being and euphoria
  - Drowsiness, sedation, and sleep disturbance
  - Hallucinations
  - Potential for diminished psychomotor performance
  - Dysphoria and agitation
  - Dizziness and seizures
  - Aberrant behavior (see addiction definition below)
  - Delirium
  - Depression
  - Cognitive impairment (i.e., memory, attention, decision-making, motor reaction)
  - Hyperalgesia (see definition below)
• Respiratory system
  o Respiratory depression is the most serious adverse effect and may result from toxicity
  o Risk for slowed breathing and death is greatly increased when opioids are taken with benzodiazepines or other CNS depressant drugs or with alcohol. To minimize risks, do not take opioids with benzodiazepines and never consume alcohol with opioids

• Ocular system
  o Constriction of the pupil of the eye

• Gastrointestinal system
  o Constipation, nausea, and vomiting
  o Delayed gastric emptying

• Genitourinary
  o Urinary retention

• Endocrine
  o Low testosterone in men and low estrogen in women
  o Reduced fertility in reproductive age women
  o Sexual dysfunction resulting from low hormone levels
  o Hypoglycemia – reported with tramadol and methadone

• Cardiovascular
  o Decreased blood pressure
  o Slowed heart rate
  o Peripheral edema (swelling)

• Musculoskeletal system
  o Muscle rigidity and contractions
  o Osteoporosis

• Skin system
  o Itching is common and not an allergic reaction

• Immune system
  o There are data suggesting that long-term administration of opioids suppresses the immune system. Research is being conducted to determine its clinical significance.
• Pregnancy* & Breast Feeding: When at all possible, avoid opioid use during pregnancy to minimize fetal risks
  o All opioids cross the placenta
  o Neonatal central nervous system depression can occur if opioids are used during labor
  o Neonatal abstinence syndrome can occur in infants born to mothers who are taking regular daily doses of opioids
  o Avoid breastfeeding when taking opioids for chronic pain
  o If an opioid is used during breast feeding, use with caution and only under a health care professional’s supervision
  o Timing of opioid dose administration is important for safe opioid use during breast feeding
  o Use of opioids during pregnancy and breastfeeding may result in fetal or newborn toxicity including central nervous system and respiratory depression along with opioid dependency

**Definition of Terms Regarding Opioids**

**Opioid-responsiveness** is the ability to achieve pain relief with evidence of improved function without the development of unmanageable or intolerable side effects.

**Opioid-induced hyperalgesia** occurs when continued opioid use causes increased sensitivity to painful stimuli, worsening pain despite increasing doses of opioids, and pain that becomes more diffuse, extending beyond the distribution of pre-existing pain. This syndrome may reduce the clinical usefulness of opioids in treating chronic pain and may require a reduction in dose or detoxification, under the supervision of a health care professional. Naloxone (Narcan, Evzio) should not be administered in an attempt to reverse opioid-induced hyperalgesia.

**Addiction** is one of the primary concerns that limits opioid prescribing. This is a term that requires clarification. Addiction is not the same thing as physical dependence (see below). **Addiction** is a primary, chronic disease of brain reward, motivation, memory, and related circuitry. Dysfunction in these circuits leads to characteristic biological, psychological, social, and spiritual manifestations. This is reflected in an individual pathologically pursuing reward and/or relief by substance use and other behaviors. In other words, the individual continues to crave and use the drug, despite harm.

**Addiction** is characterized by (A, B, C, D, E) the inability to consistently Abstain; by impairment in Behavioral control; **Craving**; Diminished recognition of significant problems with one’s behaviors and interpersonal relationships; and a dysfunctional Emotional response. Like other chronic diseases, addiction often involves cycles of relapse and remission. Without treatment or engagement in recovery activities, addiction is progressive and can result in disability or premature death. (From the American Society of Addiction Medicine, www.asam.org.)

Drugs capable of producing addiction do so by interacting with the biochemistry of the brain in such a way that the drug begins to seem essential – one feels a “need” for it as one does for food and water. In the case of pain, the “need” and craving may present as the intense desire to relieve the pain. While the media give the impression that the risk of addiction is inherent to the properties of opioids, experts in addiction generally recognize that it results from the interaction of the drug and various hereditary, biological, psychological, and situational factors unique to the individual.

**Addiction** should be distinguished from **physical dependence** (see below). Any person (or animal) that takes sufficient doses of certain types of drugs for a significant length of time can have withdrawal symptoms if the drug is suddenly stopped or reversed by another medicine. This shows the presence of physical dependence but does not constitute addiction. Physical dependence is common among people who take opioids, but it is not a sign that anything is wrong. A person taking opioids can become physically dependent without being addicted. If someone is physically dependent, the drug’s effectiveness decreases, often leading to futile increases in dose to gain relief, resulting in potentially dangerous consequences.

There is a risk that addiction will develop in anyone who takes opioids and some people have more risk of addiction than others.
When addiction develops, the pain medication has become a liability rather than an asset to the person. An older description of addiction includes four core elements (the four C’s):

- Compulsive use and preoccupation with the drug and its supply,
- Inability to consistently control the quantity used,
- Craving the psychological effects of the drug, and
- Continued use despite adverse effects from the drug.

Compulsive use or preoccupation may be demonstrated by taking the drug because it is available (as opposed to taking it exactly as a health care professional has instructed), inappropriate “stocking up,” using several different health care professionals/pharmacists to guarantee a supply, and spending scarce resources on the drug.

Other examples of inappropriate use include selling the drug or changing the drug from pill to powder for injection or snorting.

An example of loss of control is demonstrated by the person who regrets his drunkenness and “pledges” to stop after two beers the next time; instead, he has six beers and behaves regretfully again. With pain medication, loss of control tends to take the form of using up a month’s supply in a week, so that the person must go without the medication for a long time or the person may look elsewhere to increase the available supply (emergency rooms, other doctors or dentists, or illegal sources).

Craving, is the desire for the drug in the absence of the drug. Craving may present as an intense desire for a mental effect ("buzz" or "high") caused by a medicine. It may also include an intense desire to relieve pain “at any expense” even though, in the long run, the medicine is not truly helping much at all.

Examples of use despite adverse consequences may consist of smoking despite emphysema, drinking and driving despite convictions for driving under the influence, or using analgesics and tranquilizers despite experiencing adverse effect on the ability to function, mood, and family relationships.

People should be aware that they may become addicted to their opioid pain medications. Risk for addiction is increased in those who have a personal or family history of problems with drugs or alcohol and those who have a history of anxiety, depression, or other emotional conditions. People with a history of adverse experiences (including sexual abuse) during childhood or adolescence as well as adults who have experienced or witnessed trauma (like veterans, first responders and others) are also at risk. Cigarette smoking is also considered a risk factor. The risk of addiction should be discussed with a health care professional prior to taking an opioid for pain treatment.

Similarly, individuals should let their health care professional know if they are concerned about becoming addicted to opioid pain medications. There are many misconceptions that surround the use of opioids for pain relief, and a knowledgeable health care professional can provide accurate information. Signs of which to be aware during opioid treatment include taking more medication
than prescribed without checking with a health care professional first, loss of control over the medication, and feelings of craving the medication or taking the medication for the euphoric (mental) effects rather than for pain relief.

**Chemical Copers:** Chemical copers use their medications in non-prescribed ways to cope with stress, fear, anxiety, sleeplessness, etc. Some use pain medications to fall asleep, others to relax, still others to get along better with a spouse. Some individuals demonstrate inappropriate medication use but not to the level of addiction and are not likely to display a severity that rises to the level of compulsivity or loss of control. In addition, they are not likely to display behaviors indicative of drug cravings that would convince a clinician to diagnose addiction. A major hallmark of chemical coping is the overly important place in the person’s life that is occupied by obtaining drugs for pain and a corresponding inflexibility about nondrug components of care. The use of medications becomes central in the chemical coper’s life while other interests become less important. As a result, they often fail to move forward with psychosocial goals and are usually uninterested in or unwilling to treat pain non-pharmacologically; that is, they do not take advantage of other treatment options provided (i.e., functional restoration), including exploring recommendations to exercise or to see psychologists or physical therapists. Further, they remain on the fringe of appropriate use of their medication but are able to comply with their health care professional’s opioid agreement enough to avoid being removed from treatment. Chemical copers often self-escalate their medication dosage when they are faced with stress and need to have their prescriptions refilled early. Opioids in general should be avoided in this category of patients.

**Physical dependence** is a state of adaptation that is manifested by a withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug, and/or administration of an antagonist. In the short-term management of acute pain, physical dependence usually does not develop because of the limited duration of opioid use. Physical dependence is not addiction, but can develop as a part of the process of developing addiction.

**Withdrawal** involves developing signs of illness/discomfort when intake of the substance is abruptly stopped. Withdrawal is not addiction but can occur in people who are addicted and is characteristic for physical dependence. Many people who have taken opioids or sedatives for more than a few doses (but usually after one or two weeks of steady dosing) will show some tolerance with use and withdrawal on abrupt drug cessation. In addition, numerous drugs can produce tolerance and withdrawal, yet do not produce addiction (e.g., epilepsy medications, some blood pressure drugs). Symptoms of withdrawal for which to monitor include sweating, goose flesh, runny nose, abdominal cramping, diarrhea, nervousness, agitation, hallucinations, and a fast heartbeat. Tell a health care professional or pharmacist if these or other side effects occur. Obtaining refills on time will prevent withdrawal.

**Tolerance** is a phenomenon or adaptation of the body over a period of time in which one or more effects of a drug diminish with repeated use at the same dose (many patients call this becoming “immune” to the drug). For example, a person might feel drugged after the first pain pill; but with continued use, a person might require several pills to feel anything including pain relief. With analgesics, the concern is that the individual will build up tolerance to the drug and therefore require more medication to achieve results. Unfortunately, in many cases, increasing doses of
medications may lead to increased or intolerable side effects. Analgesic tolerance is not addiction, but does occur in people who are addicted.

Although questions remain, it is known that tolerance to the different side effects does not develop at the same rate. For example, one rapidly becomes tolerant to the sedating effects of the opioids. It has been shown that people with cancer who take large but stable doses of morphine show little or no sedation. However, if not prevented, they do continue to experience constipation as individuals do not develop tolerance to this side effect.

The real question, of course, is the extent to which tolerance develops to the analgesic effects of the drugs; that is, how soon do the drugs lose their ability to reduce pain? This is unclear and the answer seems to vary in different people and with different types of pain. Some people seem to benefit from the same dose of an opioid for years, while others rapidly require increased doses and still have unsatisfactory relief. Older people with pain may not become tolerant as quickly to the analgesic effects of opioids as younger people with pain. In some patients, a progression of their disease may lead to increased pain signals or to pathology that leads to pain that is not sensitive to opioids. This disease progression can be misinterpreted as opioid tolerance.

**Pseudo-tolerance** is the need to increase medications such as opioids for pain when other factors are present that may be the underlying cause, such as disease progression, new disease, increased physical activity, prescription of inadequate doses, lack of compliance, change in medication, and drug interactions.

**Functional impairment** and physical inactivity are additional concerns that make health care professionals reluctant to provide long-term opioid therapy. It is well known that a sedentary life decreases blood flow, impedes healing, decreases muscle tone, and contributes to depression, bone loss, and fatigue. Clearly, some people become inactive and passive on opioids, while others become more active. It may be that some are able to obtain good analgesia without taking enough to produce intoxication, while others are not able to do so.

**Drug misuse** refers to the intentional or unintentional incorrect use of opioids in a manner other than that prescribed.

**Diversion** is allowing others to have access to one’s prescribed opioids. Diversion can be as simple as sharing one’s medications with family members or friends on an occasional basis or can represent a conscious decision to distribute or sell them to others. Another definition of diversion is the intentional removal of a medication from legitimate distribution and dispensing channels for illicit sale or distribution. It is a federal crime to divert opioids from the person for whom they have been prescribed. Opioid diversion has been a major contributor to the steep rise in opioid-related deaths in the U.S.
The Opioid Dilemma

Considerable controversy exists about the use of opioids for the treatment of chronic pain that will last a lifetime. Many health care professionals think that chronic pain is inadequately treated and that opioids can play an important role in the treatment of all types of chronic pain, including non-cancer pain. Others caution against the widespread use of opioids, noting problems with tolerance, loss of benefit with time, and escalating usage despite decreasing function and increasing side-effects in some individuals, as well as the possibility of developing addiction for others.

The use of opioids (or for that matter any treatment) makes sense when the benefits outweigh the risks and negative side effects. Benefit is suggested when there is an increase in the person’s level of functioning, a reduction or elimination of pain complaints, a more positive, hopeful attitude, and when side effects are minimal or controllable.

Opioids are not harmless drugs. The dilemma with the long-term use of opioids is that while opioid treatment may be prescribed to reduce pain and improve function, the treatment may actually result at times in just the opposite. Use of opioids can increase adverse events and drive polypharmacy when medications are added to treat side effects.

A person who is deciding whether or not to use opioids for pain relief should not just consider the risks vs. benefits of these medications. They should ask themselves whether they are at higher risk (factors include cigarette smoking, misuse with other drugs, strong family history, environmental exposure, history of sexual abuse) for misuse, abuse, or addiction than others. They should look at the bigger picture, and compare the risks and benefits of opioids to those of other treatments, many of which are safer and as or more effective for chronic pain.

In the opioid naïve person (someone new to opioid use), the use of opioids may heighten the risk of accidental death from respiratory depression. These risks greatly increase with higher doses and when opioids are taken in combination with other drugs (sedative–hypnotics) that also slow breathing, such as benzodiazepines. In fact, current medical evidence suggests that with rare exception, opioids and benzodiazepines (e.g., Valium) should not be prescribed at the same time.

According to the US Centers for Disease Control (CDC), more people died (47,055) from drug overdoses in the United States in 2014 than during any previous year on record with increases in opioid overdose deaths the driving factor. Opioid poisoning is the leading cause of injury death overall surpassing both firearm-related and motor vehicle-related deaths a year.

Due to the seriousness of this problem, the FDA is now requiring that special safety procedures called REMS (Risk Evaluation and Mitigation Strategies) be put into place to protect people. One of the components of REMS requires that people with pain who receive certain opioids must be given an informational brochure called a Medication Guide for the specific drug they receive each time they get a new prescription. It is designed to inform people about the serious risks associated with the drug.

The Medication Guide should be read each time a new prescription is received, even if the specific opioid being used has not changed, as there may be important new information added. The FDA
is also working in cooperation with other governmental agencies, state professional licensing boards, and societies of health care professionals to increase prescribers’ knowledge about appropriate prescribing and safe use of opioids. There is renewed emphasis on home storage and safe disposal of unused medication to help patients protect their families and others.

**Risk Evaluation and Mitigation Strategies**

Further information regarding REMS can be found at:

- **FDA Basics Webinar: A Brief Overview of Risk Evaluation and Mitigation Strategies (REMS)**
  
  [http://www.fda.gov/AboutFDA/Transparency/Basics/ucm325201.htm](http://www.fda.gov/AboutFDA/Transparency/Basics/ucm325201.htm)

- **Approved Risk Evaluation and Mitigation Strategies (REMS)**
  

- **Risk Evaluation and Mitigation Strategy (REMS)**
  

- **The Substance Abuse and Mental Health Services Administration (SAMHSA) provides additional information about Prescription Drug Misuse and Abuse**
  

**OTHER RISKS ARE MUCH MORE COMMON**

One out of every two patients taking oral opioids experiences at least one adverse event/effect. Approximately one out of five patients taking oral opioids discontinue use because of an adverse event or an associated side effect.

Prolonged use of opioids may result in problems including hyperalgesia (increased pain sensitivity), hormonal effects (decreased testosterone levels, decreased libido and sex drive, irregular menses, etc.), depression, impaired sleep patterns, and suppression of the immune system. The long-term use of opioids may also impair functional improvement in an individual’s recovery from surgery or long-standing musculoskeletal disorders. The prolonged use of opioids usually causes tolerance and physical dependence. As a separate issue, the use of opioids may trigger or worsen substance abuse and addiction.

Opioids can actually prolong or even increase pain. Research shows that long-term use of large quantities of opioids may interfere with the body’s natural pain relievers: the endorphins. Physical activity is thought to promote release of endorphins, thus, it is also possible that opioids could inhibit the body’s own mechanism of reducing pain by causing a person to be less active.
Additionally, long-term opioid use may cause depression in some patients, which may impede their ability to recover. A mechanism called hyperalgesia actually increases the brain’s sensitivity to pain in some people. An article on this topic, “A Comprehensive Review of Opioid-Induced Hyperalgesia,” may be found by visiting http://www.integration.samhsa.gov/pbhci-learning-community/Opioid-Induced_Hyperalgesia_Article.pdf. Stopping the opioid reduces this type of pain.

Reducing opioid dosage or eliminating it entirely in some people result in less pain but in others may create short-term increases in pain, but for all of the reasons listed above, long-term reduction in symptoms and improved well-being may represent a worthwhile tradeoff. However, it is important to remember that opioids should be stopped under the direction of a health care professional.

**OPIOID DOSING**

Morphine equivalent dosing, or MED, is a system used to equate different opioids and their varying potencies into a standard morphine equivalent value using a conversion chart created by the Centers for Disease Control and Prevention (CDC). A patient’s cumulative daily morphine equivalent dose is an indicator of potential dose-related risks for adverse drug reactions.

Although all doses of opioids carry risks, increasing vigilance is recommended for doses above 80 mg a day morphine equivalent dose (MED) as the known risk of adverse events rises while the evidence for increased benefit remains weak.

**CLINICAL GUIDELINES FOR THE USE OF OPIOID IN NON-CANCER CHRONIC PAIN**

The American Pain Society (http://www.americanpainsociety.org/) and the American Academy of Pain Medicine (http://www.painmed.org) published “Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain” which can be found at http://www.jpain.org/article/S1526-5900(08)00831-6/fulltext. The abstract of the article is as follows:

Abstract: Use of chronic opioid therapy for chronic noncancer pain has increased substantially. The American Pain Society and the American Academy of Pain Medicine commissioned a systematic review of the evidence on chronic opioid therapy for chronic noncancer pain and convened a multidisciplinary expert panel to review the evidence and formulate recommendations. Although evidence is limited, the expert panel concluded that chronic opioid therapy can be an effective therapy for carefully selected and monitored patients with chronic noncancer pain. However, opioids are also associated with potentially serious harms, including opioid-related adverse effects and outcomes related to the abuse potential of opioids. The recommendations presented in this document provide guidance on patient selection and risk stratification; informed consent and opioid management plans; initiation and titration of chronic opioid therapy; use of methadone; monitoring of patients on chronic opioid therapy; dose escalations, high-dose opioid therapy, opioid rotation, and indications for discontinuation of therapy; prevention and
management of opioid-related adverse effects; driving and work safety; identifying a medical home and when to obtain consultation; management of breakthrough pain; chronic opioid therapy in pregnancy; and opioid-related polices. Perspective: Safe and effective chronic opioid therapy for chronic noncancer pain requires clinical skills and knowledge in both the principles of opioid prescribing and on the assessment and management of risks associated with opioid abuse, addiction, and diversion. Although evidence is limited in many areas related to use of opioids for chronic noncancer pain, this guideline provides recommendations developed by a multidisciplinary expert panel after a systematic review of the evidence.

In early 2016, the CDC will be providing a “Guideline for Prescribing Opioids for Chronic Pain.” http://www.cdc.gov/drugoverdose/prescribing/guideline.html.

**KEY STEPS TO USE OPIOIDS SAFELY**

1. **Keep the health care professional informed.** Inform the health care professional about any past history of alcohol or substance abuse. All patients treated with opioids for pain require careful monitoring by their health care professional for signs of abuse and addiction and to determine when these analgesics are no longer needed.

2. **Follow directions carefully.** Opioids are associated with significant side effects, including drowsiness, constipation, and depressed breathing depending on the amount taken. Taking more than is prescribed could cause severe respiratory depression or death. Side effects should be reported. Do not crush, break, or dissolve pills. This can alter the rate at which the medication is absorbed and lead to overdose and death.

3. **Reduce the risk of drug interactions.** Do not mix opioids with alcohol, antihistamines, barbiturates, benzodiazepines and other sedatives including some muscle relaxants (e.g., Soma). All of these substances slow breathing and their combined effects could lead to life-threatening respiratory depression.

4. **Prevent theft and diversion.** Do not store opioids in the medicine cabinet or where others have access to the medications. The best strategy is to store medications in a locked box. Do not share medications with anyone else. Although you may feel you are helping someone in need, you may cause harm and even death. Sharing opioids is against the law.

5. **Keep track of when refills are needed** to prevent going without medications which can lead to withdrawal. Discuss refill strategies with the prescriber ahead of time. Some pain clinics will not fill prescriptions without a visit to the clinic. Other clinics will not fill prescriptions on Friday afternoons or weekends/evenings.

**OPIOIDS & THE GOALS OF PAIN MANAGEMENT**

There has been disagreement as to whether the goal of pain management should be to reduce pain or to improve the way people function in their daily lives. The consensus of the members of the
American Pain Society is that the primary goal in treating people with chronic pain with opioids is to increase the level of function rather than just to provide pain relief.

When people are less uncomfortable, they usually resume activities that they had previously avoided. If a person with pain fails to do this, it suggests that symptom relief has not occurred even though the person may believe that the medications “take the edge off.” Clearly, maximizing quality of life entails both factors: minimizing suffering and maximizing function. It is important to understand that the antianxiety and sedative actions of opioids may improve the person’s well-being in the short-term, but these effects rapidly develop tolerance and the opioid dose will need to be escalated to achieve the same level of “Well-being.” Opioids should be used for analgesia alone and when prescribing them the physician should inquire about the goals of opioid treatment and the limitations of opioid therapy. If reducing anxiety or sedation is desired, more appropriate medications and physical, behavioral therapies should be tried before escalating opioid dose. Additionally, opioids work best for constant pain at rest and less well for movement evoked pain. It is important that people using opioids do not try to elevate the dose of opioids to achieve an effect that would be best served by other treatments. While opioids are very useful medications they are not a complete answer to the reduction of pain and restoration of function.

Pain management is essentially rehabilitation. The person experiencing pain and the family must ask to what end they want to be rehabilitated. What does rehabilitation mean to each of them? Webster defines rehabilitation as “to restore to useful life through education and therapy.” If a person’s goal is solely to reduce pain at the expense of function, then he or she may overlook the more important (and attainable) goal of rehabilitation. The essence of rehabilitation and maintaining wellness is for the person to take an active part in the recovery process.

It is important to mention that taking opioids precludes certain types of employment, even if one is tolerant and does not have side effects. People should be aware of the rules currently put forth by Federal and State authorities.

If you use opioids to help manage your pain, it's important to take them, store them, and dispose of them properly. Watch this video to learn more. [http://www.theacpa.org/opioids/default.aspx](http://www.theacpa.org/opioids/default.aspx)

What is the place of opioid pain medication? There is no question about the usefulness of opioids in acute pain and end-of-life pain. We do not yet know when they are most helpful for chronic non-cancer pain. Benefit is suggested when there is a significant increase in the person’s level of functioning, reduction/elimination of pain complaints, a more positive and hopeful attitude, and when the side effects can be managed safely. Those who take opioids should not have the expectation of prolonged opioid use without concomitant benefits.
MONITORING OPIOID MEDICATION USE

Health care professionals who prescribe opioids are required to monitor for pain and any unusual drug-related behaviors as part of caring for their patients.

The most relevant areas for monitoring have been termed the Five A’s:

1. Analgesia (pain relief – often measured by a 10-point rating scale).
2. Affect (what is the patient’s mood?).
3. Activities of daily living (physical, psychological, and social functioning).
4. Adverse or side effects.
5. Aberrant or abnormal drug-related behaviors.

Some of the following questions may help clarify how appropriately opioid pain medications are being used and whether they are helping or harming the person’s well-being:

- **Is the person’s day centered around taking medication?** If so, consultation with the health care professional may clarify long-term risks and benefits of the medication and identify other treatment options.

- **Does the person take pain medication only on occasion, perhaps three or four times per week?** If this is the case, then the likelihood of addiction is low.

- **Have there been any other chemical (alcohol or drug) abuse problems in the person’s life?** If so, then it is important to inform the health care professional who will need to take that into consideration when prescribing. Often, people with pain with a history of substance use disorders are not ideal candidates for opioid treatment for pain management because the opioids may trigger recurrent addiction.

- **Does the person in pain spend most of the day resting, avoiding activity, or feeling depressed?** If so, that suggests the pain medication is failing to promote rehabilitation. Daily activity is necessary for the body to produce its own pain relievers, to maintain strength and flexibility, and to keep life full and meaningful. Encourage the person with pain to request recommendations from a health care professional for a graduated exercise program.

- **Is the person in pain able to function (work, household chores, and play) with pain medication in a way that is clearly better than without?** If so, chances are that the pain medication is contributing to wellness. Most people who are addicted to pain medications or other substances do not function well.

- **Is the person a smoker?** Smoking increases pain and reduces the effectiveness of opioids. Smokers tend to take higher doses of opioids and have greater risks for problems and addiction. Smoking itself is an addictive behavior and; therefore, a clear risk for opioid addiction. Opioids should be avoided in smokers.
The following may be signs that a person is being harmed more than helped by pain medication.

- Sleeping too much or having days and nights confused
- Decrease in appetite
- Inability to concentrate or short attention span
- Mood swings (especially irritability)
- Lack of involvement with others
- Difficulty functioning due to drug effects
- Use of drugs to regress rather than to facilitate involvement in life
- Lack of attention to appearance and hygiene
- Escalation of pain
- Continual dose escalation
- Increasing number of medications prescribed to treat the side effects of opioids

The ACPA Pain Log can be a useful tool for tracking many of the symptoms and impact that pain has on a person. View at [http://www.theacpa.org/painLog/default.aspx](http://www.theacpa.org/painLog/default.aspx).

While it is impossible to make generalized guidelines for when to provide opioids on a regular, ongoing basis, the person and his or her family can often help to determine whether these agents are useful. If family members see that the person with pain has lost control of his or her life, is less functional, and is more depressed when taking or increasing the dose of opioids than he or she was before, they should seek help.

Most research suggests that family members over-report their loved one’s pain, but they also may be the only ones who can accurately determine whether the person’s life, mood, function, attitude, and comfort have changed for the better or worse. The person taking the medication may be so aware of the discomfort produced when they miss doses of pills that they incorrectly conclude that they need the medication. This severe pain may in fact only represent withdrawal due to physical dependence, as opposed to a persistent need for analgesic therapy.

ACPA offers a three-part video series focused on the many challenges that family members experience when living with a person with pain. View at [http://www.theacpa.org/family-matters](http://www.theacpa.org/family-matters).
OPIOID TREATMENT AGREEMENT

Individuals with pain have an important responsibility with respect to opioids to ensure that both they, as well as others, will be able to have access to opioids in the future. When opioids are prescribed, people with pain are usually requested to formally communicate their agreement with the written therapeutic plan (a.k.a., Opioid Treatment Agreement---sometimes termed an Opioid Contract or Opioid Therapy Plan), and in particular, their understanding that the goal of opioid therapy is not the elimination of pain but rather its reduction to the point where measurable and meaningful increases in function are apparent. This would also include agreeing that they will obtain opioids only from one pharmacy and one medical provider, abstain from using other sedatives without express permission from the health care professional prescribing the opioids, and not engage in activities that would be interpreted as representing misuse or diversion of their medication. The health care professional should clarify what activities would be interpreted as such to ensure a common understanding.

The majority of persons who abuse opioids obtain the drug from friends or family members, often without the knowledge of the person for whom the medication is prescribed. Opioids used in this way, or sold or purchased illicitly, are unacceptable and would constitute misuse and abuse that would void the opioid treatment agreement and results in discontinuation of prescribed opioids. Further, it is important to take the opioid exactly as prescribed by the health care professional with respect to dose and to timing between doses and talk with the health care professional if a change in the prescription is thought to be needed.

The discussion of safe storage and disposal not only helps to prevent theft and subsequent abuse but also prevents accidental overdose by children, cognitively impaired family members, and pets. Patients should always be aware of how many refills and how many pills remain in their prescription. The goal of the agreement is to ensure that patients and caregivers have clear communication and safe, effective procedures when opioids are used. See sample agreement at http://www.aafp.org/fpm/2010/1100/fpm20101100p22-rt1.pdf.

An opioid treatment agreement may include random urine drug testing.

URINE DRUG TESTING (UDT) / URINE DRUG SCREENING (UDS)

Urine drug testing (UDT) or urine drug screening (UDS) is often ordered by the health care professional prior to starting opioids and at random intervals during treatment. UDT is used to check that the medications prescribed are being taken and that non-prescribed and/or illicit drugs are not used. Typically, urine tests include screening for prescription opioids, benzodiazepines, cocaine, heroin, amphetamines, and marijuana.
NALOXONE KITS FOR OVERDOSE PREVENTION

Fatal drug overdose has increased more than six-fold in the past three decades, causing over 43,000 Americans to die every year. Opioids - both prescription painkillers and heroin - are responsible for most of these deaths. The death rate from prescription opioid-caused overdose nearly quadrupled from 1999 to 2013, while deaths from heroin overdose rose an astounding 270 percent between 2010 and 2013. Together, heroin and prescription pain medications take the lives of almost 25,000 Americans per year - nearly 70 people per day. They also cause hundreds of thousands of non-fatal overdoses and an incalculable amount of emotional suffering and preventable health care expenses.

Opioid overdose is typically reversible through the timely administration of the medication naloxone and the provision of other emergency care. However, access to naloxone and other emergency treatment was historically limited by laws and regulations that pre-date the overdose epidemic. In an attempt to reverse the unprecedented increase in preventable overdose deaths, the majority of states have recently amended those laws to increase access to emergency care and treatment for opiate overdose with naloxone in the form of Narcan (injection) or Evzio (self-injecting) and a new intranasal version.

Naloxone is a prescription drug and is not a controlled substance and has no abuse potential. It is regularly carried by medical first responders and can be administered by ordinary citizens with little or no formal training. Because opioid overdose often occurs when the victim is with friends or family members, those people may be the best situated to act to save his or her life by administering naloxone. At the urging of organizations including the U.S. Conference of Mayors, the American Medical Association, the American Public Health Association, and the National Association of Boards of Pharmacy, a number of states have addressed the overdose epidemic by removing some legal barriers to the seeking of emergency medical care and the timely administration of naloxone. Many states have measures to provide for the wider prescription and use of naloxone by clarifying that prescribers acting in good faith may prescribe the drug to persons who may be able to use it to reverse overdose and by removing the possibility of negative legal action against prescribers and people who administer the drug. The second encourages bystanders to become “Good Samaritans” by summoning emergency responders without fear of arrest or other negative legal consequences.

Opioid overdose kills thousands of Americans every year. Many of those deaths are preventable through the timely provision of a relatively cheap, safe and effective drug and the summoning of emergency responders. As with most public health problems, there is no magic bullet to preventing overdose deaths.

Laws that encourage the prescription and use of naloxone and the timely seeking of emergency medical assistance will have the intended effect of reducing opioid overdose deaths. Since such laws have few if any foreseeable negative effects, can be implemented at little or no cost, and will likely save lives.
Consult with your prescriber about having a naloxone kit available to you in the event of possible overdose and make sure your family and friends are aware of its potential life-saving effect.

OTHER MEDICATIONS THAT CAN RELIEVE PAIN

ANTIDEPRESSANTS

One of the most common classes of drugs used to treat chronic pain is the antidepressant group. An antidepressant prescribed for pain treatment does not mean that the pain is psychiatric in origin. Antidepressant drugs have been used for many years to relieve pain.

There has long been a longstanding association between depression and chronic pain. Not surprisingly, the chemicals (neurotransmitters, such as serotonin and norepinephrine) in the brain and nervous system that play a key role in depression are also believed to be involved in chronic pain.

Some general considerations regarding antidepressants and pain are listed below.

- They do not work for pain only by relieving depression. In fact, they work as well for non-depressed people with pain as for those with depression.

- They do not work equally well for all types of pain. For example, they tend to be helpful for fibromyalgia, headache, and pain due to nerve damage (e.g., diabetic neuropathy) but generally are less helpful for most acute pain, including musculoskeletal sports-type injuries.

- How well they work has little to do with how effective they are as antidepressants. Some very effective antidepressants have virtually no ability to reduce pain.

HOW ANTIDEPRESSANTS MAY HELP

While most people know that pain signals go up the spinal cord to reach the brain, they may not be aware that there are signals coming down the spinal cord that can increase or reduce pain transmission. By increasing levels of chemicals (norepinephrine and serotonin) at nerve endings, antidepressants appear to strengthen the system that inhibits pain transmission.

The antidepressants that increase norepinephrine seem to have better pain relieving capabilities than those that increase serotonin. This helps to explain why the selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine (Prozac®) and paroxetine (Paxil®), work well for depression but do not have the same ability to control pain.

Some antidepressants may be useful in chronic pain because they effectively reduce anxiety and improve sleep without the risks of habit-forming medications. Some people with chronic pain are depressed and treating the depression may also help reduce the perception of pain. Many people with chronic pain find that antidepressants, along with learning other pain management skills, can help them regain control of their lives and keep their pain under control.
ANTIDEPRESSANT SIDE EFFECTS

The most common side effects of antidepressants are drowsiness, constipation, dry mouth, urinary retention, weight gain, and blurred vision. Some people experience nightmares or an increased heart rate. While some people experience minimal side effects, for others the side effects can be as bad as the pain. It is worth noting that different antidepressants have different side effects and tolerance to these side effects can develop with use.

Some cause more sleepiness while some cause less. Although some lower sex drive, desire may actually increase as pain, sleep, and mood improve. Some may lower blood pressure while others raise it. Some increase appetite while others do not. Several may cause dizziness.

If a person’s pain is helped by an antidepressant but the side effects are troublesome, it may be useful to change medications. Doing so may allow the benefit to be retained while reducing the undesirable side effects.

Some antidepressant drugs, especially those within the tricyclic group, such as amitriptyline (Elavil®), nortriptyline (Pamelor®), and desipramine (Norpramin®), can be fatal in overdose and should only be available and prescribed in limited supply.

The FDA has issued the following warning regarding antidepressant prescription use:

---

Suicidality and Antidepressant Drugs

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of [Insert established name] or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber.

---

American Chronic Pain Association
Copyright 2016
The optimal role for antidepressants in chronic pain is still being defined as research progresses. The qualities listed below seem clear, however.

- They do not have the potential to cause stomach inflammation and bleeding, as do the anti-inflammatory drugs. The use of antidepressants (e.g., SSRIs) with NSAIDs should occur with caution secondary to a higher risk of GI bleeding.
- They do not seem to interfere with the body’s internal pain fighting mechanisms; in fact, they probably strengthen them by increasing the effects of chemical messengers, such as norepinephrine and serotonin, in the nervous system.
- Many act as sedatives to promote a good night’s sleep. Sleep deprivation is often one of the major obstacles in coping with chronic pain. In fact, with severe sleep deprivation, one cannot cope with much of anything.
- They may help to reduce depression.
- They may help to relieve anxiety and panic attacks.
- They may increase the effect of other pain relieving drugs or analgesics.
- They are non-addictive pain medications and loss of effect due to tolerance does not occur after the optimal dose for a given person has been determined.
- They have a record of long-term safety and are among the most widely used drugs in medicine.

There is evidence that antidepressants may work at lower doses and blood levels for chronic pain than are required for depression and they may produce responses sooner than the three to five weeks typical for depression treatment. This is not always true, however, and some people require higher doses for maximum pain relief.

### Pain States That May Respond To Antidepressants

<table>
<thead>
<tr>
<th>Pain State</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Postherpetic neuralgia</td>
<td>Migraine &amp; Tension Headache</td>
</tr>
<tr>
<td>Diabetic neuropathy</td>
<td>Chemotherapy-induced peripheral neuropathy</td>
</tr>
<tr>
<td>Phantom limb pain</td>
<td>Fibromyalgia</td>
</tr>
<tr>
<td>Stump / neuroma pain</td>
<td>Irritable Bowel Syndrome</td>
</tr>
<tr>
<td>Central pain (following stroke)</td>
<td>Rheumatoid arthritis</td>
</tr>
<tr>
<td>Sympathetic dystrophy (CRPS/RSD)</td>
<td>Neuropathic pain</td>
</tr>
<tr>
<td>Chronic musculoskeletal pain</td>
<td>Low back pain with radiculopathy</td>
</tr>
</tbody>
</table>
There are three main classes of antidepressant medications used in the management of chronic pain.

**Tricyclic Antidepressants (TCAs)**

The first class is the tricyclic antidepressants (TCAs) and includes amitriptyline (Elavil®), doxepin (Sinequan®), imipramine (Tofranil®), desipramine (Norpramin®), nortriptyline (Aventyl®, Pamelor®), protriptyline (Vivactil®), trimipramine (Surmontil®), and clomipramine (Anafranil®). Also included are trazodone (Desyrel®), maprotiline (Ludiomil®), and mirtazapine (Remeron®), which are tetracyclic antidepressants (which are structurally different from TCAs and have different side effects).

The TCAs have been used for many years to treat depression. TCAs and related drugs can be roughly divided into those with additional sedative and relaxing properties and those that are less so. Agitated and anxious patients tend to respond best to antidepressants with sedative properties whereas withdrawn individuals and those with less energy will often obtain the most benefit from less sedating antidepressants. This class of antidepressants has been proven to have pain-relieving effects, typically at lower doses than required to treat depression.

The different tricyclic drugs have varied side effects that may sometimes be used to the patient’s advantage. For the overweight patient with lethargy and tiredness, the clinician may choose a TCA with more noradrenergic selectivity (e.g., desipramine), which may be activating and can cause some anorexia. Desipramine is considered to have the lowest side effect profile of the TCAs. For others with poor sleep hygiene, the sedating properties of certain TCAs, such as amitriptyline or doxepin, may be helpful.

Some of these drugs, such as amitriptyline (Elavil®), nortriptyline (Pamelor®), and desipramine (Norpramin®), can be fatal in overdose and should only be available and prescribed in limited supply.

Tricyclic antidepressants (TCAs) can have significant anticholinergic effects, which can include confusion, blurred vision, worsening of glaucoma, constipation, dry mouth, light-headedness, and difficulty with urination or loss of bladder control. In older patients with decreased cognitive abilities, the use of a tricyclic antidepressant can lead to significant confusion. Patients with Alzheimer’s disease should not be started on TCAs. The American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults was in October 2015. They include lists of potentially inappropriate medications to be avoided in older adults. The Internet links is [http://onlinelibrary.wiley.com/doi/10.1111/jgs.13702/full](http://onlinelibrary.wiley.com/doi/10.1111/jgs.13702/full).

Also, patients with cardiovascular disease (CVD) should avoid the use of tricyclic antidepressants or be followed closely by a health care professional for cardiac abnormalities that can worsen with their use. In a study published online in December 2010 in the *European Heart Journal*, the authors assessed the association between antidepressant medication use and future risk for CVD. The study
suggested TCAs are associated with a 35 percent increased risk for CVD, which is not explained by existing psychiatric illness.

They may increase appetite and be associated with weight gain. Go to the following web site for further information about TCA toxicity at [http://www.emedicine.com/emerg/topic616.htm](http://www.emedicine.com/emerg/topic616.htm).

**SELECTIVE SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs)**

The second class includes a number of drugs that are mixed serotonin and norepinephrine reuptake inhibitors or SNRIs. These medications have no cholinergic inhibition and, thus, they are associated with fewer side effects than TCAs.

Duloxetine (Cymbalta®), venlafaxine (Effexor®), desvenlafaxine (Pristiq®), milnacipran (Savella™), and levomilnacipran (Fetzima®) are the SNRIs that are most commonly encountered in association with pain management.

Duloxetine has been approved for management of painful diabetic peripheral neuropathy, fibromyalgia, anxiety disorder, depression, and in 2010 for chronic musculoskeletal pain including osteoarthritis and chronic low back pain.

Milnacipran has been approved for the management of fibromyalgia. Milnacipran more potently inhibits the reuptake of norepinephrine than duloxetine and venlafaxine.

Venlafaxine (Effexor®) has been shown to have therapeutic benefit in the treatment of neuropathic pain. Venlafaxine is available in an extended-release formulation which has a better tolerability profile than the immediate-release formulation. Blood pressure should be monitored in these patients because venlafaxine can increase systolic blood pressure.

Some of the side effects associated with SNRIs can include nausea, vomiting, dizziness, sleepiness, trouble sleeping, abnormal dreams, constipation, sweating, dry mouth, yawning, tremor, gas, anxiety, agitation, abnormal vision such as blurred vision or double vision, headache, and sexual dysfunction. Abrupt withdrawal of SNRIs should be avoided (associated with anxiety, vivid dreams and other symptoms).

**SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)**

The third class of drugs, the selective serotonin reuptake inhibitors (SSRIs), includes fluoxetine (Prozac®), sertraline (Zoloft®), paroxetine (Paxil®), fluvoxamine (Luvox®), citalopram (Celexa™), escitalopram (Lexapro®), vilazodone (Viibryd®), and vortioxetine (Brintellix®).

The SSRIs have fewer side effects and are less sedating than the tricyclic antidepressants. They are effective antidepressants and can be used for headache prevention, but they are less effective and of questionable benefit for other types of chronic pain.
SSRIs have been disappointing for neuropathic pain. Most studies of the serotonin-selective type (non-tricyclic) antidepressants have shown little or no pain relief.

Some of the side effects associated with SSRIs include dry mouth, stomach distress with nausea and vomiting, diarrhea, sweating, poor appetite, dizziness, tremors, drowsiness, anxiety, nervousness, insomnia, headache, increased blood pressure, increased heart rate, increased cholesterol levels, and sexual problems. Abnormal bleeding can occur especially in individuals currently using an NSAID.

SSRIs should be used with caution in patients with epilepsy, history of mania, cardiac disease, diabetes, angle-closure glaucoma, concomitant use of drugs that increase risk of bleeding, history of bleeding disorders (especially GI bleeding), disorders of the liver and kidneys, pregnancy, and breast-feeding. SSRIs, particularly paroxetine, may also impair performance of skilled tasks (e.g., driving) by causing drowsiness. Use within 14 days of an MAO inhibitor should be avoided.

Abrupt withdrawal of SSRIs should be avoided (associated with headache, nausea, burning or tingling sensation in the extremities, dizziness, and anxiety).

**Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)**

A fourth class of antidepressants includes a number of drugs that are norepinephrine-dopamine reuptake inhibitors or NDRIs. They are primarily used in the treatment of depression, but are also prescribed for smoking cessation and for the treatment of attention deficit disorder. They are not particularly useful for chronic pain.

The only NDRI that is approved by The Food and Drug Administration for the treatment of depression is bupropion (Wellbutrin®).

Although marketed for different indications, Wellbutrin® (depressant) and Zyban® (smoking cessation) contain the same active ingredient and therefore, should not be taken concurrently without close health care professional supervision.

**Other Antidepressants**

Trazodone (Desyrel®) was developed for the treatment of depression, but is much more frequently used today to alleviate insomnia. It is not commonly used for chronic pain. Some of the most common side effects of trazodone are sedation, dry mouth and dizziness. Extremely rare but dangerous side effects of trazodone is Priapism – a prolonged painful erection. If it occurs, an admission to emergency department is necessary for a treatment with an antidote.

Mirtazapine (Remeron®) can cause sedation, increased appetite, weight gain, increased cholesterol, dizziness, dry mouth, and constipation.
The monoamine oxidase inhibitors (MAOIs) are very rarely used nowadays and generally not used to treat chronic pain. Those such as phenelzine (Nardil®), tranylcypromine (Parnate®), isocarboxazid (Marplan®), and selegiline (Eldepryl®) commonly cause weakness, dizziness, headaches and tremor. While selegiline is used to treat Parkinson’s disease, the other MAOIs are used as antidepressants. They also have many drug-drug and drug-food interactions further limiting their use.

**STopping Antidepressants:** As stated earlier, antidepressants rarely should be stopped abruptly. Always consult your health care provider before discontinuing an antidepressant.

**Alert: Mixing Anti-Migraine Agents & Certain Antidepressants**

*Dr. Mary Pickett responded in July 2006 to a News Review from Harvard Medical School – “Don’t Mix Migraine, Depression Meds,” and some of her comments are summarized as follows.*

The Food and Drug Administration warned people taking certain anti-migraine medications and certain drugs to treat depression that they may be at risk for a dangerous chemical imbalance. Antidepressant medications (SSRI and SNRI) include (but not limited to) in this warning but not limited to) (are fluoxetine, sertraline, paroxetine, escitalopram, duloxetine, milnacipran, and venlafaxine. Migraine drugs included naratriptan (Amerge®, almotriptan (AxertTM), sumatriptan (Imitrex®), and zolmitriptan (Zomig®).

Serotonin is a brain hormone that keeps mood stable and appetite in check, as well as serving other functions. More than 50 commonly prescribed medicines boost the amount or effect of serotonin in the body. When two or more drugs that affect serotonin levels are taken, they can increase the amount of serotonin and may lead to bothersome or dangerous symptoms. This is called "serotonin syndrome."

The combination of a "triptan" anti-migraine medicine and almost any antidepressant may increase brain serotonin level. Mild serotonin symptoms from even one medicine can occur (common serotonin-related side effects from antidepressant medicines include headache, pain in the stomach, diarrhea, nausea, flushing, or trembling).

A much more severe form of serotonin syndrome can occur not only with a single antidepressant but also if several medicines with a serotonin effect are combined. Severe serotonin syndrome (requiring a hospital stay or resulting in permanent harm) is quite rare. Serotonin can cause a variety of symptoms — no one gets all the symptoms at once, but anyone with too much serotonin will have at least a few symptoms. These symptoms can include mental changes such as anxiety, confusion, delirium, hallucinations, headaches, insomnia, mania (constant and sometimes senseless activity without rests), or coma; nerve or muscle symptoms such as tremor (shaking), unsteady coordination, muscle jerks, abnormally jumpy reflexes, jerking eye movements or changes in pupil size, restlessness, or seizures; temperature or vital sign control problems which can include sweating or flushing, fevers, hyperventilation, slowed breathing, a change in heart
rhythm, or high or abnormally low blood pressure; and digestive symptoms including abdominal pain, nausea, vomiting, or diarrhea.

Those who take an antidepressant or anti-anxiety medicine (or a close friend or family member who does) should review the following list of drugs that can add to one’s serotonin load. This is a reasonably comprehensive list. Use caution when overlapping medicines and watch for serotonin symptoms when doses of any of these medicines are increased.

Antidepressants, anti-anxiety, and mood stabilizing medicines including fluoxetine (Prozac®, Sarafem®), paroxetine (Paxil®), sertraline (Zoloft®), citalopram (Celexa®), escitalopram (Lexapro®), trazodone (Desyrel®), venlafaxine (Effexor®), desvenlafaxine (Pristiq®), duloxetine (Cymbalta®), levomilnacipran (Fetzima®), vilazodone (Viibryd®) clomipramine (Anafranil®), buspirone (BuSpar®), mirtazapine (Remeron®), lithium (Eskalith®), divalproex sodium (Depakote®), carbamazepine (Tegretol®), St. John’s Wort, phenelzine (Nardil®), tranylcypromine (Parnate®), or isocarboxazid (Marplan®).

Anti-migraine medicines in either the ‘triptan’ or ‘ergot’ groups including sumatriptan (Imitrex®), almotriptan (AxertTM), eletriptan (Relpax®), frovatriptan (Frova®), naratriptan (Amerge®), rizatriptan (Maxalt®), zolmitriptan (Zomig®), ergotamine/caffeine (Cafergot®), or dihydroergotamine (DHE 45®, Migranal®).

Diet pills, specifically L-tryptophan (5-HTP), sibutramine (Meridia®), or phentermine (Ionamin®).

Certain pain medicines including tramadol (Ultram®), fentanyl (Duragesic® patch, Actiq®), pentazocine (Talwin®), duloxetine (Cymbalta®), tapentadol (Nucynta®), or meperidine (Demerol®).

Certain drugs for nausea, specifically ondansetron (Zofran®), dolasetron (Anzemet®), granisetron (Kytril®), or metoclopramide (Reglan®).

Cough syrups or cold medicines if they contain the anti-cough ingredient dextromethorphan (DM, Delsym®), or the antibiotic linezolid (Zyvox™).

**NOT RECOMMENDED FOR CHRONIC PAIN**

**ANTI-PYSCHOTIC MEDICATIONS**

This class of drugs is marketed primarily because of its ability to reduce hallucinations and psychotic thinking, although some members of the class are used to treat nausea and migraine.

Commonly used medications in this class include aripiprazole (Abilify™), brexpiprazole (Rexulti®), haloperidol (Haldol®), olanzapine (Zyprexa®), quetiapine (Seroquel®), risperidone (Risperdal®), paliperidone (Invega®), ziprasidone (Geodon®), lurasidone (Latuda®), azenapine (Saphris®), and iloperidone (Fanapt®).
In general, their use in chronic pain is not recommended.

They are often used off label as anti-anxiety or sleep medications in low doses. They are strong drugs and have the potential to cause Parkinson’s-like reactions, e.g., tremors, stiffness, or even a permanent neurological condition called tardive dyskinesia. In mild cases, this consists of involuntary movements of the mouth and tongue, which is mostly a cosmetic problem; however, in more severe cases there can be severe muscle activity that interferes with ability to function and even to breathe. For these reasons, they are usually considered “last resort” drugs. Toxicity of antipsychotics is discussed at http://www.emedicine.com/EMERG/topic338.htm.

BENZODIAZEPINES

Benzodiazepines are listed here under a separate heading but are mentioned frequently throughout this document. Most benzodiazepines are not recommended for chronic pain.

Most people experience anxiety at one time or another in their lives. Anxiety can present as nervousness or sweaty palms, irritability, uneasiness, feelings of apprehension, tight muscles, and difficulty sleeping. Anxiety is often mild, but if it becomes severe, counseling or medications may be needed. The most widely prescribed drugs for anxiety are benzodiazepines like diazepam (Valium®), lorazepam (Ativan®), clonazepam (Klonopin®), flurazepam (Dalmane®), triazolam (Halcion®), temazepam (Restoril®), and alprazolam (Xanax®). They are also used as muscle relaxants and for insomnia (difficulty sleeping). Their use as sleep aids should be limited to only short term as they do not work well when used continuously each night to produce sleep.

Most benzodiazepines are recognized for causing depression and physical dependence when used for long periods. None of them are recommended for long term use.

Side effects are similar to those of alcohol and include sedation, slurred speech, and gait unsteadiness. Other adverse reactions include chest pain and a pounding heartbeat, psychological changes, headache, nausea, restlessness, vision problems, nightmares, and unexplained fatigue. Alcohol and tobacco should be avoided while taking these drugs. Another major side effect is respiratory depression, particularly when combined with long-acting opioids. Extreme caution should be used when prescribing both opioids and benzodiazepines concomitantly. In fact, this dangerous combination should be avoided. The majority of unintentional overdoses occurs when opioids and benzodiazepines are used at the same time.

Because of withdrawal symptoms, these drugs should be discontinued slowly under a health care professional’s supervision. Withdrawal reactions may be mistaken for anxiety since many of the symptoms are similar. Without medical supervision, benzodiazepine withdrawal can be associated with seizures or death.
**Antiepileptic (Anticonvulsant) Drugs**

Antiepileptic medications have been found to be widely effective in various neuropathic pain conditions.

Several drugs that were developed for the prevention of epileptic seizures (convulsions) have been found to help certain pain conditions. For example, carbamazepine (Carbatrol®, Tegretol®) is approved by the FDA for relieving the pain of trigeminal neuralgia. Gabapentin (Neurontin®) is approved for the management of postherpetic neuralgia (PHN; pain that lasts one to three months after shingles has healed). Pregabalin (Lyrica®) is approved for PHN, painful diabetic neuropathic pain, and fibromyalgia. Nevertheless, most use of antiepileptics for pain is “off label.”

Although these medications are not habit forming, abrupt discontinuation can be hazardous. Antiepileptics should be stopped only after discussing how to do so with a health care professional. Common side effects are drowsiness, peripheral edema (lower extremity swelling), and unsteady gait or poor balance. These symptoms tend to diminish over time.

Gabapentin (Neurontin®) is widely utilized and has proven to be effective in many people for nerve injury or neuropathic pain. Decreased mental alertness or awareness is possible especially at higher doses, but this is variable and is person specific. Generic gabapentin is now available. In January 2011, Gralise®, a once-a-day gabapentin, was approved by the FDA. Gralise® is indicated for the management of postherpetic neuralgia (PHN). Gralise® is not interchangeable with other gabapentin products because of differing pharmacokinetic profiles that affect the frequency of administration. Dosage and administration: Gralise® should be titrated to an 1800 mg dose taken orally, once-daily, with the evening meal. Gralise® should be swallowed whole. Do not crush, split, or chew the tablet. Gralise dosage forms and strengths: 300 and 600 mg tablets. There is a difference in individual tolerability and experience of adverse effects with each medication.

A similar drug to gabapentin, pregabalin (Lyrica®), has been found to be effective in postherpetic neuralgia, fibromyalgia, and diabetic neuropathy. Its primary advantage over gabapentin is thought to be pregabalin’s longer duration of action, allowing a twice daily dosing and improved absorption; however, there is no evidence that this translates to an increased clinical effect. Pregabalin is not associated with significant drug interactions and can be used over a wide dose range (150 to 600 mg/day). Its side effect profile is similar to gabapentin, and it is generally well tolerated. Side effects are mostly mild-to-moderate and transient, with dizziness and somnolence being the most common. Other adverse effects include dry mouth, peripheral edema, blurred vision, weight gain, and concentration or attention difficulties. Often, gabapentin and pregabalin require a period of time before their effectiveness in treating a person with pain is realized because the medications need to be titrated to the appropriate dose.

The FDA issued a warning on the use of antiepileptics and the risks of suicidal thoughts and suicide. Patients utilizing antiepileptics for pain control should be monitored for any signs and symptoms of suicidal thoughts. There have been scattered reports of misuse of gabapentin and pregabalin for their intoxicating effects.

American Chronic Pain Association  
Copyright 2016
Decreased mental alertness or awareness and magnified antidepressant is taken with an opioid and/or benzodiazepine.

<table>
<thead>
<tr>
<th>Antiepileptics Possibly Useful in Chronic Pain</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gabapentin</strong> (Neurontin®)</td>
</tr>
<tr>
<td>Has proven to be effective in some people for nerve injury or neuropathic pain. Seems safer, easier to use. Some mental fuzziness possible at higher doses.</td>
</tr>
<tr>
<td><strong>Pregabalin</strong> (Lyrica®)</td>
</tr>
<tr>
<td>Found to be effective in postherpetic neuralgia, diabetic neuropathy, and fibromyalgia. Some advantages over gabapentin. It is generally well tolerated.</td>
</tr>
<tr>
<td><strong>Carbamazepine</strong> <strong>(Tegretol®)</strong></td>
</tr>
<tr>
<td>Interacts with some other drugs, can affect the liver and white blood cells. Used for trigeminal neuralgia.</td>
</tr>
<tr>
<td><strong>Valproic acid</strong> <strong>(Depakote®)</strong></td>
</tr>
<tr>
<td>Used in headache or nerve pain. May affect platelets as an adverse effect.</td>
</tr>
<tr>
<td><strong>Phenytoin</strong> <strong>(Dilantin®)</strong></td>
</tr>
<tr>
<td>Stronger evidence supports the use of the above agents over phenytoin. The risk of adverse effects and drug interactions also precludes its regular use.</td>
</tr>
<tr>
<td><strong>Lamotrigine</strong> (Lamictal®)</td>
</tr>
<tr>
<td>May be useful for pain refractory to carbamazepine. Used in trigeminal neuralgia, and central pain. Not FDA approved and clinically not recommended for neuropathic pain. May cause dizziness, constipation, nausea, decreased mental awareness, etc.</td>
</tr>
<tr>
<td><strong>Tiagabine</strong> (Gabitril®)</td>
</tr>
<tr>
<td>Used in combination with other anticonvulsant agents in the management of partial seizures. Possibly useful in treating neuropathic pain. Most common side effects include nonspecific dizziness, drowsiness, and difficulty with concentration. Has been associated with new onset seizures and status epilepticus in patients without epilepsy.</td>
</tr>
<tr>
<td><strong>Lacosamide</strong> (Vimpat®)</td>
</tr>
<tr>
<td>Lacosamide is an anticonvulsant.</td>
</tr>
<tr>
<td><strong>Topiramate</strong> (Topamax®, Topiragen™)</td>
</tr>
<tr>
<td>Generally, well tolerated but sometimes causes confusion, dizziness, fatigue, and problems with coordination and concentration. Minimally useful in treating neuropathic and sympathetically maintained pain. It is also being used as a preventive migraine treatment. Side effects include strange sensations and loss of appetite. May cause secondary angle closure glaucoma and, if left untreated, may lead to permanent vision loss. It may also cause dose-related weight loss and cause or predispose the patient to kidney stones.</td>
</tr>
<tr>
<td><strong>Levetiracetam</strong> (Keppra®)</td>
</tr>
<tr>
<td>Indicated for use as adjunctive therapy in the treatment of partial seizures in adults. It is possibly effective in neuropathic pain.</td>
</tr>
<tr>
<td><strong>Oxcarbazepine</strong> (Trileptal®)</td>
</tr>
<tr>
<td><strong>Zonisamide</strong> (Zonegran®)</td>
</tr>
<tr>
<td>Indicated for use as adjunctive therapy for treatment of partial seizures (or focal seizures) in adults with epilepsy. Possibly useful in treating neuropathic pain.</td>
</tr>
</tbody>
</table>

*Only gabapentin and pregabalin are approved by the FDA and have solid evidence of efficacy in general neuropathic pain.*
Carbamazepine, Valproic Acid, and Phenytoin can reach toxic level in blood leading to death and may also cause serious damage to liver, pancreas, and blood cells leading to fatalities. Regular safety blood checks are mandated when taking these three medications, including their blood levels, complete blood count, and liver function test.

**SODIUM CHANNEL BLOCKING & ORAL ANTI-ARRHYTHMIC AGENTS**

Intravenous lidocaine has strong sodium channel blocking properties and has demonstrated efficacy in several uncontrolled studies on neuropathic pain. Some pain centers use intravenous lidocaine both as a diagnostic tool to assess responsiveness to a subsequent oral sodium channel blocker (e.g., mexiletine, oxcarbazepine, and carbamazepine) as well as a therapeutic tool when delivered in an inpatient setting.

Those anti-arrhythmics with local anesthetic properties are rarely used in refractory or difficult to treat pain. They are approved for the prevention of disturbances in heart rhythm, but just as they interrupt premature firing of heart fibers, they also diminish premature firing of damaged nerves. This leads to less firing of the nerve and hence less capability of the nerve to trigger pain.

Due to safety concerns, the only anti-arrhythmics that are occasionally used for chronic pain are mexiletine (Mexitil®) and rarely flecainide (Tambocor™) due to possible cardiac side effects. They reduce pain in diabetic neuropathy, post stroke pain, complex regional pain syndrome (CRPS), and traumatic nerve injury.

Mexiletine is chemically similar to lidocaine, an anesthetic. Common side effects of mexiletine include dizziness, anxiety, unsteadiness when walking, heartburn, nausea, and vomiting. Consult a health care professional if pregnant or planning to get pregnant, have a history of heart attack, are a smoker, or take any of the following medications: amiodarone, fluvoxamine, dofetilide (Tikosyn®), bupropion, or sodium bicarbonate. Mexiletine should be taken three times daily with food to lessen stomach irritation. Infrequent adverse reactions include sore throat, fever, mouth sores, blurred vision, confusion, constipation, diarrhea, headache, and numbness or tingling in the hands and feet. Serious symptoms occur with overdose including seizures, convulsions, chest pain, shortness of breath, irregular or fast heartbeat, and cardiac arrest.

Flecainide (Tambocor™) was approved to treat arrhythmias and can slow a fast heart rate. It has also been effective for treating certain painful conditions related to neuropathic pain. Although cardiac side effects with flecainide may be infrequent, they can be catastrophic. An EKG is recommended before treatment is started. This drug should probably not be used for pain management in patients with a history of cardiovascular or heart disease. The health care professional should be made aware of any kidney or liver problems because this may require monitoring of drug levels or a dosage reduction. Flecainide interacts with amiodarone, several antipsychotic and anti-arrhythmic medications, and ranolazine (Ranexa®). Common side effects, which usually occur within the first two to four weeks of therapy, are nausea or vomiting, constipation, headache, dizziness, visual disturbances, edema, and tremor.
TOPICAL PAIN RELIEVERS

Creams, gels, sprays, liquids, patches, or rubs applied on the skin over a painful muscle or joint are called topical pain relievers or topical analgesics. Topical agents have also gained popularity for use in certain neuropathic pain conditions such as diabetic neuropathy, postherpetic neuralgia (PHN), or neuroma pain. They are also prescribed in CRPS states. Many are available over-the-counter without a prescription.

Topical agents should be distinguished from transdermal medications, which are also applied directly to the skin. Whereas topical agents work locally and must be applied directly over the painful area, transdermal drugs have effects throughout the body and work when applied away from the area of pain (currently available transdermal drugs include fentanyl, buprenorphine, and clonidine; topical drugs include diclofenac and lidocaine with or without tetracaine and prilocaine). Transdermal medication in a patch is absorbed through the skin by the bloodstream over a period of time. (In general, never cut a transdermal patch into smaller pieces, but topical lidocaine patches may be cut into smaller sizes with scissors as noted on the packaging.)

Some of the OTC topical agents contain salicylates, a family of drugs that reduce inflammation and pain. They come from the bark of the willow tree and are the pain relieving substances found in aspirin. Small amounts relieve mild pain. Larger amounts may reduce both pain and inflammation. Salicylates decrease the ability of the nerve endings in the skin to sense pain. Large amounts can be absorbed and lead to similar adverse effects as when given orally.

Counterirritants, another group of topical agents, are specifically approved for the topical treatment of minor aches and pains of muscles and joints (simple backache, arthritis pain, strains, bruises, and sprains). They stimulate nerve endings in the skin to cause feelings of cold, warmth, or itching. This produces a paradoxical pain-relieving effect by producing less severe pain to counter a more intense one. Some topical pain relievers (counterirritants) are methyl salicylate, menthol, camphor, eucalyptus oil, turpentine oil, histamine dihydrochloride, and methyl nicotinate.

Counterirritants come in various forms such as balms, creams, gels, and patches under several brands such as BenGay®, Icy Hot®, Salonpas®, and Thera-Gesic® for ease of application. The balms, creams, and gels can be applied to the painful area(s) three to four times a day (usually for up to one week). When using the BenGay® patch product, one patch can be applied for up to 8 to 12 hours; if pain is still present, a second patch may be applied for up to 8 to 12 hours (maximum: 2 patches in 24 hours for no longer than 3 days of consecutive use). The Salonpas® Pain Relief Patch® (10% methyl salicylate and 3% menthol) is currently the only FDA-approved OTC topical analgesic patch and can be applied up to 3 to 4 times/day for 7 days; the patch may remain in place for up to 8 hours. It is approved for temporary relief of mild-to-moderate aches and pains of muscles and joints associated with strains, sprains, simple backache, arthritis, and bruises.

Even though many of these products are sold without a prescription, they still carry some risk of adverse effects (mostly skin irritation). Topical products containing NSAIDs (e.g., diclofenac) are promoted as carrying less risk of side effects versus the oral NSAIDs (e.g., ibuprofen), but they still must be considered. The FDA warning regarding NSAIDs applies to both oral and topical medications. Also, these products should not be applied on wounds, damaged skin, or the face.
Lastly, after application, hands should be washed thoroughly to avoid getting these products in sensitive areas such as the eyes. When removing and discarding used patches, fold the used patches so that the adhesive side sticks to itself. Safely discard used patches where children and pets cannot get to them.

Prescription NSAID topicals are not recommended on larger “joints” the body such as the back.

Aspirin in chloroform or diethyl ether, capsaicin (Zostrix®, Zostrix®-HP, Qutenza™), EMLA® (eutectic mixture of local anesthetics; contains lidocaine and prilocaine) cream, and local anesthetics such as the lidocaine patch 5% (Lidoderm®) are topical treatments for neuropathic pain. Of these, the topical lidocaine patch 5% and capsaicin patch are the only FDA-approved treatments for neuropathic pain, and they require a prescription.

Capsaicin (cap-SAY-sin) is the active ingredient in hot peppers, which produces a characteristic heat sensation when applied to the skin (dermal drug delivery). Several studies have suggested that capsaicin can be an effective analgesic in at least some types of neuropathic pain and arthritic conditions (osteoarthritis and rheumatoid arthritis). An adequate trial of capsaicin usually requires four applications daily, around the clock, for at least three to four weeks. Some individuals may experience a burning sensation, which usually lessens within 72 hours with repeated use. Gloves should be worn during application, and hands should be washed with soap and water after application to avoid contact with the eyes or mucous membranes.

In late 2009, the FDA approved Qutenza™ (capsaicin) 8% patch for the management of neuropathic pain attributed to PHN that may occur after an episode of herpes zoster (shingles). The Qutenza™ patch releases a synthetic form of capsaicin through a dermal delivery system at a much stronger dosage than capsaicin creams available over the counter. Only physicians or other health care professionals under the close supervision of a physician are to administer Qutenza™. Qutenza™ is applied for 60 minutes and may be repeated every three months or as warranted by the return of pain (not more frequently than every three months). Before patch application, a physician must identify and mark the painful area, including areas of hypersensitivity. A topical anesthetic is applied before Qutenza™ application as it can create significant pain during application. In clinical trials, the most common adverse reactions were application site redness, pain, itching, and bumps. The majority of these reactions were transient and self-limited. Among patients treated with Qutenza™, one percent discontinued treatment prematurely due to an adverse event. Serious adverse reactions included application site pain and increased blood pressure. Information can be found at [http://www.qutenza.com/_docs/qutenza_full_PI_.pdf](http://www.qutenza.com/_docs/qutenza_full_PI_.pdf).

EMLA® cream is a combination of the local anesthetics lidocaine and prilocaine. This combination results in a relatively constant release of dissolvable local anesthetics that can diffuse through the skin and soft tissue. A thick layer of EMLA® cream is applied to intact skin and covered with an
occlusive dressing. The minimal application time to obtain reliable superficial pain relief is one hour. However, the cream may be left on the skin for up to two hours, depending on the degree of the procedure performed. Pain relief can be expected to increase for up to three hours under occlusive dressing and persist for one to two hours after removal of the cream. Side effects to EMLA® cream include skin blanching, redness, and swelling. In younger individuals or in cases in which too much has been applied, negative effects can occur to hemoglobin (red blood cells). Therefore, EMLA® cream should be avoided in individuals less than one month old and in patients with a predisposition to methemoglobinemia (a problem with the red cell). EMLA® cream should also not be applied to broken skin or mucous membranes (e.g., mouth). EMLA® requires a prescription in the U.S.

L.M.X.4® contains 4% lidocaine and is available without a prescription. It has a shorter application time (30 minutes) and a shorter duration of action (30 minutes) than EMLA. It has not been shown to be effective for chronic pain most likely because of its short duration. L.M.X.4® is available OTC in the U.S.

Lidoderm® 5% (lidocaine) patches can be cut to fit over the area of pain. The 5% lidocaine patch is FDA approved for the treatment of a neuropathic pain condition, specifically PHN, and requires a prescription. It measures 10 cm x 14 cm and has a clear plastic backing that must be removed before application of the patch to the skin. The manufacturer states that up to three patches can be applied simultaneously to intact skin for up to 12 hours in any 24-hour period. Generic lidocaine and is available in multiple forms (e.g., patch, gel, ointment) and can be less expensive.

Potential hazards still exist, however. In 2007, the FDA issued a public health advisory to notify consumers and health care professionals of potential life-threatening side effects associated with the use of topical anesthetics, particularly before cosmetic procedures. At risk are consumers, especially those without the supervision of a health care professional. Issues may arise particularly if the consumer applies large amounts of anesthetics or cover large areas of the skin, leaves these products on for long periods of time, or uses materials, wraps, or dressings to cover the skin after anesthetic application. Application to areas of skin irritation, rash, or broken skin may also increase the risk of systemic absorption. The FDA recommends that if topical anesthetics are needed prior to medical or cosmetic procedures, consumers ask their health care professional for instructions on the safe use of these products, use only FDA-approved products, and use products with the lowest amount of anesthetic while applying the least amount possible to relieve pain.
There are additional topical agent combinations, which can be compounded at a local pharmacy. They can be very expensive. These compounded mixtures are prepared uniquely for each individual but have not passed rigorous scientific study. Any benefit from such compounded creams is anecdotal.

Use of these compounded mixtures is controversial and most insurance companies will not pay for these medications. This topic is included here for educational purposes as some physicians prescribe compounded topical agents.

Compounded medications are not commercially available; rather, they are prescribed by a health care professional and prepared by a pharmacist to meet an individual’s unique needs. These compounded medications do not go through the same FDA approval process that is required for commercially available prescription drugs. Therefore, trials may or may not be conducted to determine safety and efficacy. Such studies are not a legal requirement for compounded medications.

The most common compounded medications are topical gels. They typically contain ingredients such as lidocaine, amitriptyline, ibuprofen, gabapentin, and/or ketoprofen. Opioids, such as morphine, are also compounded for topical administration. The benefit to this type of delivery system is that medication is localized to the area of pain. Lidocaine 5% in PLO gel has been shown in studies to be effective in relieving pain with a minimal enough amount of systemic absorption to alleviate fears of approaching toxic levels.

Topical medications, such as the combination of ketamine (a dissociative anesthetic agent with abuse potential) and amitriptyline (a tricyclic antidepressant), have been proposed as an alternative treatment for neuropathic disorders including complex regional pain syndrome (CRPS). These types of topical medications in general are so far unproven. There is one study of topical baclofen, amitriptyline, and ketamine that was shown to be effective in relieving chemotherapy induced peripheral neuropathy. Continued use of these agents beyond the initial prescription requires documentation of effectiveness, including functional improvement, and/or decreased use of other pain medications.

Other compounded agents include those injected into the epidural and spinal canal. An outbreak of meningitis in 2012, secondary to epidural steroids that were compounded, produced much more scrutiny of compounding pharmacies and their quality standards by the FDA and state boards of pharmacy.

Many intraspinal or intrathecal (injection into the sheath surrounding the spinal cord) analgesics need to be compounded for improved pain relief and delivered via intraspinal drug delivery systems or pumps. The best recommendation is to work with a compounding pharmacy that has a history of quality care and can answer questions about stability and sterility of their compounding techniques. Many states now regulate and oversee compounding pharmacies under the Board of Pharmacy, thus, compounding pharmacies with active licenses in good standing should be sought out. License standing may be available by searching on the state’s Board of Pharmacy website.
Prior to using a compounded medication, it is important to know the clear risk vs. benefit and understand whether a commercially available medication might be appropriate.

**MEDICATIONS & SLEEP HYGIENE**

Chronic sleep problems, also known as insomnia, are a significant problem in society and almost a universal issue for persons with persistent or chronic pain. People who have chronic sleep problems may be getting substantially less sleep than is needed for good health.

Sleep problems can be called “chronic” when they last more than three weeks, and these can last for months or years. These sleep disturbances are more serious; sorting them out and restoring good sleep may require the help of a health care professional.

Insomnia is not a disease, but a symptom of a problem; one of which includes pain. Insomnia can be a side effect of many medications. Alcohol and drug abuse or addiction can also interfere with sleep. According to national statistics, at least one half of all instances of insomnia are caused by psychological problems. Waking up too early is common for people who are depressed. Difficulty falling asleep is often caused by anxiety.

Pain is worsened by both the physical and emotional consequences of lack of restful sleep.

When people are deprived of the restful sleep they need:

- They become fatigued and less alert and attentive.
- They are more inclined to irritability and other mood problems that can make relationships with family, friends, and co-workers difficult.
- Their cognitive ability, concentration, and judgment suffer.
- Their ability to perform even simple tasks declines and productivity is sabotaged.
- They can make mistakes resulting in reduced productivity at home and on the job and increasing the opportunity for human error and fatigue-related accidents.

Scientific studies have confirmed that practicing good sleep hygiene is as effective as or more effective than medication treatment in improving the quality and quantity of sleep. It is common for people with persistent pain to believe that they sleep poorly because of pain, which may be true; however, studies demonstrate that it often happens the other way – poor sleep increases pain.

The costs of poor sleep are significant. In addition to the general lack of feeling refreshed both physically and emotionally, there are other consequences of sleep deprivation. The negative health and economic consequences of poor quality sleep and sleep deprivation are significant.

Some medications prescribed for chronic pain may disrupt the normal sleep cycle and some may be activating and make quality sleep difficult. Substances, including caffeine, theophylline, and other stimulants, steroids, and some anti-hypertensive and antidepressant medication can precipitate insomnia.
People who snore or have sleep apnea (a condition in which the flow of air into the lungs is repeatedly blocked during the night resulting in periods when they stop breathing while asleep) are likely to have fitful, low-quality sleep often leading to daytime drowsiness. They half-waken several times a night, and wake up unrefreshed. Increased weight and obesity are often associated with chronic pain, probably because of decreased activity, the use of certain medications and even depression that can lead to poor dietary habits. Obesity can cause or worsen sleep apnea and people with chronic pain have a tendency to gain weight due to decreased activity. People with sleep apnea may be at increased risk of respiratory depression when sedatives or opioids are used. These medications should be carefully supervised by medical personnel when used in the presence of sleep apnea.

Here are some sleep hygiene tips:

- Limit consumption of caffeine after early afternoon as well as nicotine and alcohol before sleep.
- Avoid late-afternoon naps, especially greater than 30 minutes.
- Use the bedroom only for sleep-related activities.
- Restrict time in bed to sleep hours.
- Limit strenuous exercise before sleep.
- Turn off electronic devices (phones, tablets, computers) while preparing for bedtime.
- Avoid watching action or violence on TV before bed.
- Develop a bedtime routine–have a regular bedtime and wake time every day.
- Develop a meditation and relaxation therapy program before bed as this can reduce physiologic arousal and promote sleep onset.
- Warm milk or mild tea (herbal or decaffeinated) can be soothing.
- Light can be blocked with an eye mask.
- Resolve emotional distress issues whenever possible before going to sleep.
- Decrease bedroom temperature.
- Use a white noise machine.
- Make sure the bed frame and mattress are adequate.
- In general, avoid naps during the day if they are interfering with getting to sleep at night. If a nap is essential, plan this in the late morning or early afternoon.


SEDATIVES (FOR INSOMNIA)

Sleep disturbances occur in 50–88 percent of patients experiencing chronic pain. Getting a good night’s sleep is critical to the individual with chronic pain and often is hard to obtain. A restful night’s sleep provides a number of benefits, including a sanctuary for the pain exhausted brain, extended time for muscle relaxation, and a release of the growth hormone which is necessary for healing damaged tissues of the body and is only released during deep phase of sleep. Not only duration of sleep, but its architecture (going through different phases of sleep throughout the night) is important for overall functioning of the body and reduction of pain. Not only does pain lead to sleep disturbances, though, but disturbed sleep has also been shown to increase pain over both short- and long-term intervals. Additionally, sleep deprivation has been shown to cause enhanced pain sensitivity in healthy individuals, again suggesting a reciprocal relationship between insomnia and pain disorders.

Various medications may improve sleep. While sleeping pills are commonly prescribed for people with chronic pain, pain specialists rarely, if ever, recommend them for long-term use. Some can be habit-forming and may impair function and memory more than opioid pain relievers. When combined with opioids, the incidence of adverse-effects, including fatal ones’ can increase.

**Benzodiazepines:** Limitations and dangers of benzodiazepines were discussed above. Medications in this class of sedatives are not recommended as first-line or long-term treatments for chronic insomnia due to their many adverse side effects, including daytime somnolence, cognition and memory impairment, increased risk of falling, respiratory suppression, damaging sleep-architecture, high addiction potentiality, rebound insomnia, and anxiety. All medications in this class are schedule-IV controlled substances. They are, however, useful as short-term insomnia treatments (7-10 days) and include: estazolam (Prosom®), flurazepam (Dalmane®), triazolam (Halcion®) and temazepam (Restoril®). Other benzodiazepines commonly used as off-label medications in treating insomnia include lorazepam (Ativan®), clonazepam (Klonopin®), alprazolam (Xanax®), diazepam (Valium®), and oxazepam (Serax®). The use of these medications in treating insomnia is controversial, and there is no conclusive evidence supporting their use in this context.

**Diphenhydramine (Benadryl®):** Diphenhydramine is not FDA-approved for treatment of insomnia. Its efficacy is controversial; however, in low doses it is widely used and prescribed as an over-the-counter and prescription sleep aide. Adverse side effects include: sedation, dizziness, constipation, nausea, dry mouth, blurred vision, and weight gain. It may have serious side effects including: urine retention, cardiac arrhythmia, confusion, and bowel obstruction. These side effects can be particularly dangerous in older adults.

**Zolpidem (Ambien®) and Zolpidem CR (controlled release):** The difference between these two medications lies primarily in their half-lives. They were two of the most commonly prescribed insomnia medications during the first decade of the present century, yet newer hypnotics have since been shown to have better safety profiles, making the latter more popular as insomnia treatments of late. Adverse side effects include somnolence, dizziness, ataxia, amnesia,
complex sleep-related behaviors (such as sleep walking, sleep cooking/eating, sleep driving), and rebound insomnia.

Zaleplon (Sonata®): Although zaleplon was proven effective and safe for treating insomnia, its use among clinical practices has been limited, primarily because of its ultrashort half-life. Adverse side effects include: somnolence, dizziness, ataxia, and amnesia.

Eszopiclone (Lunesta®): Eszopiclone is the best-documented agent in terms of safety for long-term use and has little or no suggestion of increased tolerance, dependence, or abuse. It might even be safe to use in patients who have histories of substance abuse. Adverse side effects may include: somnolence, amnesia, ataxia, dizziness, and dry mouth and unpleasant taste in mouth.

Tricyclic Antidepressants: This class of medications was discussed in an earlier section as pain relievers. In addition, in low doses, tricyclic antidepressants have been used as sleep aids for many years.

Doxepin (Silenor®): In low doses, doxepin is the first and only FDA-approved insomnia medication in its class and it is not a controlled substance. While high doses of doxepin can be dangerous, low doses appear to be safe and have proven effective at inducing sleep with few side effects. Adverse side effects include: somnolence and nausea. Doxepin may be preferred over other sleep aids due to its very low side-effect profile and is especially helpful in treating geriatric patients for whom it is the only approved insomnia medication.

Other Sedative Antidepressants

Mirtazapine (Remeron®): Mirtazapine is an antidepressant with strong sedating properties, especially in lower doses. It is non-addictive and promotes restoring of sleep architecture. Adverse side effects include: somnolence, increased appetite and weight gain, abnormal dreams, dizziness, dry mouth, constipation, and seizures (rare).

Trazodone (Desyrel®): It is a potent hypnotic and is extensively used among clinical practices in treating insomnia despite its lack of approval from the FDA for use as a sleep medication. As with all antidepressants, it has no addiction potential and restores sleep architecture well. Adverse side effects include: somnolence, dry mouth, orthostatic drop in blood pressure causing dizziness, blurred vision, constipation, priapism (rare), and seizures (rare).

Sedating Antipsychotics

Quetiapine (Seroquel®): Quetiapine is widely used in low doses as an off-label medication in treating insomnia; however, there are very few studies evaluating its efficacy and safety in this context. Adverse side effects are not commonly reported on low doses of this medication; however, side effects that were mentioned in Antipsychotic section above, like tremors, stiffness, involuntary movements of the body, weight gain, hypertension, and elevated cholesterol cannot be excluded.
Olanzapine (Zyprexa®): Olanzapine and has been shown to improve sleep and sleep architecture, however, it is not a commonly prescribed insomnia medication for patients who do not suffer from psychiatric disorders. This is likely due to its notorious metabolic side effects, including weight gain, hypertension, elevated cholesterol and possibility of causing diabetes.

Melatonin and ramelteon (Rozerem®): Melatonin and ramelteon (Rozerem®) are both effective at inducing sleep onset, rather than sleep maintenance. In the USA, melatonin is only available as an over-the-counter supplement and is not approved by the FDA for use in treating insomnia. Moreover, its dosage is not always reliable. Nevertheless, it is widely used and often preferred as a first-line treatment for insomnia due to its low side-effect profile. Common side effects include daytime sleepiness and dizziness. Short-term ramelteon use is associated with improved sleep parameters in patients with insomnia, but its clinical impact is deemed small. That said, as it has a relatively low side-effect profile, ramelteon is often preferred over other sedatives. Adverse side effects include: somnolence, dizziness, and fatigue.

Suvorexant (Belsomra®): It is FDA approved for treating sleep-onset and -maintenance insomnia. Suvorexant does not induce sleepiness but decreases wakefulness, which makes it a unique sleep agent in terms of today’s market. It has been proven safe and effective for over one year of nightly use and is indicated for long-term use. Additionally, there is no evidence that its prolonged use causes physical dependence, nor have any withdrawal symptoms been reported in cases when its use has been discontinued. Overall, it is highly effective and has few side effects, making it a preferred choice among prescribing physicians since its February 2015 release. Nevertheless, it remains a schedule-IV federally controlled substance. Adverse effects include: somnolence, confusion, complex sleep-related behaviors, and abnormal dreams.
NON-MEDICATION TREATMENT OF INSOMNIA

Repetitive Transcranial Magnetic Stimulation (rTMS): This procedure uses an electromagnet to generate electric currents that stimulate areas of the brain. It has been used successfully as an adjuvant therapy in treating depression. Promising new research on the use of rTMS in treating insomnia has recently come to light.

Cranial Electrotherapy Stimulation (CES): This has also been shown to yield positive results in the treatment of insomnia. CES uses a small device to send weak electrical pulses to desired areas of the brain. It has been approved by the U.S. Food and Drug Administration for use in treating of anxiety, depression, and insomnia since 1979. It has been shown effective in treating insomnia, with few negative side effects and its use has also been shown to precipitate fast (as little as one week), significant improvements to sleep behaviors.

Psychotherapy: Through the years, multiple psychotherapeutic approaches to improve sleep were used. Cognitive-behavioral therapy for insomnia (CBT-I) is a specially designed insomnia-treatment approach, integrating most of the effective techniques to promote sleep. It consists of effective interventions targeting the various factors that cause insomnia. As it has proved effective in many of clinical trials, the American Academy of Sleep Medicine recommends CBT-I as a standard treatment for chronic insomnia. CBT-I has proved effective in both individual- and group-treatment settings, improving duration and quality of sleep. Although it can be used as self-help, it works best when facilitated by a trained health care provider, usually a psychologist. One of the important part of CBT-I is sleep hygiene which can be helpful in relieving insomnia while incorporated in daily life.

Meditation: Mindfulness meditation is a process during which one focuses one’s attention on the present moment without judgment. Mindfulness practices are often incorporated in relaxation training, a component of CBT-I. Meditation, however, is still considered an autonomous technique for treating insomnia.
**Muscle Relaxants**

Many drugs have been marketed as muscle relaxants, even though most do not seem to have any direct effect on muscle. Perhaps they should be called “brain relaxants,” as they are all sedating, and this may be how they actually work. In the vast majority of cases due to increased sedation and addiction potential, these medications should not be taken with opioids. If prescribed both classes of medications, be sure to have a discussion with a health care professional about the risks from taking these medications. Also be sure medications prescribed are from only one health care professional who clearly knows everything being taken.

Sedation is a concern for those who drive, operate machinery, or otherwise are engaged in safety-sensitive jobs. Some also have analgesic (pain reducing) properties. Cyclobenzaprine (Flexeril®, Amrix® extended-release) is chemically similar to the tricyclic antidepressants (TCAs) and may have a similar mechanism. Muscle relaxants have limited efficacy in the treatment of chronic pain but may be used to treat acute flare-ups. There are no studies to support the long-term use of muscle relaxants, especially for low back pain. Also, the long-term use of muscle relaxants for low back pain does not improve functional recovery and can also hinder recovery.

**Drugs Used as Muscle Relaxants in Chronic Pain**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carisoprodol (Soma®)</td>
<td>Primarily a depressant marketed as a muscle relaxant. Converted by the body into meprobamate, a barbiturate-like drug. It may cause physical dependence. It should be avoided in kidney or liver disease. With prolonged use, it is associated with dependence. <em>Avoid use in chronic pain.</em></td>
</tr>
<tr>
<td>Cyclobenzaprine (Flexeril®, Fexmid®, Amrix®)</td>
<td>Skeletal muscle relaxant that is structurally similar to the TCAs. Side effects include dizziness, drowsiness, dry mouth, constipation, confusion, and loss of balance. Avoid long-term regular use in chronic pain.</td>
</tr>
<tr>
<td>Methocarbamol (Robaxin®)</td>
<td>Skeletal muscle relaxant with sedative properties. Side effects include drowsiness and urine discoloration to brown, black, or green.</td>
</tr>
<tr>
<td>Metaxalone (Skelaxin®)</td>
<td>Skeletal muscle relaxant. Use with caution in those with liver disease.</td>
</tr>
<tr>
<td>Chlorzoxazone (Parafon-Forte® DSC, Lorzone®)</td>
<td>Skeletal muscle relaxant with sedative properties. Use with caution in those with liver disease.</td>
</tr>
<tr>
<td>Dantrolene (Dantrium®)</td>
<td>A true muscle relaxant that acts directly on skeletal muscle and produces fewer central adverse effects. Can have significant liver toxicity. The dose should be increased slowly.</td>
</tr>
<tr>
<td>Orphenadrine (Norflex™)</td>
<td>A skeletal muscle relaxant with analgesic properties.</td>
</tr>
<tr>
<td>Tizanidine (Zanaflex®)</td>
<td>A drug indicated for spasticity associated with multiple sclerosis or spinal cord injury but being used off label for chronic pain. This drug may increase liver enzyme levels. Tizanidine interacts with blood pressure medications and causes low blood pressure.</td>
</tr>
<tr>
<td>Baclofen (Lioresal® - oral and injectable), Gablofen® - injectable) - Not technically a muscle relaxant - used for painful spasm from muscle spasticity due to spinal cord or nervous system injury</td>
<td>Withdrawal should not be abrupt and can be life-threatening (mainly with intrathecal therapy). Inhibits transmission at the spinal level and also depresses the central nervous system. The dose should be increased slowly to avoid the major side effects of sedation and muscle weakness (other adverse events are uncommon). Baclofen is known to be safer for long-term use. It is not typically recommended for non-neurological muscle spasm.</td>
</tr>
</tbody>
</table>
ANTI-HYPERTENSIVE MEDICATIONS

Clonidine (Catapres®, Catapres-TTS® patch) is a centrally acting alpha-agonist that lowers blood pressure and has also been shown to have pain-relieving properties in sympathetically maintained pain conditions such as complex regional pain syndrome (CRPS). It is available as a tablet for oral administration, as an injectable solution for administration in an epidural or implanted pump, or as a once-weekly patch. As mentioned previously, clonidine may be helpful controlling withdrawal symptoms from opioids.

Side effects can include dry mouth, drowsiness (sedation and somnolence occurs in over 30% of patients), dizziness, and constipation. Transient localized skin reactions can occur with the patch. Clonidine lowers blood pressure and heart rate, thus, it should be used cautiously in patients who have low blood pressure. Safest usage would suggest measuring blood pressure prior to taking a dose of oral clonidine and not taking it for a blood pressure less than 90/60.

Due to the potential for additive affect, special caution must be taken in individuals taking other central nervous system depressant medications (opioids, sedative hypnotics, and benzodiazepines).

Clonidine should not be discontinued suddenly as this can result in symptoms such as nervousness, agitation, headache, and tremor accompanied or followed by a rapid rise in blood pressure. Some individuals can develop an allergy to clonidine with a generalized rash, itching, or swelling. It should be used with caution in patients with severe heart disease, cerebrovascular disease (stroke), or chronic kidney failure. To avoid hypertensive crisis, clonidine should not be used with tricyclic antidepressants (TCAs).

BOTULINUM TOXINS

Botulinum toxins, Botox® (onabotulinumtoxinA), Dysport® (abobotulinumtoxinA), Xeomin® (incobotulinumtoxinA), and Myobloc® (rimabotulinumtoxinB) have been found to be effective in decreasing tone in overactive (hypertonic) muscles, which may be present in a number of chronic pain conditions. A recent review article regarding the treatment of refractory pain by Dr. Jabbari summarizes that botulinum toxins have “established efficacy” to control pain of cervical dystonia, chronic migraine, and chronic lateral epicondylitis (tennis elbow).

The review also found a lower level of evidence and classified botulinum toxin as “probably effective and recommended” for post-herpetic neuralgia (PHN), post-traumatic neuralgia, pain of plantar fasciitis, piriformis syndrome, and pain in total knee arthroplasty; “possibly effective, may be used at discretion of clinician” for allodynia of diabetic neuropathy, chronic low back pain, painful knee osteoarthritis, anterior knee pain with vastus lateralis imbalance, pelvic pain, post-operative pain in children with cerebral palsy after adductor hip release surgery, post-operative pain after mastectomy, and sphincter spasms, and pain after hemorrhoidectomy; “efficacy not proven due to diverse class I and II results” for myofascial pain syndrome and
chronic daily headaches; and “negative” for episodic migraine and tension headaches (Pain Med 2011; 12:1594-1606). There appears to be additional pain relieving properties of botulinum toxin irrespective of muscle relaxation.

Botox®, Dysport®, Xeomin®, and Myobloc® are FDA-approved for the treatment of the postural abnormalities and pain associated with cervical dystonia, also known as torticollis (head tilting, neck pain, and neck muscle spasms). Only one botulinum toxin (Botox® onabotulinumtoxinA) is additionally approved by the FDA to prevent headaches in adults with chronic migraine who have 15 or more days each month with headache lasting four or more hours each day in people 18 years or older, and to treat increased muscle stiffness in elbow, wrist, and finger muscles in people 18 years and older with upper limb spasticity.

The efficacy of botulinum toxins in back, neck, and extremity muscle pain has been studied as an off-label use with mixed results. In some studies on myofascial pain, botulinum toxin has not been found to be more effective than traditional trigger point injections with local anesthetic or saline.

The dosage units for botulinum toxins are unique to each product and are not interchangeable. In addition, the FDA has specified nonproprietary names for each drug to help prevent medication errors. Many physicians are using botulinum toxins off-label for other painful conditions including types of headache other than chronic migraine treated with Botox® (onabotulinumtoxinA), osteoarthritis of the knee and shoulder and various muscle pain syndromes (myofascial pain), although the evidence for such use is not conclusive.

For treatment of chronic pain conditions, when effective, botulinum toxins typically demonstrate efficacy within 3 to 5 days after intramuscular administration and last for an average of 12 weeks.

Side effects may occur after receiving botulinum toxin (see FDA warning box below). Muscle weakness is one of the most common side effects. Swallowing problems can develop when treating cervical muscle problems, especially with injections into the sternocleidomastoid muscle. Other adverse effects include dry mouth, pain at the injection site, neck pain, headache, and flu-like symptoms. Additionally, adverse effects may include local bruising, generalized fatigue, lethargy, dizziness, and difficulty speaking or hoarseness.
FDA WARNING: DISTANT SPREAD OF BOTULINUM TOXIN EFFECT

Postmarketing reports indicate that botulinum toxin may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses, including spasticity in children, and in approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and at lower doses.

NMDA INHIBITORS (INCLUDING KETAMINE)

Numerous compounds that specifically target mechanisms mediating neuropathic pain such as the N-methyl-D-aspartate (NMDA) receptor complex are currently in clinical trials. NMDA inhibitors appear to help prevent sudden acute pain from progressing into chronic pain. These act by blocking receptors of neurotransmitters that are essential for making long-term memories.

The NMDA antagonists also reduce opioid tolerance and may enhance opioid analgesia.

The utility of these agents has been limited by their significant dose-related side effect profile, which includes lightheadedness, dizziness, tiredness, headache, nervous floating sensation, bad dreams, and sensory changes.

Agents that have clinically relevant NMDA blocking properties include ketamine, amantadine (an anti-influenza medication), memantine (an Alzheimer drug; Namenda™ — but not studied for chronic pain), dextromethorphan (an anti-cough medication), and methadone (an opioid).

Memantine and amantadine are weaker NMDA receptor blockers and consequently they are also thought to have fewer CNS side effects.

The basic concept of NMDA antagonism in neuropathic pain remains sound, but there is a strong need for more studies and perhaps development of newer agents with fewer central nervous system side effects.

There has been increasing interest surrounding the use of ketamine in complex regional pain syndrome (CRPS) and pain therapy via the continuous IV infusion of ketamine which has been reported to lead to pain reduction over a number of weeks. However, serious side effects may occur, especially if treatment is repeated including hallucinations, memory defects, panic attacks, nausea/vomiting, somnolence, cardiac stimulation and in a few subjects, liver toxicity. Much of
the evidence is anecdotal, but increasing research is suggesting some possible benefit from this therapy although many guidelines do not feel that there is enough evidence to support its use clinically. Reviews of ketamine use for chronic pain and CRPS specifically from 2013 and 2015 concluded that the evidence from available literature is inconclusive and the quality of the research is low with small sample size, lack of blinding or controls and serious methodological flaws.

Because their potential for harm outweighs evidence of limited short-term benefit in patients with CRPS, NMDA receptor antagonists are not recommended.

**LOW-DOSE NALTREXONE**

Naltrexone is an opioid antagonist. The best evidence for pain treatment shows that at low doses (4.5 mg) naltrexone effectively reduces fibromyalgia pain intensity and improves mood. Low-dose naltrexone has a low side effect profile. However, it should never be co-administered with opioids because it is an opioid antagonist. Low-dose naltrexone has shown promise in treating migraine and complex regional pain syndrome (CRPS), though larger studies are needed. The primary mechanism of low-dose naltrexone is thought to be immune modulation.
ADRENERGIC DRUGS, BISPHOSPHONATES, THALIDOMIDE, & CALCITONIN

Alpha adrenergic antagonists (e.g., clonidine, phentolamine, phenoxybenzamine, reserpine, dexametomidine, and others) have been used clinically for the treatment of CRPS without good evidence from clinical research studies. The rationale for their use is the recognized role of the sympathetic nervous system in CRPS and the theory that blockade will provide pain relief. Oral clonidine has not demonstrated significant efficacy in neuropathic pain and is challenging to use due to its side effect profile. It is more widely utilized in implantable intrathecal (injection into the sheath surrounding the spinal cord) drug pumps for pain.

Bisphosphonates are a class of drugs used primarily to increase bone mass and reduce the risk of fractures in patients with osteoporosis. There are seven FDA-approved bisphosphonates: alendronate (Fosamax®, Fosamax Plus D™), etidronate (Didronel®), ibandronate (Boniva®), pamidronate (Aredia®), risedronate (Actonel®, Actonel® with calcium), tiludronate (Skelid®), and zoledronic acid (Reclast®, Zometa®). They are more popularly known for treatment and prevention of osteoporosis. For chronic pain, they have been used in the treatment of CRPS in several studies. While the primary mechanism of these agents has been thought to be reduction in pain by preventing the osteoporosis associated with CRPS, other peripheral and central mechanisms may be responsible and deserve investigation. Adverse effects can include gastritis and erosive esophagitis (stomach and esophagus distress), and rarely, damage of the jaw bone (osteonecrosis). In October 2010, the FDA also issued a special alert on the association between the use of bisphosphonates and the risk of atypical fractures of the thigh. Patients are encouraged to consult their health care professionals for new hip or thigh pain.

Calcitonin is the lesser known of the thyroid’s two main hormones. It decreases bone resorption and has direct effects on the kidneys and gastrointestinal tract. It is also thought to have anti-pain effects. Recently, the salmon calcitonin formulation that is nasally inhaled has been more commonly used than injectable calcitonin due to ease of administration. Calcitonin has been used to treat the bone pain associated with compression and sacral insufficiency fractures.
**ACTIVATING MEDICATIONS (CENTRAL NERVOUS SYSTEM STIMULANTS)**

Side effects from medications prescribed for chronic pain can be bothersome at the least, and if significant enough, may cause the need to discontinue the offending medication. One of these side effects is daytime drowsiness, making it difficult for the individual to function and carry out day to day activities and work.

Rather than give up the benefits of the prescribed medication, some health care professionals will try to treat the side effect of sleepiness and lethargy by prescribing an “activating” medication such as methylphenidate (Ritalin®️, Concerta®️, and Metadate®️), dextroamphetamine (Dexedrine®️), modafinil (Provigil®️), armodafinil (Nuvigil®️), and combination products (Adderall®️).

While these activating drugs may be appropriate for some individuals, consideration for weaning of the pain medication that is causing the drowsiness is recommended instead of adding a medication to address side effects. It should be a rare patient who takes medication (with potential side effects) to control the side effects of another medication rather than discontinuing the offending medication. This combination is generally not considered appropriate therapy, as many patients will show improved functionality when the dose of the sedating drug is reduced or discontinued. Adding additional medications adds more risk for the patient.

Methylphenidate (Ritalin®️, Concerta®️, and Metadate®️) is a medication prescribed for individuals (usually children) who have an abnormally high level of activity or attention-deficit hyperactivity disorder (ADHD). It is a central nervous system stimulant. It has effects similar to, but more potent than, caffeine and less potent than amphetamines. It is occasionally used off-label as a stimulant when daytime sleepiness from chronic pain medications is a problem. It may be effective when used appropriately, but it does have potential for abuse. Marked anxiety, tension, and agitation are contraindications to methylphenidate since the drug may aggravate these symptoms. Methylphenidate should be given cautiously to emotionally unstable patients and those with a history of drug dependence or alcoholism, as such patients may increase the dose on their own initiative.


Dextroamphetamine (Dexedrine®️) is an amphetamine used to treat narcolepsy and attention-deficit hyperactivity disorder in children. In some cases, this drug has been used to treat depression or as an adjunct in the treatment of exogenous obesity.

Modafinil (Provigil®️) is approved by the FDA to improve wakefulness in patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder. It is also being used off-label for persons with chronic pain and excessive daytime sleepiness. It is generally well tolerated, with mild-to-moderate side effects. It reportedly does not
affect nighttime sleep. Headaches are the most common reason for discontinuing Provigil®. Less frequent side effects include nausea, nervousness, anxiety, insomnia, and cardiovascular adverse reactions including chest pain, palpitations, shortness of breath and transient ischemic EKG changes. Increased monitoring of heart rate and blood pressure may be appropriate when using modafinil. There have been rare cases of serious or life threatening rash including Stevens-Johnson syndrome and toxic epidermal necrolysis reported in adults and children. Caution should be exercised when Modafinil is given to patients with a history of psychosis, depression, or mania.

Armodafinil (Nuvigil®) is a wakefulness-promoting agent for oral administration. It is indicated to improve wakefulness in patients with excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome, narcolepsy, and shift work sleep disorder. Headaches are the most common reason for discontinuing Nuvigil®. This drug carries similar warnings modafinil (see above).
**Migraine Headache Treatment**

Migraine headache treatment typically includes one or a combination of abortive (rescue) and/or prophylactic (preventive) agents. Abortive therapy has been revolutionized with the advent of the triptans. These include sumatriptan (Imitrex®—also available by injection or nasal spray, Sumavel® DosePro®—needle-free delivery), zolmitriptan (Zomig®—also available by nasal spray or as orally-disintegrating tablets), naratriptan (Amerge®), rizatriptan (Maxalt®—also available as orally-disintegrating tablets), and almotriptan (Axert™). More recently introduced triptans include frovatriptan (Frova®) and eletriptan (Relpax®).

Preventive agents include beta-blockers, antidepressants, and anti-convulsant medications that are prescribed to be taken on a scheduled basis, whereas abortive therapies are typically used on an as needed basis and are to be taken at the first onset of a migraine. Because of frequent unpleasant and sometimes debilitating side effects, preventive drugs are only prescribed for those whose quality of life is significantly adversely affected. The drugs are started at a low dose, and gradually increased until therapeutic effects develop, the ceiling dose for the chosen drug is reached, or side effects become intolerable.

The key to effective treatment, however, is still a combination of avoidance of migraine triggers, stress management and relaxation techniques, and non-medication symptom relief through the use of locally applied heat or cold, massage, hot showers, and rest in a quiet, darkened room. Some people benefit from complementary or alternative therapies such as relaxation techniques, training in self-hypnosis, biofeedback, yoga, aromatherapy, acupuncture, spinal manipulation, and homeopathic remedies.

Unfortunately, while migraine headaches can now be better controlled, it is unrealistic to expect instant, complete, or permanent pain relief for what is essentially a chronic, recurring disease.

Effective migraine treatment begins with the early recognition that an attack is pending followed by immediate treatment. Migraine sufferers are encouraged to take an active role in managing their headaches by avoiding common triggers, making lifestyle changes, and taking their medication at the first sign of migraine pain.

Botox® was granted approval in 2010 as a preventive treatment option for patients who are diagnosed with Chronic Migraine, a neurological disorder characterized by headaches on 15 or more days per month with headaches lasting four hours a day or longer.

Patients taking certain migraine and antidepressant medications together may be at risk for a dangerous chemical imbalance. Antidepressant medications included in this warning are duloxetine (Cymbalta®), escitalopram (Lexapro™), fluoxetine (Prozac®), paroxetine (Paxil®), sertraline (Zoloft®), and venlafaxine (Effexor®). Migraine drugs include almotriptan (Axert™), naratriptan (Amerge®), sumatriptan (Imitrex®), and zolmitriptan (Zomig®). Serotonin is a brain hormone that keeps our mood stable and our appetite in check, as well as serving other functions. When two or more drugs that affect serotonin levels are taken together, it can increase the amount of serotonin and may lead to bothersome or dangerous symptoms. This is called “serotonin syndrome.” Please see the discussion about antidepressant medications in this ACPA Resource.
Here are a few web sites about migraine headaches:

- [http://my.clevelandclinic.org/disorders/migraine_headache/hic_migraine_headaches.aspx](http://my.clevelandclinic.org/disorders/migraine_headache/hic_migraine_headaches.aspx)

Treximet® is a product that was FDA-approved in August 2008 as a combination medication for migraine treatment and contains naproxen 500 mg and sumatriptan 85 mg. Treximet® works to relieve the pain of migraines in two ways; the sumatriptan portion works by increasing the amount of the hormone serotonin in the blood vessels and by causing constriction of the arteries in the head, and the naproxen works to decrease inflammation and pain. The FDA issued black box warnings regarding the cardiovascular and gastrointestinal risks associated with Treximet®. This combination may cause an increased risk of serious cardiovascular complications including heart attack and stroke. Also, since this product contains naproxen (an NSAID), there is an increased risk of gastrointestinal adverse reactions including bleeding, ulceration, and perforation of the stomach or intestines. Caution should be used in patients with a history of kidney or liver disease.

Diclofenac potassium powder for solution (Cambia®) is a NSAID drug indicated for the acute treatment of migraine attacks with or without aura in adults 18 years of age or older. Cambia® is not indicated for the prophylactic therapy of migraine. Safety and effectiveness of Cambia® is not established for cluster headache, which is present in an older, predominantly male population. Dosage and administration: Single 50 mg dose: mix single packet contents with 1 to 2 ounces (30 to 60 ml) of water prior to administration. This drug carries the same warning as for other NSAIDs.
SELF-MEDICATION: ALCOHOL, TOBACCO, MARIJUANA, AND ILlicit SUBSTANCES

ALCOHOL & CHRONIC PAIN

Alcohol is also a drug. Alcohol has no place in the treatment of chronic pain, although some individuals turn to alcohol for relief of their pain. It is important to discuss the use of alcohol with your health care provider, including the amount, frequency, and type of alcohol consumed.

Alcohol can enhance the effects of certain prescription drugs as well as markedly increase potential toxic side effects (i.e., liver damage when used in conjunction with acetaminophen, or increased sedation and respiratory depression in conjunction with opioids and other sedating medications, like benzodiazepines and other sleeping medications). The mixture of alcohol and opioids along with sedatives or anti-anxiety drugs can cause death.

Alcohol affects the nervous system as a depressant, not as a stimulant. It depresses normal mental activity and normal muscle function. Short-term effects of an average amount of alcohol include relaxation, breakdown of inhibitions, euphoria, and decreased alertness. Short-term effects of large amounts of alcohol include nausea, stupor, hangover, unconsciousness, and even death. Alcohol increases stomach acid and impairs liver function. Chronic alcoholism frequently leads to permanent damage to the liver. Alcohol also affects the heart and blood vessels by decreasing normal function, leading to heart disease. Bleeding from the esophagus and stomach frequently accompany liver disease caused by chronic alcoholism. Many medications cannot be given to patients with abnormal liver function, thus making it more difficult to treat chronic pain.

The early signs of alcoholism include the prominent smell of alcohol on the breath and behavior changes such as aggressiveness, passivity, decreased inhibitions, poor judgment, depression, and outbursts of uncontrolled emotion such as rage or tearfulness. Signs of intoxication with alcohol include unsteady gait, slurred speech, and poor performance of any brain or muscle function. Signs of severe alcohol intoxication include stupor or coma with slow, noisy breathing, cold and clammy skin, and an increased heartbeat.

The long-term effects of alcohol addiction (alcoholism) include craving, the compulsive use and continued use despite harm to family, job, health, and safety. When alcohol is unavailable to persons who are severely addicted, withdrawal symptoms will occur and may be life threatening if not treated immediately. Even with successful treatment, individuals addicted to alcohol may have a tendency to relapse suggesting the need for ongoing treatment (such as involvement in 12-step programs, counseling, and family support).

Simply put, alcohol and pain medications are dangerous when mixed together.

Additional information is available from the Substance Abuse and Mental Health Services Administration (SAMHSA) at http://www.samhsa.gov/atod.
THE EFFECTS OF CIGARETTE SMOKING ON PAIN

Cigarette smoking, mediated by nicotine, causes blood vessels to become constricted; this restricts the amount of oxygen-rich blood flowing to areas of pain. Smoking not only reduces blood flow to your heart but also to other structures such as the skin, bones, and discs. Due to this, the individual may get accelerated aging leading to degenerative conditions. The lack of blood supply caused by cigarette smoke is also responsible for increased healing time after surgery. After back fusion surgery, smoking cigarettes can increase the risk of the fusion not healing properly. Smoking should be avoided both before and after spine surgery. Cigarette smoke triggers the release of pro-inflammatory cytokines, thus increasing inflammation and intensifying pain. Smoking makes the bones weak and increases the prevalence of osteoporosis, spinal degenerative disease, and impaired bone and wound healing. Symptoms of depression are more commonly seen among smokers. Cigarette smoking is also considered a risk factor for misuse of opioid medications and should be considered when prescribing opioids.

Below are some tips to help individuals stop smoking.

Assess readiness to quit smoking and ask a health care professional or pharmacist for help. They will make recommendations, modifications, and develop a treatment plan to optimize success. Even one less cigarette a day is a step in the right direction. Keeping a log may help individuals pinpoint when and why they are smoking. Knowing these triggers can help replace smoking a cigarette with healthier habits.

Smoker’s Log:

<table>
<thead>
<tr>
<th>Cigarettes per day</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Time of each cigarette</td>
<td></td>
</tr>
<tr>
<td>What triggered the craving?</td>
<td></td>
</tr>
<tr>
<td>What were you doing while smoking?</td>
<td></td>
</tr>
<tr>
<td>How did you feel while smoking?</td>
<td></td>
</tr>
</tbody>
</table>

Nicotine replacement therapy, such as lozenges, gum, or patches, is available.

Some medications can help with the craving of cigarettes that many people experience when they are trying to quit. These medications work by affecting dopamine. Nicotine triggers dopamine release in the brain. Dopamine is a neurotransmitter, a chemical messenger that plays a prominent role in addiction. Dopamine affects movement control, emotional response, and pleasure/pain. It is responsible for the reward pathway and the “feel good” phenomenon experienced when smoking.

Norepinephrine is also a neurotransmitter that sends signals from one neuron to the next. Norepinephrine is similar to noradrenaline and adrenaline and is responsible for constricting and narrowing the blood vessels. It can therefore increase blood pressure. It can also increase blood sugar levels and affect both mood and behavior.

Bupropion (Zyban®) is an antidepressant; however, it is also used in the smoking cessation
process. Bupropion inhibits the reuptake of both dopamine and norepinephrine, increasing their concentrations within the brain. By increasing dopamine, the frequency and severity of nicotine cravings and urges are reduced. Norepinephrine plays a role in alleviating symptoms associated with nicotine withdrawal. Bupropion effects are not fully seen until one week of treatment is complete. Therefore, it is important for patients to start this medication one to two weeks prior to their “quit-date.” Bupropion is associated with several FDA black box warnings; there is an increased risk of suicide, and neuropsychiatric symptoms may be exhibited. These symptoms include behavior changes, hostility, agitation, and depression. Seizures may occur; however, they are dose dependent. Less severe, more common side effects include dry mouth, headache, nausea, dizziness, sweating, and insomnia.

Varenicline (Chantix®) mimics nicotine at the receptors in order to aid in smoking cessation. Varenicline is similar in structure to cytosine, a natural compound that has aided in smoking cessation since the 1960s. Varenicline works via two different mechanisms. First, varenicline is effective because it provides partial nicotine effects to help with nicotine withdrawal symptoms. Second, varenicline also binds to nicotine receptors to block nicotine’s effect if the person relapses. Duration of therapy is normally 12 weeks. Patients who respond to treatment may receive another 12 weeks of therapy to increase their success rate. There is an FDA black box warning for neuropsychiatric symptoms, such as change in behavior and mood, agitation, and risk of suicide, associated with this drug. Common side effects include nausea, vomiting, insomnia, headache, and abnormal dreams.
**ILLEGAL DRUGS &Marijuana**

Health care professionals will not prescribe opioids and other medications to individuals who are known to use illegal “street” drugs (heroin, methamphetamines, cocaine, and others) or to be irresponsible with prescription pain medication.

The use of marijuana for pain is controversial. It is allowed by some states for medicinal and now recreational purposes, but overall it is banned for distribution by the United States federal government. At the time of the writing of this ACPA Resource Guide to Chronic Pain Treatment, marijuana is considered a Schedule I Narcotic.

Depending on state law, some health care professionals may supply patients with medical marijuana recommendations, some will not provide a recommendation but will not object to a patient’s use of marijuana with other pain medicines, and some will refuse to prescribe other medications (especially opioids) to individuals who are using marijuana. Some health care professionals take a “don’t ask, don’t tell” philosophy and don’t check for marijuana when doing urine drug testing. Nevertheless, the use of any substances should be discussed openly and honestly between the person and his or her health care professional.

The most well-known active ingredient found in marijuana (THC) may decrease pain, but can also lead to dependence and addiction in certain individuals and has significant side effects. Some scientific studies have claimed that other active ingredients in marijuana (e.g., CBD) are more effective at reducing pain without creating a “high.”

Although some states allow the legal use of marijuana for medicinal purposes, which may or may not include pain, there is no high-level scientific research supporting the long-term use of marijuana for chronic pain. In fact, there is good evidence that excessive smoking of marijuana can be harmful (especially in young people).

More frequent marijuana smoking is associated with an increased risk of severe respiratory illnesses, especially chronic bronchitis. Use also leads to reduced workplace productivity, as well as impaired judgment, even hours after use. Marijuana intoxication impairs cognitive and psychomotor performance with complex, demanding tasks. Individuals who have used marijuana over long periods of time demonstrate impaired performance on a variety of neuropsychological tests (e.g., attention, memory, and processing complex information), even when not acutely intoxicated. A recent review of the existing medical literature concluded that the use of marijuana at a young age increased the risk of schizophrenia or a schizophrenia-like psychotic illness by approximately three-fold. Emerging evidence suggests a link between more frequent, or severe, marijuana use and anxiety symptoms and disorders.

People who are self-medicating with marijuana may not recognize the presence of marijuana withdrawal symptoms. Marijuana causes physical dependence, and withdrawal symptoms can start as early as hours after smoking marijuana and last for up to a month and include sleep disturbances, substantial anxiety (which can worsen pain), discomfort, lack of appetite, and commonly trigger marijuana craving.
Despite some states allowing medicinal marijuana, it is a federal crime for a health care professional to prescribe a scheduled drug to a person known to be using the drug illegally. It is also important to remember that possessing marijuana when traveling through a state where medicinal marijuana is not allowed could result in being charged with possession of an illegal substance, even if the person is using the drug under the supervision of a physician and has the proper home state documentation. Additionally, an individual can be denied employment or fired if the employer or prospective employer conducts drug screenings as a part of the hiring process or has a ‘no-drug tolerance’ policy. Also individuals can be charged with driving under the influence (DUI) if their driving is impaired and they test positive for marijuana, even in states where medicinal marijuana is allowed.
INVASIVE INTERVENTIONS

INTRA-ARTICULAR STEROID INJECTIONS

Invasive therapeutic interventions for osteoarthritis include steroid injections into the joint. Intra-articular steroids are effective for short-term (one to three weeks) pain relief but do not seem to improve function or provide pain relief for longer time periods. The number of steroid injections should be limited secondary to associated side effects including fat necrosis, loss of skin pigmentation, skin atrophy, avascular necrosis of the femoral head, Cushing’s disease, and in some cases, acceleration of joint degeneration. Following a steroid injection, the treated joint should be rested (limit its use) for a minimum of 24 hours in order to prolong and to improve effects on function and pain control.

VISCOSUPPLEMENTATION

Viscosupplementation may also be used for osteoarthritis (OA) of the knee. Viscosupplementation involves injecting lubricating substances (hyaluronic and hylan derivatives) into the knee joint in order to restore the lubrication of the joint, and as a result, decrease pain and improve mobility. Although viscosupplementation may be effective short-term treatment for osteoarthritis of the knee, the improvements in pain and function are relatively small. Viscosupplementation seems to have a more prolonged pain relieving effect than intra-articular steroids.

There are currently six available products on the market: Orthovisc®, Monovisc®, Synvisc®, Hyalgan®, Supartz™, and Euflexxa™. In 2009, Synvisc-One™ (hylan G-F 20) was approved as a single-injection viscosupplement for the treatment of OA knee pain in the United States.

In late 2015, the FDA gave premarket approval for Hymovis (High Molecular Weight Viscoelastic Hyaluronan). The manufacturer (Fidia) lists Hymovis as “a new generation of HA-based intra-articular (IA) therapy indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy or simple analgesics. The product has a shorter treatment cycle of only two intra-articular injections as compared to many other IA HA viscosupplement regimens to provide pain relief for the patient.”

SPINAL CORD STIMULATION (SCS)

Neurostimulation therapy is delivered with a small device implanted under the skin, typically in the abdomen or buttock area. The neurostimulator generates mild electrical signals that are delivered to an area near the spine. The impulses travel from the device to this spinal area over thin insulated wires called leads. http://www.theacpa.org/video/implantables.

Medical researchers are still investigating exactly how SCS controls pain and are considering
multiple theories. The originally proposed mechanism of action of SCS is the “gate control theory.” This theory states that by providing a pleasant vibratory and touch sensation via the SCS system, pain signals that reach the brain are decreased.

The current SCS devices are programmable via a remote control that allows the patient to adjust the therapy within certain limits to help them receive the best pain relief each day, depending on his or her activity level or changes in pain during the day. It is not uncommon for patients being considered for a SCS to have a psychological evaluation as part of the overall evaluation process. The purpose of this psychological evaluation is to see if the person has any emotional or other difficulties that may adversely affect the surgery or recovery and to ensure the person has realistic expectations and goals for what can be achieved with the therapy. During the psychological evaluation, the person can expect to be asked questions about how the pain is currently affecting sleep, mood, relationships, work, and household and recreational activities. Some are also asked to complete paper-and-pencil tests. The results of this evaluation should be shared with the person with pain and the referring physician who will consider all the information to determine if SCS is an appropriate option.

Two stages are involved in SCS implantation. In both stages, a physician, guided by an x-ray, places a lead into the epidural space located within the bony spinal canal. The first stage is the trial phase, which provides information to predict the success of permanent implantation.

During the trial phase, one or two leads are placed via an epidural needle in the appropriate position. This is an outpatient procedure done under light sedation. Once the lead is in position, it is tested to see if the patient's painful area is covered with a tingling sensation (paresthesia). It is important that the patient is alert during the insertion and testing of the lead so he or she can inform the health care professional if the lead is in the appropriate position.

The lead is programmed with a computer. The patient then goes home for 3 to 5 days. He or she has an external power source and remote control that allows him or her to control the amount of stimulation being received. During the trial, the patient should keep an activity record to determine if the treatment is helpful in relieving pain and improving function. At the end of the trial, the patient returns to the physician's office to discuss the results and have the lead removed.

Together, the health care professional and the patient decide whether or not to advance to permanent implantation. In this stage, the lead is again placed and implanted underneath the skin with a power source the size of a pacemaker battery. Either a rechargeable or non-rechargeable power source is implanted. For the non-rechargeable systems, the battery cannot be recharged and needs replacement every several years with a minor surgical procedure. The rechargeable system needs recharging when the power source runs low. While it typically lasts longer (up to 9 years) than a conventional system, eventually it will need to be replaced with a minor surgical procedure when it can no longer be recharged in a reasonable period of time. The SCS recipient goes home with a remote-control and battery charger (if they have a rechargeable battery). The patient is instructed to limit activity for about 12 weeks to allow for healing. Occasional re-programming will be needed to optimize coverage of the painful area.

The reader should understand that this discussion of SCS systems is limited. These devices are
invasive and costly, and their use is limited to selected individuals as a treatment alternative for specific conditions after consideration of the risks, after failure of a reasonable trial of less invasive methods, and following a successful temporary trial. A psychological evaluation is recommended prior to implantation. There is some literature to suggest that in carefully selected patients, despite the initial cost, there may be long-term cost savings after a few years related to reduced use of medications and other medical care services.

When utilized, spinal cord stimulation should be part of an overall rehabilitation treatment strategy combining behavioral and physical medicine approaches to pain management. Effectively treating pain by implanting an SCS system requires a responsive, long-term relationship between the person with pain and his or her health care professional. A significant advantage of a SCS system is that it is a reversible and nondestructive treatment option.

An important consideration is that the ability to obtain subsequent spinal imaging (such as an MRI) may be compromised after implantation of an SCS system. While some SCS systems are safe to use with MRI, others are not. Patients should discuss current and potential needs for MRI with their health care professional to ensure that they are being treated with a system that will meet their needs.

As with most treatments for chronic pain, it is important for the patient and health care provider to have realistic expectations regarding treatment, with the goal being pain reduction and control rather than complete elimination. It is also important for people with SCS to involve themselves in a multidisciplinary treatment plan if they are to get the best results. In appropriately selected individuals, SCS treatment can be a viable tool in a treatment plan and can significantly reduce pain and associated limitations.

In general terms, spinal cord stimulation is primarily suited to certain neuropathic and ischemic (loss of oxygenated blood flow) pain states. Currently, conditions that can respond favorably to SCS treatment include:

- Failed back surgery syndrome with radicular symptoms
- Complex regional pain syndrome (previously known as RSD and causalgia)
- Peripheral neuropathic pain
- Peripheral vascular disease
- Ischemic heart disease

SCS has been proven to be effective for many of these conditions with lasting results in terms of pain relief, pain medication reduction, and improvement in quality-of-life indices and satisfaction scores. Although SCS can also be quite effective in relieving ischemic pain due to peripheral vascular disease and even coronary artery disease, these are currently not FDA-approved indications.

Potential complications that may occur include lead migration or fracture and infection. Lead migration after implantation may require revision surgery to regain appropriate coverage. An infection of any kind requires an immediate assessment by the physician. An unrecognized and untreated infection around the hardware can progress to more serious complications such as an
epidural abscess or meningitis.

**Implanted Targeted Intrathecal Drug Delivery Systems ( Pain Pumps )**

Unlike medications that circulate through the body and in the bloodstream, programmable intrathecal (injection into the sheath surrounding the spinal cord) drug delivery systems release medication directly into the fluid surrounding the spinal cord, which may lead to fewer or more tolerable side effects, and in some instances is the only route possible for certain drugs.

Intrathecal Drug Delivery is an FDA-approved pain therapy shown to be safe and effective for people who have not had success with other chronic pain treatments. Intrathecal therapy has been used successfully in long-term pain management for patients with failed back surgery syndrome, complex regional pain syndrome, spinal stenosis, osteoporosis with compression fractures, pancreatitis, phantom limb pain syndrome, and peripheral neuropathies. [http://www.theacpa.org/video/implantables](http://www.theacpa.org/video/implantables)

With Programmable Targeted Intrathecal Drug Delivery Therapy:

- Pain medication is delivered via a drug pump directly to the fluid around the spinal cord in an area called the intrathecal space.
- The drug pump is connected to a thin, flexible tube called a catheter.
- Both the pump and the catheter are surgically implanted under the skin.
- Pain medication is dispensed according to instructions programmed by the physician, which allows noninvasive changes in dose and drug infusion patterns.

The reader should understand that this discussion of programmable, targeted implanted drug delivery systems is limited to a general overview. More information can be found in the anesthesia and pain medicine literature.

These systems are invasive and costly, and their use is limited to select individuals who find oral opioids beneficial but cannot tolerate the side effects and as a treatment alternative for specific conditions after consideration of the risks, after failure of a reasonable trial of less invasive methods, and following a successful temporary trial. There is some literature to suggest that in carefully selected patients, despite the initial cost, there may be long-term cost savings after a few years related to reduced use of oral medications and other medical care services.

A psychological evaluation of the person being considered for an intrathecal pump is usually recommended as part of the overall evaluation process. These are often done by a psychologist or psychiatrist. The purpose of the evaluation is to see if the person with pain has any emotional or other difficulties that may adversely affect the surgery or recovery and to ensure the person has realistic expectations and goals for what can be achieved with the therapy. During the psychological evaluation, the person with pain will be asked questions about how the pain is currently affecting sleep, mood, relationships, work, and household and recreational activities. Some may also be asked to complete paper-and-pencil tests. The psychologist or psychiatrist
should share the results of this evaluation with the person with pain and with the referring physician who will consider all the information to determine if an intrathecal pump is an appropriate option.

A decision to proceed with an implanted drug delivery system should include:

- Failure of a reasonable trial of other conservative treatment modalities (medication, surgical, psychological, or physical);
- Intractable pain secondary to a disease state with objective evidence of pathology;
- Documentation that further surgical intervention is not indicated;
- Psychological evaluation has been obtained and evaluation states that the pain is not primarily psychological in origin and that benefit can be anticipated with implantation despite any psychiatric comorbidity;
- No contraindications to implantation exist such as body size too small to hold the pump; presence of spinal anomalies that may complicate the implantation and fixation of a catheter; the pump cannot be implanted 2.5 cm or less from the surface of the skin; or, presence of known or suspected meningitis, ventriculitis, skin infection, bacteremia, and septicemia;
- A life span of at least 3-6 months; and
- If the above criteria are met, a successful temporary trial of spinal (epidural or intrathecal) medications must be achieved prior to implantation as defined by a significant reduction in pain and improved function and associated reduction in oral pain medication use.

Opioids (e.g., morphine) are the most common medications delivered by intraspinal infusion. Other medications (e.g., bupivacaine, clonidine, and baclofen) may be added to opioids, particularly in patients with nerve injury pain states (neuropathic pain).

Just as when one is taking opioids orally or transdermally, the doses of intraspinal opioids should be limited to the lowest dose possible required to achieve pain relief and increased function, as complications can occur with any dose of opioids regardless of the route of delivery.

As with any opioid, constipation, urinary retention, nausea, vomiting, and pruritus (itchiness) are typical early adverse effects of intrathecal morphine and are readily managed symptomatically. Other potential adverse effects include amenorrhea, loss of libido, edema, respiratory depression, and technical issues with the intrathecal system.

High doses of intrathecally-administered morphine or opioid mixtures, including compounded drugs, have uncommonly been linked to the development of a chronic inflammatory or granulomatous mass (an abnormal tissue growth) at the tip of the catheter that can compress the spinal cord or associated nerve roots. Thus vigilance is important just as is the case when one is taking opioids orally or transdermally. Patients on intraspinal morphine therapy should be monitored carefully by their health care professional for any new neurological symptoms because inflammatory mass can, in some cases, lead to neurological impairment, including paralysis. Even though a direct cause and effect relationship has not been established, the dose of continuously-administered intrathecal morphine should be limited to the lowest dose possible to achieve pain relief and increased function, as complications can occur with any dose of opioids regardless of the route of delivery.
Apart from morphine, chronic intrathecal infusion of preservative-free, sterile ziconotide solution is approved for the management of severe, chronic pain. Ziconotide (Prialt®) is a non-opioid analgesic reserved for patients who are refractory to or who cannot tolerate intrathecal morphine. Typical side effects include dizziness, nausea, vomiting, and states of confusion. Other potential adverse effects include psychosis, convulsions, rhabdomyolysis (muscle breakdown), and problems with the intrathecal infusion system. These side effects can be prevented entirely or may be well managed by raising the dose very slowly to achieve the right level of pain relief with the least amount of drug.

The only drugs that have been approved by the FDA for continuous intrathecal use with implanted intrathecal delivery devices include ziconotide, morphine, and baclofen.
Epidurals, Nerve & Facet Blocks, & Radiofrequency Ablation (Rhizotomy)

An epidural steroid injection involves the injection of steroid into the epidural space in the cervical spine (neck) or lumbar spine (low back). Sometimes, a local anesthetic (numbing medicine) may be injected with the steroid. The epidural space is located in the spine just outside of the sac containing the spinal fluid. Epidural steroid injections are often provided to individuals with herniated discs, degenerative disc disease, or spinal stenosis who have associated nerve pain in the arm or leg.

The steroids are injected into the epidural space in order to reduce inflammation in and surrounding the spinal nerve roots and adjacent tissues. By reducing inflammation and compression, the level of pain may be decreased. Epidurals are most useful in patients with acute nerve pain from the above conditions. A majority of individuals (80 to 90 percent) with acute low back pain and associated nerve pain will recover spontaneously within three months, therefore, these injections should be viewed as a way to facilitate earlier pain relief and return to function. These injections have not been demonstrated to provide long-term successful pain relief for people suffering solely from chronic (long-standing) back pain or chronic nerve pain.

Epidurals rarely provide long lasting benefit but may be useful in these chronic pain conditions to manage a flare-up. Some people who have residual pain after the first injection may receive a second epidural steroid injection. However, individuals who do not receive any relief from the first injection are unlikely to benefit from a second injection. Furthermore, the number of steroid injections per year should be limited in order to avoid side effects that may occur including osteoporosis (weakening of the bones) and avascular necrosis (bone cell death often seen in the hip). Diabetic patients receiving epidural steroids should monitor their blood sugars closely following the procedure since an elevation can occur.

Nerve and facet blocks use a combination of local anesthetic and steroid for diagnostic purposes to identify pain generators. These blocks can also be used therapeutically to “block” a painful condition. Unfortunately, these procedures do not provide lasting benefit and are best used as part of an overall treatment plan to relieve discomfort temporarily while the patient engages in an active rehabilitation program.

Radiofrequency ablation (rhizotomy) or lesioning involves inserting a probe to destroy the nerve that supplies the facet joint. The facet joint, a small joint that connects the back portion of the spine, can become arthritic and cause neck or back pain. Facet joints allow bending and twisting movements in the back and neck. These movements can be very painful and may limit daily activities in an individual with facet joint disease. People with lumbar (low back) facet joint syndrome often complain of hip and buttock pain, low back stiffness, and pain that is made worse by prolonged sitting or standing. People with cervical (neck) facet joint syndrome often complain of neck pain, headache, and/or shoulder pain. In addition, they will often have pain when they rotate or bend their neck.

In order to determine if facet joints are responsible for neck or back pain, medial branch blocks are performed. A medial branch block is a block that is performed under fluoroscopy (x-ray), and

American Chronic Pain Association
Copyright 2016
Local anesthetic (numbing medicine) is injected on the nerves that supply the facet joint in the back or neck. Following the procedure, patients are asked to keep a pain diary in order to record any pain relief, the amount of pain relief, and for how long pain relief lasts. Based on the response to this block, it can be determined if the person is a candidate for medial branch radiofrequency ablation (rhizotomy). Patient selection is imperative for achieving successful results.

Following radiofrequency ablation, patients are often asked to resume physical therapy for flexibility and strengthening exercises. Radiofrequency usually blocks the signal for a prolonged period of time (six months to a year). Eventually, the nerve grows back and can allow the pain signal to be transmitted again. If this happens, the procedure can be repeated. This procedure often does not relieve all back pain, but it relieves the pain associated with facet joint arthritis.

Denervation of the spinal muscles is possible with rhizotomies, thus repeated rhizotomies can cause atrophy of these muscles and lead to other untoward effects.

As with any procedure, there are certain risks involved which should be discussed with a treating physician. In order to achieve optimal results, it is important that these interventions be incorporated into a multidisciplinary treatment plan.
COMPLEMENTARY, ALTERNATIVE & INTEGRATIVE MEDICINE (CAM)

Complementary and Alternative Medicine (CAM) includes a diverse group of healing systems, practices, and products that are typically considered allopathic medicine, although some have proven scientific validity and have become mainstream (acupuncture, meditation, hypnosis, yoga, certain herbal preparations, etc.). Other CAM approaches have strong followers, but their “proof” of value is really anecdotal rather than based on scientific fact.

In fact, what is considered to be CAM changes continually, as those therapies that are proven to be safe and effective become adopted into conventional health care and as new approaches to health care emerge.

Complementary medicine and alternative medicine are different from each other. Complementary medicine is used together with conventional medicine while alternative medicine is used in place of conventional medicine. Integrative or integrated medicine combines treatments from conventional medicine and CAM for which there is some high-quality evidence of safety and effectiveness. Always check with your health care provider or pharmacist as drug interactions can occur with many alternative or “natural” medications.

The reader is referred to the following Internet web sites for further information.

The National Center for Complementary and Integrative Health (NCCIH) ([http://nccam.nih.gov](http://nccam.nih.gov)) is part of the National Institutes of Health (NIH) and is the lead agency for scientific research on CAM.
PASSIVE THERAPIES & PHYSICAL MODALITIES

Passive therapy (those treatment modalities that do not require energy expenditure on the part of the patient) can provide short-term relief during chronic pain flare-ups and is directed at controlling symptoms such as pain, inflammation, and swelling. These therapies can include massage, ultrasound, iontophoresis, paraffin (wax) treatment, light therapy, or traction. Passive therapies may be useful over the short term but have limited benefit for chronic pain conditions overall.

HYPERBARIC OXYGEN

Hyperbaric oxygen (HBO) involves the administration of oxygen in a pressurized chamber to increase oxygen delivery to the tissues of the body. It has been used to treat a number of conditions with problematic microvascular blood supply, including diabetic foot ulcers and decubitus ulcers.

HBO therapy recently has shown promising results for some chronic pain syndromes, but its use is far from proven.

Several authors claim HBO is a reliable method of treatment and may be beneficial if appropriate persons are selected. Further research is required to identify the best treatment protocol, the cost/benefit ratio, and the safety of HBO in chronic pain management—and whether it actually works.

ACUPUNCTURE

Acupuncture originated in China and is based in part on the theory that many diseases are manifestations of an imbalance between yin and yang as reflected by disruption of normal vital energy flow (Qi) in specific locations, referred to as meridians. Needling along one of the 361 classical acupuncture points on these meridians is believed to restore the balance. This stimulation is classically done with thin, solid, metallic needles, which are then manipulated (or turned) manually or stimulated electrically (electroacupuncture). Besides needling, acupuncture frequently involves moxibustion and cupping. Beyond traditional Chinese acupuncture, there are many other types of acupuncture that have arisen, including accessing non-traditional acupuncture points.

Acupuncture has been utilized to treat many different disorders including smoking cessation, nausea, and chronic pain. It has gained wide and increasing acceptance and is now covered by many insurance policies.

MANIPULATION & MOBILIZATION

Spinal Manipulative Therapy (SMT) is a therapeutic intervention performed for what is described as “restricted joint(s)” in the spinal column.

Spinal manipulation is a historically recognized therapeutic intervention that has been employed in various cultures for thousands of years. In modern time, the procedure is utilized by Doctors of Chiropractic (DCs), Doctors of Osteopathy (DOs), and physical therapists (PTs). Chiropractors
prefer the term "adjustment" whereas physical therapists apply the word "mobilization."
Adjustment is described as a more specific type of SMT, often provided to address a specifically
identified biomechanical fault.

Manipulation and mobilization are two types of manual (hands-on) therapy that include a wide
array of different techniques and schools of thought. Traditional manipulation involves high force,
high velocity, and low amplitude action (HVLA) forces with a focus on moving a targeted, fixated
or hypomobile joint(s). In general, mobilization involves assisted low force, low velocity
movement often directed to one or more restricted vertebral segments and typically uses long lever
arms to deliver the force. The term adjustment is commonly used a synonym for manipulation.

The effects of spinal manipulation include relief of acute and chronic back pain, improved spinal
motion, and affecting the nervous system mostly at the local spinal level. There are research studies
which support the benefits of SMT.

Overall, studies have shown that spinal manipulation can provide relief from acute and chronic
low back and neck pain. SMT can be as effective, or more effective, than conventional medical
treatments. In 2007 Guidelines, the American College of Physicians and the American Pain
Society include spinal manipulation as one of several treatment options for practitioners to
consider using when pain does not improve with self-care. Research studies have shown that spinal
manipulation can be a more effective treatment for chronic back pain than bed rest, traction, topical
gels, or no treatment; some studies show superiority of SMT over acupuncture, physiotherapy, and
back school for low back pain.

**ELECTRICAL STIMULATION DEVICES (EXTERNAL)**

Electrotherapy represents the therapeutic use of electricity and is another modality that can be used
in the treatment of pain. Transcutaneous electrotherapy is the most common form of electrotherapy
in which electrical stimulation is applied to the surface of the skin. The earliest devices were
referred to as TENS (transcutaneous electrical nerve stimulation) and are the most commonly used.

Interferential Current Stimulation (ICS) allows for deeper penetration of tissue, whereas TENS is
predominantly a cutaneous or superficial stimulus. Interferential current is proposed to produce
less impedance in the tissue, and the intensity provided is supposed to be more comfortable.
Because there is minimal skin resistance with the interferential current therapy, a maximum
amount of energy goes deeper into the tissue. It also crisscrosses, as opposed to the linear
application of the TENS. This crisscrossing is postulated to be more effective because it serves to
confuse the nerve endings, preventing the treated area from adjusting to the current.

**TRIGGER POINT INJECTIONS**

Trigger point injections are given to individuals with a myofascial pain syndrome, a regional
painful muscle condition. These injections may provide short-term benefit only, but are curative
for some individuals.
The California Chronic Pain Medical Treatment Guidelines reports the following: a trigger point is a discrete focal tenderness located in a palpable taut band of skeletal muscle, which produces a local twitch in response to stimulus to the band. Trigger points may be present in up to 33-50 percent of the adult population. Myofascial pain syndrome is a regional painful muscle condition with a direct relationship between a specific trigger point and its associated pain region. These injections may occasionally be necessary to maintain function in those with myofascial problems when myofascial trigger points are present on examination.
INTERNET PAIN-MANAGEMENT RESOURCES

There are a number of stand-alone and Internet-based programs to help in the management of pain. The American Chronic Pain Association website can be a great source of information (www.theacpa.org). This and other pain management programs include ways to track daily pain and activity and can be a useful vehicle to easily summarize progress over time. They can be especially helpful when starting an exercise routine by tracking progress based on frequency and duration of the exercises. These programs can also suggest warm-up and cool-down stretching routines catered for each individual’s pain problem. They also can be useful for monitoring medication use and giving helpful reminders throughout the day. A daily food diary can help in identifying healthy and unhealthy eating habits. Smart phone applications (apps) are in development specifically for persons with chronic pain. These programs are useful in identifying important information about the pain, summarizing progress for the health care professional, and offering daily tips and recommendations for improving pain management.

Many things can affect your pain. These can include stress, sleep, money worries, and even the weather. This log can help you track the everyday things that have an impact on your pain.

When you understand what makes your pain worse, you can begin to work on ways to reduce or deal with your pain “triggers.”

The more you know about how your body reacts, the more you can be in control. Being in better control can help you be less afraid and better able to manage your pain. We encourage you to fill out a chart at the end of each day or several times a week. You also can print out a report and take it to your doctor visits. It can help you talk more openly with your health care provider so that together you can find ways to improve your quality of life.

http://www.theacpa.org/painlog/default.aspx

Back pain can be complex and difficult to describe in the short time you may have with your health care provider. This tool can help you create a detailed picture of your pain—where it is, how it feels, how much it hurts, and what triggers it. Fill it out before your visit, print it, and share it with your provider.

http://www.theacpa.org/backpainapp/

The beginning journey from patient to person with this workbook is designed to help anyone who has a chronic pain problem gain an understanding of how to cope with the problems that his or her pain creates.

Topics include:
• Understanding Chronic Pain
• Knowing Yourself
• Learning to Live With Others
• Helping Your Body

http://www.theacpa.org/product.aspx?guid=740dd14d-70da-4de5-b2a7-a24002f81f6a
**FINAL COMMENTS**

An essential concept in pain management is that each person is different and will respond differently to situations, interventions, surgeries, and medications.

It is important for the person with pain, family members, and others to avoid quick judgments based on what they hear or read about any particular treatment or medication. The best place to get advice about treatments and medications is from the health care professional assisting the person with pain.

Families need to be good reporters—observant, truthful, and honest about what they see in the person who is provided a certain treatment or who is taking medication. Sometimes the person provided the treatment or taking the medication does not realize the changes that are produced. Family member observations will be helpful to the health care professional.

There is no question that there are many treatment approaches (tools) in the “tool chest” of the treating health care professional or therapist, but they should be used judiciously. Benefit should be based on less pain, more function, and return to everyday activities with the least, manageable side effects possible.

This *ACPA Resource Guide to Chronic Pain Treatment* only deals with certain treatments and medications, but it is important to understand that there are many other treatment approaches to chronic pain that may not be covered in this document. This document is a work in progress, and the ACPA welcomes comments and recommendations.

The ACPA once again reminds readers that this *ACPA Resource Guide to Chronic Pain Treatment* is not meant to serve as medical advice for pain conditions or treatment or medication needs. The best source of information is health care professionals and therapists who understand the treatment and medication options available to people with chronic pain.
REFERENCES: LINKS TO CHRONIC PAIN SITES & RESOURCES

MEDICATION RELATED


OTHER REFERENCES


Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) maintains a collection of educational materials on topics related to buying and using medicine safely at [http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm296593.htm](http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm296593.htm)


American Chronic Pain Association
Copyright 2016


**PAIN RELATED ORGANIZATIONS & WEB SITES**

The American Chronic Pain Association (The ACPA) at [http://theacpa.org/](http://theacpa.org/)

American Society for Pain Management Nurses (ASPMN) at [http://www.aspmn.org/Pages/default.aspx](http://www.aspmn.org/Pages/default.aspx)


Opioid Induced Constipation [http://www.theacpa.org/opioid-induced-constipation](http://www.theacpa.org/opioid-induced-constipation)


Understanding NSAIDS [http://www.theacpa.org/NSAIDs-safety](http://www.theacpa.org/NSAIDs-safety)


Vets In Pain [www.vetsinpain.org](http://www.vetsinpain.org)

Youth Living with Pain [www.growingpains.org](http://www.growingpains.org)